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SUMMARY 
Obesity is the foremost contributory factor in the progression to type 2 diabetes 
mellitus (T2DM). Moreover, chronic inflammation, through activation of innate 
immunity is proposed to link obesity, insulin resistance and T2DM. Adipose tissue, 
traditionally considered a storage compartment for triglycerides, also functions as an 
active endocrine organ. Adipocyte-secreted products, termed adipokines, may link 
obesity-associated inflammation and insulin resistance. Adipokines exert multiple 
effects on insulin sensitisation, glucose homeostasis, inflammatory processes or 
central systems mediating energy expenditure. This thesis principally examined two 
adipokines; resistin and adiponectin. Resistin and components of innate immunity 
were assessed in human obesity. In-vitro analysis established that resistin was 
expressed and secreted by human adipocytes. Furthermore, key factors in the innate 
immune pathway were highly expressed in obese and T2DM adipose tissue. This 
thesis further explored the pro-inflammatory actions of resistin in adipocytes. Resistin 
stimulated the secretion of inflammatory cytokines from adipocytes and, the 
expression of key intermediates of the innate immune and insulin signalling pathways. 
Clinical studies entailed examination of resistin as a marker of inflammation in 
childhood obesity. Serum analysis revealed gender-differences in resistin levels in 
obese children. Furthermore, bacterial endotoxin correlated with several markers of 
inflammation and cardiovascular disease; suggesting endotoxin as a contributor to 
inflammation in childhood obesity. This thesis subsequently examined another 
adipokine, adiponectin; considered to have a `ying-and-yang' relationship with 
resistin. Studies explored a central role for adiponectin in energy homeostasis. Gel- 
filtration liquid chromatography established that the adiponectin trimer was 
predominant in human cerebrospinal fluid. Such identification of trimeric adiponectin 
in vivo implicates the pharmacologically generated globular adiponectin in central 
regulation of energy expenditure. In conclusion, resistin may serve as a pathogenic 
pro-inflammatory factor, exacerbating inflammation within adipose tissue; potentially 
contributing to the progression of obesity-driven T2DM. Alternatively, adiponectin 
may have favourable central actions, influencing energy expenditure through its basic 
trimeric form. Collectively, this thesis suggests that resistin and adiponectin, with a 
range of opposing properties, may substantially affect whole-body metabolism. 
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Chapter 1 
Introduction 
1.1. Obesity: The Epidemic. 
The development of type 2 diabetes mellitus (T2DM) occurs as a consequence of 
several metabolic disorders and is now considered a `polygenic disease'. Obesity is 
rapidly becoming a worldwide epidemic and is acknowledged as one of the single 
most contributory factors in the pathogenesis of T2DM and insulin resistance. 
Epidemiological data show that the prevalence of obesity has significantly increased 
over the past 25 years by almost 400% (D'Arcy 2006) and continues to do so at an 
alarming rate (Wang et al. 2005). More specifically, within the UK, approximately 
50% of the adult population are either overweight or obese, with more than a million 
people affected with T2DM (Canoy D et al. 2007). Moreover, a global epidemic of 
paediatric obesity has increased in recent years and is continuing to do so (Chinn et al. 
2001; Els et al. 2005; Reilly 2006). In particular, there is a rising incidence of T2DM 
in children within the UK (Haines et al. 2007). The worldwide spread of the obesity 
epidemic has been highlighted by the MONICA World Health Organisation (WHO) 
project; detailing increased rates of obesity in 48 different countries (Berrios et al. 
1997; Heseker et al. 2000). 
The epidemiological link between obesity and diabetes is largely apparent in western 
societies. Whilst the incidence of obesity is clearly increasing in many ethnic 
populations, synergistically is the prevalence of T2DM. Globally, the prevalence of 
diabetes for all age-groups was estimated to be 2.8% in 2000 and 4.4% in 2030 (Wild 
et al. 2004); the total number of people with diabetes is projected to rise from 171 
million in 2000 to 366 million in 2030 (Engelgau et al. 2007). As such, the obesity 
epidemic is now termed the `diabesity' epidemic. The epidemiological association 
between obesity and T2DM has been acknowledged by numerous studies; in 
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particular, the Nurses Health Study and Health Professionals Follow up Study (Chan 
et al. 1994; Colditz et al. 1995). This study specified that, as body mass index (BMI) 
increases, the risk of developing T2DM also increases, to such an extent that women 
with a BMI of 35 kg/m2 or above have a 40-fold increased risk of developing T2DM. 
Similar findings were reported for men, whereby a BMI of 35 kg/m2 or above, 
increased the risk of TD2M by 60-fold.. `Moderate' weight gain has additionally been 
shown to enhance diabetic risk. Recent studies have highlighted that for each 
kilogram in body weight gained, the relative population risk of developing T2DM 
increases by 4.5% (Ford et al. 1997) and, in some cases, 9% per kilogram (Mokdad et 
al. 2000). The increased diabetic risk following obesity is, to an extent, reversible 
with weight reduction. A near 50% reduction in diabetic risk was observed following 
a weight loss of 5-11 kg (Chan et al. 1994). Moreover, the study reported that the risk 
of developing T2DM was almost eradicated in subjects having lost 20 kg or with a 
BMI below 20 kg/m2 (Chan et al. 1994). Similar observations were described in the 
Swedish Obese Subjects Study; one of the largest long-term evaluations for the use of 
surgery for weight reduction in obese patients (Sjostrom et al. 1997). Following 
gastric bypass surgery, 69% of subjects diagnosed T2DM subjects were no longer 
classified as diabetic (Sjostrom et al. 1997). Moreover, only 0.5% developed T2DM 
over the following two years (Sjostrom et al. 1997). It has therefore been proposed 
that the effect of sustained weight loss, achieved through surgical intervention, results 
in a reduced risk in the development of T2DM (Ballantyne et al. 2006; Ferchak et al. 
2004). 
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To understand the importance of adipose tissue mass within T2DM, this introduction 
will highlight the impact of obesity on the pathogenesis of T2DM; detailing the role 
of the adipose-secreted factors and several pathogenic mechanisms that increase 
diabetic risk. Within this context, our current understanding of the emerging link 
between obesity-induced T2DM and inflammation will be described. 
1.1.1 Obesity in Childhood & Adolescents: The Emerging Epidemic. 
In the developed world, obesity is now the most common disease in children and 
adolescence. This striking global epidemic of paediatric obesity has occurred in recent 
years, with its prevalence dramatically continuing to increase. Using international 
definitions, at least 10% of children are overweight or obese worldwide (Libman et al. 
2007; Lobstein et al. 2004); with the highest percentages in American (32%), 
European (20%) and Middle Eastern (16%) populations. An important concern is the 
onset of cardiovascular and metabolic risk factors that are consequently associated 
with paediatric obesity; the impact of such detrimental consequences have, to date 
been underestimated (Reilly 2006). 
1.1.2 The Definition of Obesity. 
Obesity is an excess of whole body fat (adipose tissue) mass; a level of adipose tissue 
mass that is considered harmful. Over recent years, obesity has been classified using 
body mass index (BMI). The BMI is the most routinely used indicator of obesity, due 
to its ease of determination. BMI is defined as the weight in kilograms of a subject 
divided by the square of their height in metres (kg/m2). The WHO classified a BMI 
between 25-29.9 kg/m2 as overweight; values above this are categorised as clinically 
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obese. Within the defined `obese' category there is further sub-division, as 
demonstrated in Table 1.1.2.1. 
WHO classification for Europids BMI (kg/m2) 
Underweight <18.5 
Healthy/Lean 18.5-24.9 
Overweight 25-29.9 
Obese I 30-34.9 
Obese II 35-39.9 
Morbid Obesity >40 
Table 1.1.2.1 Table of the BMI scale, highlighting the classified limits (Weisell 
2002). 
BMI is further considered a good correlate of body-fat (Webster et al. 1984) and 
associated mortality/morbidity (Willett et al. 1999). However, BMI does not take into 
consideration differences in extremities; for example, subjects with high-fat mass or 
high-muscle mass. It has been proposed that obesity is best diagnosed using BMI 
centile charts; such centile charts take into account BMI alterations with differences in 
age and sex (Reilly 2006). 
Although BMI definitions were generated for international use, it is now 
acknowledged that the prevalence and risk of T2DM varies amongst ethnic minorities. 
For instance, Japanese Americans have a higher rate of incidence of T2DM in 
comparison to those of European origin (Seidel! et al. 2001). Furthermore, in certain 
areas of Asia, some populations with an average BMI of below 25 kg/m2 have 
remarkably high rates of T2DM and cardiovascular risk. Additionally, when matched 
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for BMI, certain Asian populations have considerably higher percentage body-fat than 
Caucasian Europeans (Deurenberg et al. 1998; Swinburn et al. 1999; He et al. 2001). 
In particular, Pakistani, Indian and Bangladeshi men have relatively high levels of 
central obesity, with 41% of Indian men classified as centrally obese compared to 
28% of men in the general population (Joint Health Surveys Unit 2000). It was 
therefore apparent that the original BMI limits designated for `at risk groups' did not 
account for variation caused by difference in ethnicity; to address this issue, the BMI 
scale was adjusted for several Asian populations. The results of such a BMI scale 
adjustment are highlighted in Table 1.1.2.2. As an alternative to setting BMI limits 
for each nationality, the WHO established new BMI limits for people of Asian origin. 
New upper boundaries for the BMI scale were 23.0,27.5,32.5 and 37.5 kg/m2 for 
lean, overweight, obese and morbidly obese respectively (WHO Expert Consultation 
(2004)). Such new boundaries for BMIs reflect the increased risk of metabolic 
syndrome in Asian populations with proportionately lower levels of body fat. 
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Ethnic Overweight Obesity 
Origin Point ANCOVA Point ANCOVA Analysis Analysis 
China 24 25 29 30 
China (Hong 23 22 27 27 Kong) 
Indonesia 24 22 26 27 
Japan 25 24 30 29 
Singapore 22 23 27 27 
Thailand 25 23 30 28 (Urban) 
Thailand 27 25 31 30 (Rural) 
Table 1.1.2.2 Established thresholds (kg/r2) calculated for overweight and obese 
groups of different Asian origins. Point analyses are calculated by the assumption that 
BMI limits for Caucasians equate to the same percentage body-fat in each Asian 
group. ANCOVA values are based on the analysis of co-variance with BMI as one 
variable, the ethnic group as a grouping variable and age, sex and percentage body fat 
as co-variates (WHO Expert Consultation (2004)). 
1.1.3 Gender, Ethnicity & Specific Adipose Tissue Distribution. 
The distribution of adipose tissue is altered by gender and ethnicity. Male subjects 
have a tendency to accumulate surplus adipose tissue around the abdominal area of 
the body, whereas female subjects accumulate adipose tissue predominantly around 
the hips and thighs. This was originally described by Vague, who observed 
differences between male `android' obesity and female `gynoid' obesity (Vague 
1956). A stereotype of `apple' versus `pear' shaped fat-distribution has been described 
(Figure 1.1.3); highlighting that men and women with a comparable BMI have 
significantly different percentages of body-fat. Interestingly, subjects with a gynoid 
`pear-shaped' fat-distribution are at a lower risk of developing disease in comparison 
to BMI matched subjects with an `apple-shaped' fat-distribution (Vague 1956). 
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Furthermore, only women with a similar fat-distribution to men seemed to develop 
diabetes at a high-rate of incidence (Vague 1956). 
Percentage Body Fat 
Android Gynoid 
Normal weight 
Overweight 
Obese 
14-28% 
29-32% 
> 32% 
Figure 1.1.3 Diagrammatic representation highlighting the differences in body-fat 
percentage in each BMI category between males with an `android' fat-distribtution 
and females with `gynoid' fat-distribution. Figure adapted from (Vague 1956). 
In terms of ethnicity, it has been reported that Asian populations gain excess fat more 
centrally, therefore have a high degree of central obesity (Pi-Sunyer FX 2004). Asian 
populations are therefore likely to adopt an `apple shaped' rather than a `pear shaped' 
body-fat distribution; as such, are more pre-disposed to abdominal obesity than people 
of European origin, which confers higher risks of T2DM and cardiovascular disease 
(CVD). It has further been reported that waist circumference is highly correlated with 
metabolic syndrome components and health risks than percentage body-fat and BMI 
(Shen et al. 2006). 
Post-menopausal women also accumulate fat more centrally; this consequently 
conferes a higher risk of developing T2DM (Ruderman et al. 1998). Although 
speculative, androgens are postulated to regulate adipose tissue distribution. Post- 
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menopausal women have reduced levels of oestrogen. As a result, adipose tissue 
becomes the major source of oestrogen (Bjorntorp 1995); this may be responsible for 
re-distribtuion of adipose stores, causing central adiposity. Central adiposity has been 
shown to be re-distributed by Hormone Replacement Therapy (Haarbo et al. 1991), 
therefore implying oestrogen treatment to positively influence fat-distribution. 
1.1.4 Types of Abdominal Adipose Tissue. 
Abdominal adipose tissue is compartmentalised into two distinct anatomical 
regions/depots. These are `subcutaneous' adipose tissue, surrounding the abdominal 
cavity beneath the skin, or infra-abdominal `visceral' adipose tissue. Visceral adipose 
tissue consists of mesenteric omental adipose tissue mass; comprising of 
approximately <10% of total adipose tissue mass in lean subjects, which can reach up 
to twice the size in obese subjects (Wajchenberg 2000; Gasteyger and Tremblay 
2002). Magnetic resonance imaging has shown that visceral fat accumulation confers 
a higher risk of T2DM than subcutaneous fat (Despres et al. 1995; Albu et al. 1997; 
Albu et al. 2000). Conversely, other studies have proposed that subcutaneous fat 
accumulation is the predominant contributor to the increased risk of T2DM, rather 
than visceral fat accumulation (Abate et al. 1996). Such controversy may arise from 
the relative proportions of visceral and subcutaneous fat. Visceral fat accounts for up 
to 20% of an obese subject's total fat-mass; whereas subcutaneous fat comprises the 
remaining 80% of total fat-mass (Montague et al. 1997), therefore implying that 
subcutaneous fat may have more of an impact on an obese subjects' metabolic profile. 
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1.2 The Composition of Adipose Tissue & the Development of Obesity. 
In humans, white adipose tissue is the major storage site for excess energy; this in 
itself is stored in the form of lipids or triglycerides. More specifically, lipid 
composition consists primarily of myristic, palmitoleic, stearic, palmitic, linoleic and 
oleic fatty acids. Water (5-30%) and proteins (2-3%) contained within adipocytes 
form the remaining fraction, which is subsequently bound by a framework of collagen 
fibres. 
For normal tissue function, adipose tissue mass is comprised of many cell types; these 
include adipocytes, pre-adipocytes, leukocytes, macrophages and endothelial-vascular 
cells. Adipocytes are uniocular cells, ranging in diameter from 25-200 microns and 
have a variance in diameter of up to 20-fold; this consequently allows the adipocyte 
cells to increase in volume of up to a 1000-fold (Fruhbeck et al. 2001). Adipocytes are 
therefore the predominant cell-type in adipose tissue. Pre-adipocytes are adipocyte 
precursor cells, serving as a store for adipocyte recruitment. Upon activation of 
hyperplastic growth, pre-adipocytes differentiate into fully mature adipocyte cells. 
Endothelial cells function to supply adipose tissue with blood, transporting proteins to 
and from the periphery, thus forming the tissue vasculature. Leukocytes, in particular 
macrophages, reside within adipose tissue, prompted to a site of inflammation to 
eliminate infected cells. 
Obesity occurs when energy intake exceeds energy expenditure; such a notion is 
termed `positive energy balance' and can occur as a result of overnutrition and lack of 
physical activity. This excess energy is stored in white adipose tissue (Frayn et al. 
1995; Gregoire et al. 1998) and can, consequently, acutely modify the tissues 
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architecture and framework. For instance, one such modification of adipose tissue is 
to rapidly expand in size through hyperplastic and hypertrophic growth of adipocytes. 
Hyperplastic growth increases adipocyte number, via cell proliferation and 
differentiation. Whereas hypertrophic growth increases the adipocytes cell size, due to 
an uptake of lipids by the cell. Both processes are regulated at hormonal and genetic 
levels. Furthermore, key genes activate the `formation of triglyceride' (TG) 
(lipogenesis) and the `breakdown of TG' (lipolysis) (Gregoire et al. 1998). 
1.2.1 Hyperplastic Growth of Adipocytes. 
Shortly after birth, adipose tissue is formed by an increase in hyperplastic and 
hypertrophic growth of adipocytes (Gregoire et al. 1998). This early accumulation of 
adipocytes occurs through `clonal expansion' of pre-adipocytes, resulting in the 
formation of new populations of precursor cells (Prins et al. 1997); such a process is 
termed `proliferation'. Pre-adipocytes are derived from pluripotent stem cells, of 
which can develop into several different cell-types, including adipocytes, 
chondrocytes, osteoblasts or myocytes; such a process is known as cellular 
`differentiation' or `maturation'. Hyperplastic growth is regulated through both pre- 
adipocyte proliferation followed by differentiation; collectively, these processes are 
termed `adipogenesis' (Figure 1.2.1). 
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Figure 1.2.1 The stages in adipogenesis. Clonal expansion or proliferation of pre- 
adipocytes is followed by differentiation of the fibroblast-like precursor cells into 
mature adipocyte cells. 
During differentiation, pre-adipocytes undergo drastic morphological changes, 
transforming from fibroblast-like structures to spherical cells. These alterations are 
coupled with changes in the surrounding extracellular matrix and cytoskeleton 
(Hansen et al. 1999). Differentiating pre-adipocytes are further subject to external 
stimuli; this determines whether the pre-adipocyte remains quiescent, proliferates, or 
commits to differentiation. Factors that stimulate adipogenesis include `insulin-like 
growth factor-l receptors' that signal through insulin receptor substrate (IRS) 
molecules (Miki et al. 2001) and free fatty acids (FFAs). Alternatively, factors that 
inhibit adipogenesis promote hypotrophic growth of existing mature adipocytes, thus 
hindering hyperplastic growth; such factors include inflammatory cytokines, such as 
tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6) (Knowler et al. 1981; 
O'Rahilly 1997) and interferon-y. 
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1.2.2 Hypertrophic Growth of Adipocytes. 
Adipocytes store post-prandial triglycerides, thus increasing the adipocytes size; such 
a process is termed `adipocyte hypertrophy'. Triglycerides, cholesterol and 
phospholipids circulate as lipoprotein complexes; these include very low density 
lipoproteins, low density lipoproteins and high-density lipoproteins. However, non- 
esterified free fatty acids (NEFAs) are the most abundant molecules in adipose tissue, 
circulating complexed with albumin. The regulation of triglyceride concentrations in 
circulation is maintained by `lipogenesis' (TG formation) and `lipolysis' (TG 
breakdown). More specifically, lipogenesis involves the hydrolysis of systemic 
triglycerides to form NEFAs, of which are transported into mature adipocytes; here 
the NEFAs are re-esterified to form triglycerides and stored intracellularly in the lipid 
droplet. Lipolysis involves the hydrolysis of intracellular triglycerides back into 
NEFAs, then released back into circulation; this reduces the amount of stored 
intracellular triglycerides and thus reduces the adipocytes' size; such a process is 
termed `adipocyte hypotrophy'. The balance between lipolysis and lipogenesis has 
profound effects on systemic levels of NEFAs; of which elevated levels are a 
characteristic of obesity and T2DM and consequently, alter the mass and distribution 
of adipose tissue. 
1.3 Obesity & Insulin Resistance. 
The processes of adipogenesis, lipolysis and lipogenesis all alter the dynamic 
morphology of adipose tissue in response to nutrient intake. T2DM develops 
progressively within obese subjects; initially, subjects become resistant to insulin 
(Gulli et al. 1992; Jackson et al. 2000; Tripathy et al. 2000) due to an increase in 
systemic insulin levels, referred to as `hyperinsulinemia'. Such an increase in 
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systemic insulin counteracts insulin resistance by maintaining hepatic glucose 
production and the response to glycemic load, thus overcoming impaired glucose 
uptake in peripheral tissues (Vauhkonen et al. 1997; Weyer et al. 1999). Once 
hyperinsulinemia cannot overcome whole body insulin resistance, the condition 
progresses to a state of Impaired Glucose Tolerance (IGT). The progression to T2DM 
is therefore not associated with an increase of insulin resistance, rather the gradual 
inability of the pancreas to maintain high levels of insulin production (Bogardus et al. 
1984; Saad et al. 1989; Polonsky et al. 1996). As insulin production deceases, the 
progression from IGT to overt T2DM occurs. The processes whereby insulin regulates 
whole body metabolism and the key stages that influence insulin resistance and 
glucose intolerance are briefly outlined. 
1.3.1. Insulin Signalling & Glucose Uptake. 
To overcome periods of fasting, nutrients, for instance glucose are stored in tissues. 
Normal fasting glucose levels range from 4-7 mM (Saltiel et al. 2001). However, 
when systemic levels of glucose are high, for instance, >10 mM, the secretion of 
insulin is enhanced. Insulin serves to maintain glucose homeostasis by increasing 
glucose absorption in the intestine and glucose uptake in skeletal muscle and adipose 
tissues, whilst further inhibiting hepatic glucose production (Klip et al. 1990). 
Insulin signalling is initiated through binding of insulin to its receptor. The insulin 
receptor (IR) is comprised of two identical a and ß subunits; insulin binds to the a 
subunit, causing autophosphorylation hence activation of the two adjacent ß subunits. 
Activation of the IR initiates phosphorylation of tyrosine residues on insulin receptor 
substrate (IRS) molecules (Sesti et al. 2001). Such phosphotyrosine residues serve as 
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docking sites for proteins with a Src homology 2 (SH2) domain. For example, binding 
of the SH2 domain of phosphoinositide 3-kinase (P13K) to IRS, catalyses the 
fomiation of phosphatidylinositol 3,4,5-triphosphate (PIP3/PtdIns(3,4,5)P1) from 
phosphatidylinositol-4,5-bisphosphate (PIP2/PtdIns(4,5)P2), which then activates 3- 
phosphoinositide-dependent protein kinase-1 (PDK-1) (Rameh et a!. 1999), 
consequently activating protein kinase B (PKB)/Akt, which in turn mediates glucose 
transporter-4 (GLUT-4) translocation to the cell membrane (Kotani et al. 1995; Ono 
et al. 2001). The key sequential stages of insulin signalling are highlighted below in 
Figure 1.3.1. 
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Figure 1.3.1 Insulin signalling. This diagram outlines the interaction between IRS and 
the catalytic and regulatory p110 and p85 subunits, respectively, of phosphoinositide 
3-kinase (P13K); such binding eventually causes the translocation of GLUT-4 from 
intracelluar sites to the cell membrane, for cellular glucose uptake (adapted from 
(Bevan 2001)). Ins, insulin; IRS, insulin receptor substrate; PIP2, 
phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5- 
trisphosphate; PDK-l, 3-phosphoinositide-dependent protein kinase-1; PKB/Akt, 
protein kinase B; P, phosphorylation; GLUT-4, glucose transporter-4. 
Insulin signalling enhances the storage of glucose as glycogen, thus reducing hepatic 
glucose production. Such enhanced glycogen synthesis is mediated through 
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deactivation of a key enzyme in glycogen synthesis, glycogen synthase kinase-3 
(GSK-3), by PKB/Akt (Miron et al. 2001). Hepatic glucose output is regulated by the 
rate of gluconeogenesis and glycogenolysis; insulin directly inhibits both processes 
(Michael et al. 2000). Insulin signalling further regulates the activity and expression 
of several key hepatic enzymes (Pilkis et al. 1992); these include 
phosphoenolpyruvate carboxylase (PEPCK), an enzyme involved in the rate-limiting 
step in gluconeogenisis and, the glycolytic enzymes glucokinase and pyruvate kinase 
(Sutherland et al. 1996). The development of insulin resistance therefore involves 
defects in insulin signalling. For instance, elevated NEFA levels cause insulin 
resistance through inhibition of IRS-1 signalling (Shulman 2000), by activating 
protein kinase-CO (Kelley et al. 2000), this induces serine phosphorylation of IRS-1, 
consequently suppressing tyrosine phosphorylation (De Fea and Roth 1997; 
Ravichandran et al. 2001; Greene et al. 2004). Similarly, acute and chronic elevation 
of systemic NEFA levels has been shown to inhibit interactions between P13K and 
IRS-1 (Dresner et al. 1999; Kruszynska et al. 2002) and further inhibit insulin- 
stimulated activity of PKB/Akt (Chavez et al. 2003). 
In obese and glucose intolerant subjects, insulin has been shown to suppress hepatic 
glucose output, which further correlates with elevated NEFA levels and enhanced 
lipid oxidation (Bogardus et al. 1984; Seppala-Lindroos et al. 2002). The relationship 
between plasma NEFA levels, NEFA oxidation and hepatic glucose output in T2DM 
and obesity can be demonstrated by the following (Bays et al. 2004): increased 
plasma NEFA increases NEFA uptake by hepatocytes, thus causing accelerated lipid 
oxidation. Accelerated lipid oxidation stimulates rate-limiting enzymes in 
gluconeogenesis and glucose-6-phosphatase (G6Pase), a rate limiting enzyme in 
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glucose release (Williamson 1966; Massillon et al. 1997). Additionally, elevated 
plasma NEFA levels induce hepatic insulin resistance by inhibiting insulin signalling 
(De Fea and Roth 1997; Dresner et al. 1999; Ravichandran et al. 2001). 
1.4 The Endocrinology of Adipose Tissue. 
Traditionally, it was considered that the major role of adipose tissue was to merely 
serve as an inert energy storage compartment for triglycerides. However, it is now 
recognised that adipose tissue functions as an active endocrine organ (Ahima and 
Flier 2000; Scherer 2006); integrating and responding to inflammatory, metabolic and 
neuronal stimuli by secreting a vast array of cytokines and hormones (Fruhbeck et al. 
2001; Rajala and Scherer 2003; Faraj et al. 2004), collectively referred to as 
`adipokines'. Such adipose-derived factors include leptin, TNF-a, IL-6, adiponectin, 
resistin and visfatin (Tilg et al. 2006) (Figure 1.4). Several adipokines are capable of 
exerting multiple endocrine and immunological effects; simultaneously influencing a 
variety processes, such as glucose homeostasis, insulin sensitivity, energy 
expenditure, inflammation and lipid metabolism (Fasshauer et al. 2003). 
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Figure 1.4 Adipose tissue secretes multiple factors that can alter lipid metabolism, 
glucose homeostasis and inflammatory processes. IGF-1, Insulin-like growth factor-1; 
IGFBP, IGF-I binding protein; ANG-II, Angiotensin-II; ASP, Acylation-stimulating 
protein; PAI-l, Plasminogen Activator Inhibitor-1; TGF-ß, Transforming Growth 
Factor-ß; FGF, Fibroblast Growth Factor; EGF, Epidermal Growth Factor. 
Whilst under normal physiological conditions, adipokines play an influencial 
regulatory role in glucose metabolism and lipid oxidation. With increased adiposity 
however, these processes can be substantially dysregulated (Mohamed-Ali et al. 1998; 
Shoelson et al. 2006). Such abnormal endocrine behaviour of adipose tissue in states 
of obesity consequently implicates adipokines in obesity-related inflammation, insulin 
resistance and the progression of T2DM. Table 1.4 below describes several 
adipokines in relation to human obesity the pathogenesis of T2DM. 
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Adipokine FUNCTION/ DISTRIBUTION EFFECT OF 
EFFECT OBESITY 
Leptin Satiety and appetite. Secreted by WAT, BAT, T in human obesity and 
Signals to brain to skeletal muscle, stomach correlates with BMI and, 
regulate energy and placenta. after fasting or weight loss. 
homeostasis and Sc (2.5X) > Om AT 
peripheral skeletal (Adipocytes > Pre- 
muscle effects. adi oc es . 
TNF-a Reduces insulin Predominant in adipocytes Correlates with BMI, T in 
secretion and insulin in WAT. human obesity: Obese 2X 
signalling in AT, Sc (1.67X) > Om AT. > Lean. 
pancreatic cells, liver i' in rodent models of 
and muscle. obesity. 
ý adipose differentiation. 
IL-6 Effects glucose and 35% of the basal supply is Tin morbidly obese 
lipid metabolism. derived from WAT. patients. 
Improves insulin Produced by macrophages, j after weight loss. 
sensitivity & glucose fibroblasts, endothelial cells 
tolerance. and skeletal muscle cells. 
PAI-1 Potent inhibitor of Correlation with abdominal 1' in humans to T 
fibrinolytic pathway. adiposity; pattern of adipose thromboembolic 
tissue distribution. complications. 
Angioten- Precursor of ANG-II. mRNA Om AT > Sc AT. i' in humans. 
sinogen Regulates blood Induces differentiation of 
(AGT) supply. re-adi oc es. 
Adiponectin Improves energy Secreted exclusively by .t in mouse models of 
homeostasis, insulin adipocytes. obesity and insulin 
sensitivity and mRNA and protein > in Sc resistance (ob/ob and 
glucose uptake. AT than Om AT. db/db) 
Anti-inflammatory I in human obesity and 
properties. T2DM. 
after weight loss. 
TGF-/J Varied role in Multifunctional, produced 1' ob/ob obese and db/db 
proliferation, by variety of cells. mice. 
differentiation, Inhibitor of differentiation. 1' pre-adipocyte cell 
apoptosis and proliferation, as with T 
development TNF-a. 
PPAR-y Regulates adipose Sc Ad = Om Ad T Sc (2X) WAT > Om 
cell differentiation. (BMI < 28 kg/m2). WAT (BMI < 30 kg/m2). 
Ghrelin implicated in the Secreted by endocrine cells j in morbidly obese 
coordination of in the gastrointestinal tract. subjects. 
energy balance and T circulating levels after 
weight regulation. chronic weight loss in 
humans. 
Adiponutrin Possible contribution Non-secreted adipocyte I mRNA (50-fold) in 
to energy protein. obese fa/fa rats. J, fasting 
homeostasis, Expressed exclusively in mRNA levels. 
vesicular targeting inguinal and epididymal Human gene expression 
and protein transport. WAT and in interscapular may be regulated by 
BAT. changes in energy balance. 
Table 1.4 Summary of factors implicated in the pathogenesis of obesity-related 
T2DM. PAI-1, plasminogen activator inhibitor-1; AGT, angiotensinogen; ANG-II, 
angiotensin-II; mRNA, messenger ribonucleic acid; TGF-ß, transforming growth 
factor-ß; PPAR-y, peroxisome proliferator-activated receptor-y; AT, adipose tissue; 
WAT, white adipose tissue; BAT, brown adipose tissue; Sc AT, Subcutaneous 
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adipose tissue; Om AT, Omental adipose tissue; Sc Ad, subcutaneous adipocytes; Om 
Ad, omental adipocytes; ob/ob, leptin-deficient mouse; db/db leptin receptor-deficient 
mouse; fa/fa, obese Zucker rat (adapted and updated from Frübeck et al. (Fruhbeck et 
al. 2001)). 
This thesis focuses primarily of two adipokines, resistin and adiponectin. Detailed 
descriptions of these two adipokines are therefore given. Resistin is firstly detailed in 
terms of its role in glucose homeostasis and its recently established inflammatory 
functions. Similarly, adiponectin is described in terms of its peripheral effects on 
hepatic insulin sensitisation and, its emerging effects central actions on lipid oxidation 
and energy expenditure. Other adipokines, such as TNF-a, IL-6 and leptin are 
additionally described, albeit to a lesser extent. 
1.4.1 Resistin: The Discovery. 
Resistin, the novel adipocyte-derived polypeptide, was originally isolated and cloned 
by three independent groups, each with different perspectives (Holcomb et al. 2000; 
Kim et al. 2001; Steppan et al. 2001). Holcomb and co-workers initially screened for 
secreted proteins implicated in allergic pulmonary inflammation, subsequently 
identifying the protein `found in inflammatory zone 1' (FIZZ1); as a result, they 
discovered the expression of a sequence-tag related to this protein, which they termed 
`FIZZ3' (Holcomb et al, 2000). Meanwhile, using subtractive screening on 3T3-L1 
adipocytes to identify potential targets of peroxisome proliferator activated receptor-y 
(PPAR-y) agonist treatment, Lazar and colleagues discovered a novel adipocyte- 
specific transcript, induced during adipogenesis and suppressed by thiozolidinedione 
(TZD) treatment (Steppan et al. 2001). This mouse Retn gene encoded a 10 kDa 
secreted protein, which was titled `resistin' (Steppan et al. 2001). Finally, using 
cDNA microarray analysis to identify novel genes induced during 3T3-Ll pre- 
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adipocyte differentiation in rats, Kim et al. identified a 12.5 kDa protein, termed 
`adipocyte-specific secretory factor' (ADSF) (Kim et al. 2001). Due to the potential 
implications resistin had in the pathogenesis of obesity and T2DM, work by Lazar 
and colleagues brought resistin to much scientific attention. 
Initial studies by Steppan et al. (Steppan et al. 2001) demonstrated that resistin is 
expressed almost exclusively in white adipose tissue; furthermore, circulating levels 
of resistin are increased in both high-fat diet-induced and genetic (leptin-deficient, 
ob/ob; leptin receptor-deficient, db/db) models of obesity and insulin resistance. 
Moreover, administration of recombinant resistin has antagonistic effects on glucose 
tolerance and insulin action in wild-type mice (Steppan et al. 2001). 
Immunoneutralisation of resistin in obese mice using anti-resistin IgG antibodies was 
shown to reduce hyperglycaemia and improves insulin sensitivity. Additionally, both 
resistin messenger ribonucleic acid (mRNA) and protein expression was down- 
regulated by the TZD rosiglitazone (RSG) treatment rodent models of obesity and 
diabetes (Steppan et al. 2001). Kim and colleagues further reported that treatment of 
3T3-L1 adipocytes with ADSF impairs adipocyte differentiation (Kim et al. 2001). 
Collectively, these initial observations characterised resistin as a potential molecular 
link between obesity and diabetes. This discovery not only incited much interest in 
the field of resistin, but revealed possibilities of mechanistic action for TZDs and 
their therapeutic applications. 
1.4.1.1 The Structure of Resistin. 
The resistin gene encodes a 114 amino acid polypeptide (Steppan et al. 2001), which 
contains a 20 amino acid signal sequence and comprises of an unique 10 cysteine 
residue repeat motif (CX12CX8CXCX3CXIOCXCXCX9CC) (Kim et al. 2001). 
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Resistin belongs to a family of cysteine-rich C-terminal proteins, known as resistin- 
like molecules (RELMs). These include RELM-a/FIZZ 1, RELM-ß/FIZZ 2 and the 
recently discovered RELM-y (Holcomb et al. 2000; Gerstmayer et al. 2003); all of 
which are characterised by their conserved cysteine motif (Steppan et al. 2001; 
Gerstmayer et al. 2003). Mutagenesis studies further revealed that the N-terminal 
cysteine (Cys) residue, Cys-26, mediates disulfide-dependent dimerisation (Chen et 
al. 2002). 
A significant contribution to the research of resistin was made in 2004 when Patel and 
colleagues used X-ray crystallography to determine resistins' complex multimeric 
structure, as highlighted in Figure 1.4.1.1.1 (Patel et al. 2004). The group established 
that in mice, resistin circulates in two distinct assembly states; the more abundant 
high-molecular-weight (HMW) hexamer and the substantially more bioactive low- 
molecular-weight (LMW) monomeric form (Patel et al. 2004). The monomeric form 
of resistin corresponds to a mutant version (Cys26Ser), unable to form intertrimer 
disulfide bonds and is substantially more bioactive in terms of impairing hepatic 
insulin action in vivo (Patel et al. 2004). 
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Figure 1.4.1.1.1 Ribbon diagram representations of resistin. (A) The monomeric 
form of resistin, consisting of a carboxy-terminal disulfide-rich (3-sandwich `head' 
domain and an amino-terminal a-helical `tail' segment. (B) The a-helical segments 
associate to form three-stranded parallel coiled coils; tail-to-tail disulfide-linked 
trimers form the resistin hexamer. (C) Orientation of highly exposed interchain 
disulfide linkages binding N-terminal regions in the resistin hexamer; suggesting 
possible instability of this hexamer. Structures obtained from (Patel et al. 2004). 
Resistin demonstrates a high degree of structural similarity to RELM-ß; as each are 
covalently linked disulfide-dependent homodimers (Blagoev et al. 2002). In contrast, 
RELM-a, acquires a covalently linked monomeric form, as it lacks the critical 
cysteine residue (Cys-26) necessary for dimerisation (Banerjee et al. 2001). 
Furthermore, the RELM family members have five cysteine residues featured in the 
globular head domains that are topologically conserved amongst species (Patel et al. 
2004). Recently, Gerber et al. detected the presence of several HMW isoforms of 
resistin in human serum (Gerber et al. 2005). Using size-exclusion chromatography, 
major peaks of 660 and 55 kDa were detected (Figure 1.4.1.1.2); this implied 
oligomerisation of resistin (Gerber et al. 2005) or aggregation with other RELM 
members (Chen et al. 2002). 
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Figure 1.4.1.1.2 Recombinant resistin (A) and pools of human serum (B) were 
fractionated by size exclusion chromatography. Both figures demonstrate the 
presence of several HMW isoforms of resistin in human serum (Gerber et al. 2005). 
Major peaks were detected at approximately 660 and 55 kDa, therefore indicating the 
formation of multimeric structures of resistin. 
Graveleau et al. further reported that oligomerisation of human and mouse resistin is 
required to impair insulin-stimulated glucose uptake in mouse cardiornyocytes 
(Graveleau et al. 2005); additionally providing the first evidence that human resistin 
has properties similar to those of murine resistin. The study further highlighted key 
fundamental differences between liver and muscle in the response to monomeric and 
HMW hexameric resistin (Graveleau et al. 2005). In contrast to the monomeric form 
of resistin exerting potent effects in the liver (Patel et al. 2004), the biological actions 
of resistin in cardiac muscle cells required oligomerisation. The HMW form of 
resistin may therefore undergo processing in the liver to generate the monomeric form 
(Graveleau et al. 2005). Different resistin oligomers may therefore exhibit different 
bioactivities in muscle and liver tissues (Fruebis et al. 2001; Pajvani et al. 2003; Tsao 
et al. 2003), especially in models of obesity and insulin resistance. 
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1.4.1.2 Tissue Distribution of Resistin & Other RELM Family Members. 
Each RELM family member has an unique differential tissue distribution (Holcomb 
et al. 2000; Steppan et al. 2001; Gerstmayer et al. 2003). Resistin expression was first 
characterised in adipose tissue (Steppan et al. 2001). RELM-ß is localised within 
proliferating cells of the colonic epithelium (Steppan et al. 2001). Whilst absent from 
adipose tissue, RELM-ß is readily detectable in plasma (Rajala et al. 2003). RELM-a 
on the other hand, is expressed in stromal-vascular constituents of WAT, heart, 
tongue (Steppan et al. 2001; Rajala et al. 2002) and pulmonary inflammatory zones in 
rodents (Holcomb et al. 2000), whilst absent in humans. Gerstmayer et al. recently 
identified an additional RELM family member, RELM-y, which demonstrates a high 
degree of homology to RELM-a (Gerstmayer et al. 2003). Gene expression of 
RELM-y is located predominantly in haematopoietic tissues (Gerstmayer et al. 2003). 
Table 1.4.1.2 details the current knowledge of the distribution of resistin, RELM-a, ß 
and y in human and rodent tissues. 
Resistin RELMß RELMa RELMy 
Rodent Human Rodent Human Rodent Rodent 
Tissue R PR P RPRP RP RP 
WAT X XX X X x 
Pre-adipocytes x X X 
Adipocytes x Xx x 
PBMCs x x 
Hypothalamus x x 
Pituitary gland x 
Adrenal gland x x 
Spleen x x x 
Skeletal muscle x x x 
Pancreas x x x 
Placenta x x 
GI-tract x x xxx x x 
Lung x x XX X 
Table 1.4.1.2 The distribution of niRNA and protein expression levels of resistin and 
RELM-ß in rodents and humans and, RELM-a and RELM-y in rodents. RELM, 
resistin-like molecule; R, mRNA expression; P, protein expression; WAT, white 
adipose tissue; PBMCs, peripheral blood mononuclear cells; GI, Gastrointestinal. 
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In rodents, resistin is expressed primarily in adipocytes (Steppan et al. 2001). Unlike 
the mouse gene, the human homologue of resistin is expressed at low levels in human 
adipocytes (Nagaev et al. 2001). There is controversy as to whether or not human 
resistin is secreted primarily from adipocytes, pre-adipocytes, or macrophages 
(Savage et al. 2001; Janke et al. 2002; Fain et al. 2003; Kaser et al. 2003; McTernan 
et al. 2003; Patel et al. 2003). It has however, been recognised that adipose tissue 
overproduction is responsible for increased systemic levels of resistin. Several studies 
have reported that macrophages are the predominant source of systemic resistin in 
humans (Kaser et al. 2003; Patel et al. 2003). Adipocytes and pre-adipocytes may 
also contribute to the circulating levels of resistin in humans, which may become 
increasingly relevant in states of increased adipose tissue mass. Finally, although 
recent evidence highlights the similarity in function of mouse and human resistin 
homologues (Graveleau et al. 2005); there are still significant quantitative differences 
of resistin expression between the species. Whilst a difference in resistin mRNA 
levels between adipocytes and macrophages is apparent (Janke et al. 2002; Fain et al. 
2003; Patel et al. 2003), further studies will need to fully substantiate whether this 
difference is observed at protein level. 
1.4.1.3 Homology of Human & Rodent Resistin. 
Whilst four genes for the family of RELMs have been identified in mice (Retn, 
Retnla, Retnlß and Retnly encoding four distinct proteins (resistin/FIZZ3/ADSF, 
RELM-a/FIZZ1, RELM-f3/FIZZ2 and RELM-y), only two homologues have been 
identified in the complete human genome (Steppan et al. 2001; Gerstmayer et al. 
2003). Additionally, an alternatively spliced variant of the Retn gene was identified in 
humans (Resistin delta2) (Nohira et al. 2004), whilst another in rats, termed `S- 
Resistin' (short resistin) (Del Arco et al. 2003). 
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The human REIN gene is located on chromosome 19 in a region syntenic to the 
mouse Retn gene on chromosome 8. One group proposed that orthology exists 
between human and mouse genes (Steppan et al. 2004), whereas another questioned 
the relevance of resistin, due to the absence of a true homologue for the murine Retn 
gene in humans (Ghosh et al. 2003). Contrasting opinions regarding the orthology 
may relate to how the genomic, transcribed and translated sequence identities are 
viewed. At the mRNA level, mouse and human resistin display 64.4% sequence 
homology, whereas at the genomic level, mouse resistin shares 46.7% sequence 
identity with the human resistin (Ghosh et al. 2003). Notably, the mouse genomic 
sequence is approximately three times bigger than human resistin (Ghosh et al. 2003). 
Furthermore, whilst the same numbers of introns are present in the coding regions, 
the human sequence lacks a 3'extreme intron (Ghosh et al. 2003). This intron, termed 
`intron X' has been proposed to contribute to TZD-dependent regulation of mouse 
resistin, as it contains PPAR-y response elements (PPREs) (Ghosh et al. 2003). 
At protein level, human resistin encodes a 108 amino acid polypeptide and is 55% 
identical to its murine counterpart, as demonstrated in Figure 1.4.1.3. Interestingly, 
the highest degree of protein sequence homology to human resistin sequence is 
observed between porcine and bovine resistin (76% and 73% respectively). The 
moderate amino acid sequence homology between mouse and human resistin may 
explain the diverse expressional and regulatory patterns of this protein, or simply 
suggest that, murine biology may only moderately relate to humans, and, resistin may 
not be evolutionary well conserved across species. 
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Figure 1.4.1.3 Amino-acid sequence identities of human (h), rodent (r), porcine (p), 
bovine (b) resistin, other RELM family members and the recently identified human 
alternatively spliced variant of resistin, resistin delta2. Percentage sequence identities 
were obtained from the EMBL-EBI (European Bioinformatics Institute) server 
(http: //www. ebi. ac. uk). The different colours represent the different RELM family 
members. 
1.4.1.4 The Metabolic Functions of Resistin in Obesity. 
1.4.1.4.1 Initial Observations. 
Resistin was initially linked to obesity-mediated insulin resistance based on the 
observation that serum and plasma levels of resistin were elevated in diet-induced and 
genetic (ob/ob and db/dh) murine models of obesity and diabetes (Steppan et al. 
2001). Comparative increases were further observed between resistin and BMI in 
Fischer 344 rats (Levy et al. 2002). These rodent studies were subsequently 
reinforced by human analysis showing increased resistin expression in adipose tissue 
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(Savage et al. 2001), particularly abdominal depots (McTernan et al. 2002; McTernan 
et al. 2002). Positive associations between human serum resistin and body-fat content 
were further reported (Zhang et al. 2002). On the contrary, several studies failed to 
demonstrate such correlations in rodents, reporting either reduced (Le Lay et al. 2001; 
Way et al. 2001; Fukui and Motojima 2002; Rajala et al. 2002; Steppan and Lazar 
2002) or no alteration in resistin expression in various genetic and diet-induced 
murine models of obesity (ob/ob, db/db) (Makimura et al. 2002). The following 
sections will thus review cases for and against the role for resistin as an important 
pathogenic factor in obesity, insulin resistance and T2DM in light of recent studies. 
1.4.1.4.2 Recent Observations Supporting a Role of Resistin in Obesity. 
Studies by Lee et al. showed that various murine models of obesity had higher 
circulating resistin levels compared to their lean counterparts (Lee et al. 2004). 
Recently, Asensio et al. determined that high-fat fed mice had enhanced adipocyte 
differentiation, as denoted by fatty acid binding protein (ap2) gene expression, a 
surrogate marker of differentiation; this induction further positively correlated with 
resistin gene expression (Asensio et al. 2004). Subsequently, in view of this and 
previous studies (Haugen et al. 2001; Kim et al. 2001), it was suggested that elevated 
resistin expression was a result of adipocyte differentiation (Asensio et al. 2004). 
Moreover, the increase in adipocyte number may have caused a rise in local resistin 
production, inhibiting insulin-action on glucose-uptake in adipose tissue and thus 
preventing further adipocyte differentiation (Asensio et al. 2004). Therefore, at least 
in rodents, a feedback regulatory mechanism for resistin in adipogenesis may occur, 
acting as an adipose sensor for nutritional status. In accordance with these 
observations, Kim et al. generated transgenic mice over-expressing a dominant 
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inhibitory form of resistin that functioned to block the inhibition of resistin mediated 
adipocyte differentiation (Kim et al. 2004). These transgenic mice developed obesity, 
possibly owing to enhanced adipocyte differentiation and adipocyte hypertrophy, 
indicated by increased circulating levels of adiponectin and leptin (Kim et al. 2004). 
Recent investigations of human resistin in relation to obesity reported higher serum 
resistin levels in obese subjects in comparison to lean subjects (Degawa-Yamauchi et 
al. 2003; Schaffler et al. 2004; Vendrell et al. 2004), which positively correlate with 
the changes in BMI and visceral fat area (Azuma et al. 2003; Degawa-Yamauchi et 
al. 2003; Yannakoulia et al. 2003; Vozarova de Courten et al. 2004). The implication 
that resistin is important in human adipose tissue has been corroborated by studies 
showing increased protein expression with obesity (Degawa-Yamauchi et al. 2003) 
and protein secretion from isolated adipocytes (McTernan et al. 2003). A further 
study has shown a significant reduction in circulating resistin levels following 
moderate weight loss (Valsamakis et al. 2004) and post gastric bypass surgery in 
morbidly obese patients (Vendrell et al. 2004). Collectively, these observations 
suggest resistin may be subjected to nutritional regulation in humans. 
1.4.1.4.3 Observations that Argue Against a Major Role for Resistin in Obesity. 
Contrary to the studies suggesting a role for resistin in obesity, Maebuchi et al. 
reported resistin was undetectable in serum of obese mice (Maebuchi et al. 2003), 
with the same study indicating reductions of resistin mRNA and protein expression in 
obese db/db and high-fat fed mice. Similarly, two other groups independently 
revealed that resistin gene and protein expression levels showed a lack of 
concordance with increased adiposity in ob/ob mice (Asensio et al. 2004; Rajala et al. 
2004). However, it has been suggested that resistin mRNA expression does not 
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necessarily correlate with protein expression (Rajala et al. 2004). Recent human 
studies have also demonstrated no correlation of serum (Lee et al. 2003) or plasma 
resistin concentrations with any markers of adiposity (Silha et al. 2003). Heilbronn et 
al. further reported no relationship between circulating resistin levels and percentage 
body-fat, visceral adiposity or BMI (Heilbronn et al. 2004). However, the authors 
further suggested the lack of correlation of serum resistin with increased adiposity 
was possibly due to the confounding variable of age; as non-obese subjects were 
significantly younger than obese subjects (Heilbronn et al. 2004). 
Although there is some degree of controversy surrounding resistin, it is worth 
highlighting the importance of developing highly accurate methods of determining 
serum resistin concentrations. With reference to the use of commercially available 
ELISAs, both rodent and human ELISAs may have the potential to cross-react with 
circulating RELMs. Furthermore, due to recent advances in the understanding of the 
tertiary and quaternary structure of resistin (Patel et al. 2004), further studies are 
required to establish whether the complex distribution of the individual structural 
forms of resistin affect the validity of the currently available human and rodent 
assays. This may thus require development of a human and mouse assay specific to 
the individual structural forms of resistin to understand the complex distribution of 
circulating levels of this protein and subsequently its biological functions. 
1.4.1.5 The Metabolic Functions of Resistin in Insulin Resistance & T2DM. 
It has been established that central obesity is a contributory factor to the pathogenesis 
of insulin resistance and T2DM. Although it is apparent that inconsistencies remain in 
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the data for a role of resistin in obesity, there is a growing body of evidence 
suggesting a role for resistin in the aetiology of insulin resistance and T2DM. 
1.4.1.5.1 The Regulation of Resistin in Models of Insulin Resistance & Glucose 
Intolerance. 
Initital rodent studies demonstrated that reduced serum resistin levels are associated 
with improved insulin sensitivity (Hirosumi et al. 2002). Furthermore, resistin mRNA 
and protein levels are elevated in high-fat fed rats exhibiting insulin resistance (Chen 
et al. 2003). Rajala et al. further reported that circulating resistin levels are 
significantly elevated and positively concordant with rising levels of insulin, glucose, 
and lipids in ob/ob mice (Rajala et al. 2004). This study also highlighted the potential 
interplay between resistin and leptin, with leptin suppressing resistin mRNA and 
protein levels (Rajala et al. 2004). Similarly, Asensio et al. highlighted that leptin 
administration to ob/ob mice improves insulin sensitivity, concomitant with a 
decrease in resistin expression (Asensio et al. 2004). Collectively, these studies 
suggest leptin may exert insulin resistance-ameliorating effects via counter-regulatory 
interactions and further, exert potential suppressive mechanisms towards resistin. In 
contrast, Lee and co-workers reported that neither transcriptional regulation of 
resistin nor circulating resistin levels correlated with serum insulin or glucose levels 
(Lee et al. 2004). Subsequent studies have reported that resistin expression was either 
suppressed in rat models of insulin resistance (Juan et al. 2001) or unchanged 
following adrenalectomy of ob/ob mice (Makimura et al. 2002). 
In evaluating resistin and its association with insulin sensitivity in humans, several 
studies have identified positive correlations between resistin levels and insulin 
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resistance in obese subjects in vivo (Silha et al. 2003) and in vitro (Smith et al. 2003). 
Serum resistin levels are increased by -20% in T2DM subjects (McTernan et al. 
2003); such findings were re-affirmed by Fujinami et al. (Fujinami et al. 2004). In 
contrast, several studies have reported no associations between serum resistin levels 
and markers of insulin resistance in T2DM patients (Lee et al. 2003; Pfutzner et al. 
2003; Stejskal et al. 2003). Moreover, serum and plasma resistin levels were either 
reduced in T2DM patients, or increased with no significant correlation with HOMA- 
IR, waist circumference, BMI or total cholesterol (Yang et al. 2003; Youn et al. 
2004). Consequently, these studies suggest resistin may be unlikely to play a key 
endocrine role in insulin resistance or energy homeostasis in humans. Nevertheless, a 
paracrine or autocrine manner of resistin to moderately affecting metabolism cannot 
be ruled out. 
1.4.1.5.2 The Effects of Resistin on Glucose Homeostasis. 
Rodent studies highlight that the major target of resistin action in vivo is the liver, 
causing hepatic insulin resistance (Rajala et al. 2003; Banerjee et al. 2004; Muse et 
al. 2004; Rangwala et al. 2004), with secondary peripheral effects on skeletal muscle 
and adipose tissue (Pravenec et al. 2003; Satoh et al. 2004). Steppan et al. initially 
demonstrated that administration of recombinant resistin to mice impairs glucose 
homeostasis and insulin action (Steppan et al. 2001). Alternatively, transgenic 
overexpression of resistin was shown to impair insulin-mediated glucose transport, 
reducing intrinsic activity of cell-surface glucose transporters (GLUTs) (Moon et al. 
2003). Euglycemic-hyperinsulinemic pancreatic clamp studies demonstrated that 
infusion of either resistin or RELM-ß into rats decreases hepatic insulin sensitivity 
(Rajala et al. 2003), by impairing insulin-mediated suppression of hepatic 
gluconeogenesis (Rajala et al. 2003). In contrast, resistin null mice exhibit low blood 
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glucose levels, due to reduced hepatic glucose production (Banerjee et al. 2004). 
Such a glucose-lowering effect was shown to be mediated by an increase in activation 
of hepatic AMP-activated protein kinase (AMPK) (Banerjee et al. 2004), thus 
reducing expression of key gluconeogenic enzymes, G6Pase and PEPCK (Banerjee et 
al. 2004). Furthermore, treatment of resistin to these knock-out mice enhanced 
hepatic glucose production and increased glucose levels by -25% (Banerjee et al. 
2004). Similarly, high-fat feeding or transgenic overexpression of resistin was shown 
to enhance glucose levels and hepatic insulin resistance, due to increased levels of 
PEPCK and G6-Pase (Rangwala et al. 2004); treatment of these mice with resistin 
anti-sense oligonucleotides however, reversed hepatic insulin resistance (Muse et al. 
2004). Similar metabolic defects have been observed in peripheral tissues; transgenic 
over-expression of resistin and adenovirus-mediated hyper-resistinemia in rats 
impaired insulin-stimulated glucose utilisation and dyslipidemia (Pravenec et al. 
2003; Satoh et al. 2004). Additionally, resistin was shown to decrease lipid 
metabolism in skeletal muscle, by targeting AMPK (Palanivel et al. 2005). Resistin 
may therefore induce hepatic insulin resistance by direct action on the liver or, by 
altering the effects of skeletal muscle on lipid homeostasis. 
Whereas rodent studies demonstrate pro-diabetogenic properties for resistin in 
glucose metabolism, human studies are somewhat inconsistent; describing the lack of 
association of resistin with insulin resistance in various diseased states. Although 
circulating levels of resistin are higher in T2DM patients than in normal glucose- 
tolerant patients (Zhang et al. 2003), studies in Pima Indians report that serum resistin 
levels are not associated with glucose or insulin levels (Vozarova de Courten et al. 
2004). However, the first assessment of serum resistin and insulin sensitivity in 
human subjects using the insulin-clamp technique revealed that resistin levels are 
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inversely correlated with glucose-disposal rates (Heilbronn et al. 2004). Furthermore, 
HIV-positive patients with insulin resistance have hyper-resistinemia; resistin levels 
were shown to decrease in concordance with insulin-stimulated glucose-disposal, 
following RSG treatment (Kamin et al. 2005). 
In vitro analysis of resistin revealed that treatment of human differentiated pre- 
adipocytes with recombinant resistin moderately effects glucose-uptake (McTernan et 
al. 2003). Furthermore, resistin impairs insulin signalling in 3T3-L1 adipocytes, by 
inhibiting factors in the insulin signalling cascade and further, up-regulating 
suppressor of cytokine signalling-3 (SOCS-3) (Steppan et al. 2005), a known 
inhibitor of insulin signalling (Steppan et al. 2005). The underlying mechanisms by 
which resistin operates in the insulin signalling cascade in humans are however, not 
fully established. 
1.4.1.5.3 Regulation of Resistin by Insulin Sensitisers. 
Several studies have reported the downregulation of resistin following RSG, 
darglitazone (Haugen et al. 2001) and troglitazone (Shojima et al. 2002) treatment in 
WAT of db/db mice, diabetic fatty rats (Moore et al. 2001; Steppan et al. 2001) and 
3T3-L1 adipocytes (Haugen et al. 2001). Conversely, other studies report that 
pioglitazone (Way et al. 2001), troglitazone (Fukui et al. 2002) and metformin (Fujita 
et al. 2002) increase resistin expression levels. Similarly, treatment of monocytes 
with PPAR-y agonists failed to have any effect on resistin (Savage et al. 2001). These 
initial observations suggest downregulation of resistin may not be crucial for the 
antidiabetic effect of TZDs in all model systems. However, recent in vitro analysis 
revealed that RSG reduced resistin secretion from human isolated adipocytes 
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(McTernan et al. 2003) and resistin expression in human macrophages (Patel et al. 
2003; Lehrke et al. 2004). Whether the downregulation of resistin expression by RSG 
occurs via a PPAR-y-mediated transcriptional mechanism is yet to be determined. 
However, five putative PPREs in the resistin gene have been identified (Patel et al. 
2003). One such response element, PPAR-y response element-2 (PPRE2), was shown 
to bind PPAR-y (Patel et al. 2003). RSG has also demonstrated anti-inflammatory 
effects in human macrophages (Ricote et al. 1998); reducing inflammatory cytokine 
production, which may consequently affect resistin production (Hong et al. 2003). 
Collectively, these human studies indicate that suppression of resistin expression may 
contribute to the insulin sensitising and glucose-lowering actions of the TZDs. 
Furthermore, the potential anti-inflammatory effects of TZDs on adipocytokine 
mediation maybe of equal importance in the prevention of T2DM. 
1.4.1.5.4 Hormone and Cytokine Modulators of Resistin Expression. 
Various hormones and cytokines associated with insulin resistance and diabetes have 
been investigated in concordance with resistin. Such studies are thus detailed below 
in Table 1.4.1.5.4. 
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Hormone/Cytokine Effect on Resistin 
Pituitary hormones Growth hormone (1 mg/kg/day) I resistin gene expression (720-950%) in 
WAT of spontaneous dwarf rats. 
T gene expression levels in response to hyperprolactinemia in mice. 
j mRNA and protein expression (30-50%) in 3T3-L1 adipocytes. 
Steroid hormones Dexamethasone T mRNA and protein levels (2.5 to 3.5-fold) in 3T3-L1 
adi oc es and - 70% mouse WAT. 
Sex hormones j in mice with elevated androgen levels. 
T by hyperprolactinemia and testosterone. 
Administration of dehydroepiandrosterone I gene expression in WAT of 
male Wistar rats. 
Oestrogen j adipose gene expression in ovariectomized rats and in 
isolated rat adipocytes. 
Testosterone j adipose tissue mRNA levels in male rats. 
Thyroid hormone Severely expression in hyperthyroid rats. 
Somatotrophin Moderate inhibitory effects on resistin mRNA and protein (30-50%) levels 
in 3T3-L1 adipocytes. 
Epinephrine j mRNA and protein levels by 30-50% in 3T3-L1 adipocytes. 
Neuropeptide Y (NPY) Intraceberoventricular administration of NPY T gene expression in mice 
WAT. 
p3-Adrenoreceptors p3-agonist isoproterenol j gene expression levels by 20% in 3T3-Ll 
adipocytes; reversible by the p3-antagonist propranolol. 
Endothelin-I 100 nM significantly j basal resistin secretion by 59%. 
Insulin j gene expression (-50%) in 3T3-L1 adipocytes. 
T secretion from 3T3-L1 adipocytes. 
T mRNA synthesis (23-fold) in streptozotocin-diabetic mice or Zucker 
diabetic fatty rats. 
Gene expression and protein concentration j in fasted mice. 
T resistin protein secretion in a concentration-dependent manner in human 
subcutaneous adi oc es. 
Table 1.4.1.5.4 The effects of hormones and cytokines on the level of resistin 
expression and secretion. WAT, white adipose tissue; NPY, neuropeptide Y; mRNA, 
messenger ribonucleic acid. 
1.4.1.5.5 Gender & Resistin Regulation. 
In both white and brown adipose tissues, resistin mRNA expression is higher in male 
than female rats (Nogueiras et al. 2003; Nogueiras et al. 2003); albeit contrasting a 
another study whereby resistin mRNA levels were significantly higher in female than 
male mice (Gui et al. 2004). In humans, several studies reported that resistin 
concentrations are significantly higher in female subjects in comparison to male 
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subjects (Lee et al. 2003; Silha et al. 2003; Yannakoulia et al. 2003). Gender-related 
differences on the level of resistin expression in rodents and humans therefore, 
remain to be fully determined. 
1.4.1.6 Resistin & Inflammation. 
Initial in vitro investigations into the role of resistin in relation to inflammatory 
processes revealed that the bacterial endotoxin, lipopolysaccharide (LPS), in addition 
to IL-1, TNF-a and IL-6 upregulated resistin gene expression in 3T3-L1 adipocytes 
(Lu et al. 2002) and human peripheral blood mononuclear cells (PBMCs) (Kaser et 
al. 2003); this was however, attenuated by aspirin and RSG (Lehrke et al. 2004). 
Subsequent clinical data revealed that resistin correlates with IL-6 and intercellular 
adhesion molecule-1 in obese patients with obstructive sleep apnoea syndrome 
(Harsch et al. 2004). Similarly, resistin was shown to correlate with the leptin, soluble 
TNF-receptor 2 (sTNF-R2) and C-reactive protein (CRP) in patients with severe 
inflammatory diseases, obesity and T2DM (McTernan et al. 2003; Stejskal et al. 
2003; Vendrell et al. 2004). Resistin gene expression has been demonstrated to be 
high in PBMCs (Kaser et al. 2003; Lehrke et al. 2004). 
Recent studies have further provided evidence of the potential immuno-modulatory 
functions of resistin. Silswal et al. recently documented that human resistin stimulates 
the secretion of pro-inflammatory cytokines, TNF-a and IL-12 in macrophages via a 
nuclear factor-KB (NF-KB)-dependent pathway (Silswal et al. 2005). Similarly, the 
potent pro-inflammatory nature of resistin was further evident in a study showing an 
association between resistin and inflammation in rheumatoid arthritis (Bokarewa et 
al. 2005). The group further reported that resistin may be an important regulatory 
cytokine, triggering the release of other pro-inflammatory cytokines, such as TNF-a, 
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IL-I P and IL-6; these pro-inflammatory effects of resistin were shown to be mediated 
through the NF-xB signalling pathway (Bokarewa et al. 2005). 
New questions are therefore being asked regarding the functional role of resistin; can 
resistin act in concordance with inflammatory molecules? If so, deducing whether 
resistin has mechanistic action within inflammatory pathways may prove beneficial. 
This may further subsequently lead us to ask the question, does resistin have the 
potential to be a therapeutic target? 
1.4.1.7 Human Genetics of Resistin. 
Obesity is not the only contributory factor of insulin resistance, often defects in key 
genes that dictate glucose homeostasis can also contribute to the development of 
insulin resistance. As such, relationships between single nucleotide polymorphisms 
(SNPs) and insulin resistance may reflect such associations. Several SNPs have been 
identified in the REIN gene; however, . only few have minor allele frequencies over 
5% and are associated with disease risk (Engert et al. 2002; Mattevi et al. 2004; 
Osawa et al. 2004). In a study of non-diabetic French Canadians in Quebec, two 
REIN 5'-flanking SNPs (-537 and -420) were associated with increased BMI (Engert 
et al. 2002). Furthermore, a resistin genotype at nucleotide +299 (IVS2 + 181G-), A) 
and obesity was a significant determinant of T2DM risk among type 2 diabetic 
Caucasians in Boston, Mass., USA (Ma et al. 2002). Additionally, the -420 C>G 
SNP (-180 relative to putative transcription start site) was associated with higher 
resistin mRNA levels in abdominal fat of obese subjects (Smith et al. 2003). 
Conversely, Mattevi et al. showed an association between the -420 C>G 
polymorphism with lower BMI, in non-diabetic individuals from a Brazilian 
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population of European descent (Mattevi et al. 2004). Whilst amongst non-diabetic 
Caucasians in Sicily and Gargano, Italy, an ATG triplet repeat in the 3'-untranslated 
region of the resistin gene was associated with a decreased risk of insulin resistance 
(Pizzuti et al. 2002). 
Genetic analysis of resistin using a Japanese population demonstrated that a -420G/G 
genotype was associated with human T2DM and could accelerate the onset of disease 
by 4.9 years (Osawa et al. 2004), moreover, the genotype itself was a primary variant 
determining T2DM susceptibility (Osawa et al. 2004). Consistent with these findings, 
elevated levels of serum resistin were reported in T2DM subjects carrying the - 
420G/G genotype (Azuma et al. 2004). In contrast, studies in a Japanese obese 
population reported the -638G>A, -420C>G, and -358G>A SNPs, which whilst 
associated with serum resistin, did not confer any association with obesity or insulin 
resistance (Osawa et al. 2002; Ochi et al. 2003). These genetic studies highlight the 
discrepancies amongst resistin SNP analysis examining the association with obesity 
related insulin resistance; these may partly be explained by different genetic 
backgrounds or environmental conditions of the populations studied. 
1.4.2 Adiponectin: Structure & Function. 
Adiponectin, in its most basic form, is a 30 kDa protein secreted exclusively from 
adipocytes (Scherer et al. 1995). In comparison to other adipokines, adiponectin is 
extrememly abundant in circulation, with levels reaching up to 30 µg/ml in healthy 
subjects (Matsubara et al. 2002). Adiponectin was identified and isolated during 
comparative analysis of mRNAs from a differentiating a 3T3-L1 adipocyte cell-line 
(Scherer et al. 1995). Structural analysis revealed that adiponectin consists of an 
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amino-terminal signal sequence, a variable region, a collagenous-tail domain and a C- 
terminal globular head domain (Pajvani et al. 2003) (Figure 1.4.2.1). 
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Figure 1.4.2.1 Diagrammatic representation of adiponectin, highlighting the structural 
domains. The residue cysteine (Cys) 39 is critical to HMW formation, whereas 
cysteine 155 is maintains the integrity of the HMW species of adiponectin (Scherer et 
al. 1995). 
The globular domain of adiponectin shares homology with collagens Viii and X, 
complement factor Clq and, the hibination protein hib27 (Tsao et at. 2002; Pajvani et 
al. 2003). The 3D crystalline structure of the globular head unit shares striking 
homology with TNF-a (Matsubara et al. 2002); suggesting an evolutionary link 
between the function of these proteins. Intermolecular bonding between globular head 
domains causes the formation of a tightly bound trimer (Figure 1.4.2.2), the smallest 
unit of this protein observed in circulation. 
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Figure 1.4.2.2 3D crystalline structure of the globular head domain of adiponectin. 
Diagram demonstrates three single units bound in a trimeric formation (Shapiro et al. 
1998). 
Adiponectin trimers associate through disulphide bonds within the collagenous 
domains of single monomers to form `bouquet-like' higher-order structures (Pajvani 
et al. 2003). Such higher-order structures include LMW hexamers of 180 kDa and, 
HMW structures, consisting of up to 18 units of the protein (Figure 1.4.2.3), 
approximately >500 kDa in size and, by far the most prominent form of adipnectin in 
serum (Trujillo et al. 2005). Oligomerisation of adiponectin depends on disulphide- 
formation, mediated by the residue cysteine at position 39 (Figure 1.4.2.1); as 
demonstrated by the failure to produce HMW species when this residue is mutated 
(Pajvani et al. 2003). Furthermore, bonding between cysteine residues at position 155 
is critical to the integrity of the HMW structures (Pajvani et al. 2003; Waki et al. 
2003). 
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Figure 1.4.2.3 Model of assembly of adiponectin. Three monomers of adiponectin 
form a trimer (30 kDa) through the globular domains. Trimers then associate through 
interactions within the collagneous domain to form low-molecular-weight (LMW) 
hexamers (180 kDa) and high-molecular-weight (HMW) subunits (>500 kDa) 
(Pajvani et al. 2003). 
Adiponectin mRNA and serum levels are lower in obese subjects in comparison to 
lean subjects (Arita et al. 1999) and, are linked to decreased insulin sensitivity and 
reduced thrombogenic risk. Furthermore, weight reduction in morbidly obese patients 
results in a dramatic increase in plasma adiponectin levels, following by substantial 
improvement in whole-body insulin sensitivity (Yang et al. 2001). Similarly, 
circulating adiponectin levels are significantly lower in patients with T2DM, with a 
further reduction associated in subjects with coronary artery disease (Hotta et al. 
2000; Hirose et al. 2002; Lihn et al. 2003). Interestingly, low adiponectin serum 
levels have been shown to independently predict the future risk of developing T2DM 
(Lindsay et al. 2002). Such a protective role of adiponectin was further highlighted in 
a study on rhesus monkeys, in which adiponectin levels decreased with the onset of 
obesity in primates, prior to the development of insulin resistance (Hotta et al. 2001). 
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Adiponectin also exhibits sexual dimorphism with respect to circulating levels and 
percentage of HMW species rather than total adiponectin levels; both are significant 
higher in female subjects when compared with male subjects (Cnop et al. 2003; 
Combs et al. 2003; Pajvani et al. 2004). 
TZDs are insulin-sensitising drugs that ameliorate insulin resistance and lower plasma 
glucose levels (Vasudevan et al. 2004). Administration of TZDs results in marked 
increases in adiponectin expression and secretion in non-diabetic and insulin-resistant 
humans and rodents (Berg et al. 2001; Combs et al. 2002; Yu et al. 2002; Phillips et 
al. 2003; Ye et al. 2003). As adiponectin levels are associated with improved insulin 
sensitivity in TZD-treated subjects, adiponectin may therefore be partially responsible 
for such an improvement in health (Phillips et al. 2003). 
Genetic studies that have reported mutations in the proximal promoter regions of the 
adiponectin gene that are associated with the development of T2DM (Vasseur et al. 
2002; Gu et al. 2004). Similarly, several SNPs identified in the adiponectin locus are 
associated with many of the complications linked with insulin resistance (Menzaghi et 
al. 2002; Hu et al. 2004). Furthermore, the human adiponectin gene has been mapped 
to genomic locus 3q27; a region previously linked to the susceptibility of T2DM and 
the metabolic syndrome (Kissebah et al. 2000). 
1.4.2.1 Adiponectin Bioactivity: Adiponectin Oligomers in Hepatic Glucose 
Metabolism & Skeletal Muscle Lipid Oxidation. 
The production of recombinant adiponectin in both mammalian and bacterial 
expression systems has allowed detailed studies concerning the effects of adiponectin 
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on in vivo and in vitro systems. Several laboratories have generated bacterially 
produced full-length adiponectin (Berg et al. 2001) or a proteolytic cleavage product, 
encapsulating only the `globular head' domain of adiponectin (Fruebis et al. 2001; 
Yamauchi et al. 2001); the latter was initially recognised as the functionally active 
portion of adiponectin. Treatment of mice with the globular adiponectin was shown to 
reduce the postprandial rise in glucose, triglycerides and NEFAs (Fruebis et al. 2001; 
Yamauchi et al. 2001). Further in vitro analysis revealed that such metabolic 
improvements were attributable to globular adiponectin increasing the clearance of 
NEFAs in skeletal muscle, by enhancing ß-oxidation (Fruebis et al. 2001). Another 
group generated a recombinant mutant form of adiponectin (Cys-39), whereby the 
Cys-39 residue crucial for adiponectin oligomerisation was substituted with a serine 
residue, thus generating only the trimeric form of adiponectin (Pajvani et al. 2003). 
This Cys-39 mutant trimeric form of adiponectin demonstrated a high level of 
bioactivity (Pajvani et al. 2003). 
Conversely, diabetic mice injected with full-length recombinant adiponectin exhibit 
low circulating levels of glucose (Berg et al. 2001); suggesting that the native full- 
length adiponectin acts primarily on the liver, to reduce glucose output (Berg et al. 
2001). Interestingly, full-length adiponectin was also shown to inhibit both the 
expression of hepatic gluconeogenic enzymes and, the rate of endogenous glucose 
production (Combs et al. 2001). In vitro analysis of full-length adiponectin action on 
isolated hepatocytes further revealed that glycosylation and hydroxylation of the 
collagenous domain was critical to its bioactivity (Wang et al. 2002). Understanding 
of the bioactivity of this molecule and its mode of action was further achieved by 
examination of the function of both the globular head domain and full-length 
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adiponectin in hepatocytes and myocytes (Yamauchi et al. 2002). This study focused 
on the effect of both forms of adiponectin on 5'-AMPK to elucidate whether this 
enzyme featured downstream of adiponectin signalling. In the study, globular 
adiponectin was shown to enhance AMPK activity in myocytes, whereas full length 
adiponectin stimulated AMPK in the liver. Interestingly, the globular head domain 
was identified to bind to muscle membranes with a higher binding affinity than full- 
length adiponectin (Yamauchi et al. 2002). Although initial studies highlight different 
functions for full-length adiponectin and globular adiponectin, more recent studies 
have demonstrated an overlap in peripheral and hepatic functions of full-length 
adiponectin (Waki et al. 2003; Tonelli et al. 2004; Wang et al. 2005), as highlighted 
in Figure 1.4.2.1 below. 
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Figure 1.4.2.1 Illustration of target tissues of full-length adiponectin and the two 
trimeric forms of adiponectin; the Cys-39 mutant and the globular head domain. Full- 
length adiponectin can exert both effect both hepatic and peripheral skeletal muscle 
metabolism, whereas the trimeric forms of adiponectin affect only peripheral skeletal 
muscle tissue. HMW, high-molecular-weight; AMPK, AMP-activated protein kinase; 
TG, triglyceride. 
In 2003, two putative adiponectin receptors were identified (Yamauchi et al. 2003); 
these novel receptors, termed ADIPORI and ADIPOR2, contain seven 
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transmembrane domains and were noted to be functionally distinct from G protein- 
coupled receptors (Yamauchi et al. 2002). ADIPORI is predominantly expressed in 
skeletal muscle and exhibits high affinity for globular adiponectin and low affinity for 
full-length adiponectin; whereas, ADIPOR2 is abundantly expressed in the liver and 
has intermediate affinity for full-length adiponectin (Yamauchi et al. 2002). A novel 
extracellular receptor, T-cadherin, has been observed to bind the more prevalent larger 
multimeric forms of adiponectin (Hug et al. 2004). Unlike ADIPORs, T-cadherin is 
expressed widely in endothelial and smooth muscle cells (Hug et al. 2004). The 
precise role in T-cadherin is unknown; however, it has been suggested to function as a 
co-receptor in modulating responses to adiponectin (Hug et al. 2004). 
1.4.2.2 A Central Role for Adiponectin in the Brain. 
Recent evidence has emerged suggesting that adiponectin may function centrally to 
affect energy expenditure and peripheral glucose metabolism. Using 
radioimmunoassay, Qi et al. were the first to demonstrate that adiponectin could cross 
the blood-brain barrier (BBB) in mice; as intravenous injection of adiponectin resulted 
in a rise in cerebrospinal fluid (CSF) adiponectin (Qi et al. 2004). Interestingly, 
intracerebroventricular (i. c. v) administration of full-length, Cys-39 mutant or globular 
adiponectin was shown to stimulate energy expenditure and decrease body weight (Qi 
et al. 2004); suggested to be attributable to enhanced lipid oxidation by peripheral 
action on skeletal muscle. Additonally, ADIPOR1 and ADIPOR2 have been shown to 
be expressed in the central nervous system (CNS) (Ahima 2005), further suggesting a 
central role for adiponectin. Limited studies to date have addressed the potential role 
of adiponectin in the brain and, in some cases have provided negative data regarding 
its importance in the CNS (Pan et al. 2006; Spranger et al. 2006). Further studies are 
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therefore required to elucidate the precise mechanistic action of adiponectin and its 
various oligomeric forms in the CNS. 
1.4.3 Tumour Necrosis Factor-a. 
TNF-a is a 26 kDa transmembrane protein that is cleaved into its 17 kDa soluble 
bioactive form. TNF-a was initially identified as an endotoxin-induced factor, 
secreted by macrophages and causing necrosis of tumours (Cerami et al. 1985). The 
first association between obesity, increased TNF-a expression and insulin action was 
reported by Hotamisligil and colleagues. The group identified TNF-a expression in 
white adipose tissue of obese rodents and humans (Hotamisligil et al. 1993; 
Hotamisligil et al. 1995), which further correlated with increasing adiposity and 
insulin resistance (Hotamisligil et al. 1993; Fernandez-Real et al. 2003; Hotamisligil 
2003). Additional rodent studies revealed that ob/ob mice null for TNF-a or TNF 
receptor have improved insulin sensitivity and are more resistant to the development 
of T2DM, when compared to TNF-sufficient ob/ob mice (Uysal et al. 1997). 
Furthermore, immunoabsorption of TNF-a in rodent models of obesity was shown to 
increase insulin sensitivity (Hotamisligil et al. 1996). Furthermore, elevated levels of 
TNF-a in states of obesity and insulin resistance have been suggested to directly 
interfere with insulin signal transduction, through phosphorylation of critical serine 
residues in IRS-1 (Hotamisligil et al. 1996). Senne phosphorylation of IRS-1 results 
in early degradation (Trayhum et al. 2001), thus causing desensitisation of insulin 
signalling (Hotamisligil et al. 1994). Subsequent studies revealed that adipocytes 
expressed both TNF receptors in soluble and membrane bound forms (Ruan et al. 
2003). The production of TNF-a is mediated through activation of specific 
transcription factors, such as NF-KB and c-Jun N-terminal kinase (JNK). Such 
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activation of NF-xB causes profound changes in the gene expression profile of 
adipose tissue (Ruan et al. 2002). Many of these genes are thought to negatively 
impact on insulin signalling and lipid metabolism. It is now recognised that TNF-a is 
a multifunctional cytokine, influencing apoptosis, insulin signalling and many 
inflammatory processes (Hotamisligil et al. 1994). 
1.4.4 Interleukin-6. 
IL-6 is cytokine commonly associated with the immune system. IL-6 is functionally 
involved in the release of acute phase reactants from the liver, during the innate 
immune response. IL-6 has further been associated with complications such as 
melanoma, cachexia and T2DM. IL-6 is produced by a number of cells, including 
activated macrophages, lymphocytes, skeletal muscle cells and WAT (Febbraio et al. 
2002). However, its major source may be from WAT, since approximately 30% of 
systemic IL-6 in humans is contributed by mature adipocytes (Mohamed-Ali et al. 
1997); suggesting involvement of IL-6 with adipocyte metabolism and obesity-related 
insulin resistance. An increase in fat mass positively correlates with elevated 
circulating levels of IL-6 (Kern et al. 2001; Skurk et al. 2002), with a reduction in IL- 
6 further associated with weight loss (Bastard et al. 2000). IL-6 plasma concentrations 
are also upregulated in murine and human insulin resistance (Fried et al. 1998; 
Pradhan et al. 2001), with baseline IL-6 levels independently predicting future risk of 
developing T2DM (Kern et al. 2001; Vozarova et al. 2001). Alternatively, 
administration of recombinant IL-6 in rodents and humans has shown to induce 
hepatic gluconeogenesis, which in turn, leads to hyperglycaemia and compensatory 
hyperinsulinemia (Stith and Luo 1994; Tsigos et al. 1997). In contrast, several studies 
have demonstrated that insulin enhances IL-6 mRNA and protein expression in 3T3- 
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LI adipocytes and human adipocytes (Vicennati et al. 2002; Fasshauer and Paschke 
2003). Furthermore, studies have also revealed that elevated levels of IL-6 impair 
insulin signalling via distinct mechanisms. In vitro analysis using cultured hepatocytes 
and 3T3-Ll adipocytes demonstrated that IL-6 decreased activation of IRS-1 (Rotter 
et al. 2003); such an affect was mediated through the `suppressor of cytokine 
signalling (SOCS) family of proteins (Senn et al. 2003). SOCS inhibit insulin 
signalling directly through the insulin receptor (Mooney et al. 2001). This data 
therefore suggests that IL-6 is pro-insulin resistance. Taken together, obesity and 
T2DM are associated with an increased state of inflammation; in which IL-6, along 
with TNF-a, play integral roles as mediators (Pickup et al. 1997; Engeli et al. 2003; 
Esposito et al. 2003). 
1.4.5 Leptin. 
Leptin was discovered in 1994 by positional cloning of the gene responsible for 
obesity in the ob/ob mouse (Zhang et al. 1994). This gene encoded a 146 amino acid 
protein, 16 kDa in size and, secreted predominantly by adipocytes (Madej et al. 1995). 
Soon after, the leptin receptor (OB-Rb) was cloned (Tartaglia et al. 1995) and defects 
were found in the gene in the genetically obese db/db or ob/ob mice (Figure 1.4.5) 
(Chen et al. 1996; Chua et al. 1996). As deficiency or mutations in the protein were 
associated with obesity in rodents, it was not surprising that leptin treatment to ob/ob 
mice resulted in a weight loss and improved diabetic status (Pelleymounter et al. 
1995). Initial reports indicated that leptin serves as a key mediator in a negative 
feedback loop from adipose tissue to the brain, supressing appetite in response to 
excess adipose tissue mass (Considine et al. 1996; Van Gaal et al. 1999). However, 
initial rodent data regarding the biology of leptin did not readily translate to humans. 
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Few leptin mutations were present in humans and conversely, plasma leptin levels 
were severely elevated in obese subjects (Considine et al. 1996). 
Figure 1.4.5 The genetically obese, leptin deficient (ob/ob) mouse. 
Leptin administration is known to cause weight loss in excess of the effects of 
reduced food-intake (Levin et al. 1996). As such, leptin was proposed to regulate 
energy expenditure through mechanisms via the CNS; as central administration of 
leptin to rhesus monkeys demonstrated increases in norepinephrine and a significant 
reduction in food-intake (Tang-Christensen et al. 1999). Mutations resulting in 
complete leptin loss in humans (Montague et al. 1997; Strobel et al. 1998), in addition 
to defects in the receptor, resulted in marked hyperphagia and severe obesity (Strobel 
et al. 1998). However, with acute treatment of leptin to such leptin-deficient subjects, 
hyperphagia was reduced, followed by a severe reduction in fat-mass (Farooqi et al. 
1999). It was further reported that obese individuals are severely resistant to leptin 
action. Such leptin resistance may occur during transport of leptin into the CNS (Caro 
et al. 1996) or impairment of signalling downstream of the leptin receptor (Bjorbaek 
et ul. 1999; El-Haschimi et al. 2000). It would appear from such leptin resistance, that 
the action of leptin is profound when systemic levels fall below normal physiological 
levels. Therefore, it is thus proposed that reduced leptin levels serve as a signal for 
negative energy balance when energy reserves are low (Havel 2004). 
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Once in circulation, leptin is transported across the blood-brain barrier, where it then 
exerts its effects by interacting with receptors located in the hypothalamus (Flier 
2006). At this site, leptin interacts with the melanocortin-4 receptor, melanocyte- 
stimulating hormone and neuropeptide Y (NPY), a powerful stimulator of appetite 
(Halaas et al. 1995; Zierath et al. 1998). In contrast, leptin is also capable of 
increasing expression of anorexigenic proteins, proopiomelanocortin (POMC) and 
cocaine amphetamine-related transcript (CART), causing a decrease in appetite 
(Schwartz et al. 2000; Spiegelmau et al. 2001). 
1.5 Obesity, Insulin Resistance & Inflammation: Adipokines Link Metabolic & 
Inflammatory Pathways: The Emerging Paradigm. 
Adipose tissue has received much attention over recent years not only for its 
endocrine characteristics, but equally for its immunological activity. Mounting 
evidence has focused on the notion that chronic low-grade inflammation and 
activation of the innate immune system are closely involved in the obesity-associated 
insulin resistance and the progression of T2DM (Dandona et al. 2004; Pickup 2004) 
Such chronic inflammatory responses in obesity are characterised by an abnormal 
level of cytokine production and increased activation of inflammatory signalling 
pathways. Various adipokines can themselves regulate several inflammatiory 
processes or alternatively, serve as markers of inflammation (Tilg et al. 2006). Such 
pro-inflammatory adipokines, referred to as `adipocytokines' include TNF-a, IL-6, 
PAI-1, C-reactive protein (CRP), resistin and leptin. Dysregulation of systemic levels 
of adipocytokines may therefore contribute to chronic inflammation, resulting in 
endocrine abnormalities observed in obesity and T2DM. Consequently, these factors 
are considered to have dual regulatory metabolic and immunological properties. More 
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specifically, adipocytokines may have key roles in mediating inflammation, in 
particular, within innate immunity. It is therefore considered that adipose tissue 
represents an initiation site for an innate immune response; however, its molecular 
basis, precise mechanistic action in the pathogenesis of T2DM, is yet to be fully 
elucidated. 
1.5.1 Innate Immunity. 
The innate immune system is the body's rapid first line of defence against 
environmental threats, such as microbial pathogens and physical or chemical injury 
(Medzhitov and Janeway 2000; Takeda and Akira 2005). Such pathogens initiate a 
`hard wired' non-specific, however rapid, reaction to infection. Unlike the adaptive 
immune response, instead of utilising T and B-lymphocytes, innate immunity uses 
Toll-like receptors (TLRs) to recognise specific microbial components, including 
bacteria, fungi, protazoa and viruses (Kaisho et al. 2000). 
The TLRs were first characterised in Drosophila in 1996 (Lemaitre et al. 1996). One 
year later, a mammalian homolog of the Toll receptor, termed TLR-4, was shown to 
induce the expression of genes involved in inflammatory responses (Medzhitov et al. 
1997). Since the initial discovery of TLR-4,11 family members have been identified 
in mammalian systems (Takeda et al. 2005). TLR-4 is an essential receptor for 
lipopolysaccharide (LPS), from Gram-negative bacteria; whereas TLR-2 recognises 
fungen-derived components, such as zymosan, from Gram-positive bacteria (Takeda 
et al. 2002). Upon binding of microbial components, TLRs dimerise and, along with 
their co-receptor, CD 14, both initiate downstream signalling events. This firstly 
involves the recruitment of a common adaptor protein, MyD88, which binds to the 
cytoplasmic domain of the Toll-like receptor (TLR) (Schnare et al. 2001). Such 
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receptor binding recruits downstream IL-1 receptor-associated kinase (IRAK) (O'Neill 
et al. 1998) to the receptor complex. IRAK is then autophosphorylated and recruits 
TNF receptor-associated factor-6 (TRAF-6); this leads to the activation of the 
`inhibitor of NF-KB kinase' (IKK) complex, which consists of the catalytic subunits 
IKK-a and IKK-ß and, the regulatory subunit, NEMO/IKK-y. Activation of the IKK 
complex sequentially phosphorylates `inhibitor of NF-KB' (IiB), therefore causing its 
degradation; simultaneously, such activation releases the sequestered transcription 
factor, NF-KB, thus allowing it to translocate from the cytoplasm into the nucleus to 
initate transcription of inflammatory molecules (Figure 1.5.1), such as TNF-a, IL-1 
and IL-6 (Zhang et al. 2000; Barton et al. 2003; Goldstein 2004). 
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Figure 1.5.1 Key components of the innate immune signalling pathway. Upon 
activation, myeloid differentiation primary response gene-88 (MyD88) associates with 
the cytoplasmic domain of toll-like receptor (TLR), thus recuiting IL-1 receptor- 
associated kinase (IRAK) to the receptor. IRAK then activates TNF receptor 
associated factor-6 (TRAF-6), causing activation of the inhibitor of NF-KB kinase 
(IKK) complex (including inhibitor of NF-KB kinase-y (NEMO/IKKy), inhibitor of 
NF-KB kinase-ß (IKK(3) and inhibitor of NF-KB kinase-a (IKKa)); this activated 
complex phosphorylates inhibitor of NF-KB (IKB), resulting in nuclear translocation 
of nuclear factor-KB (NF-KB), which induces the expression of inflammatory 
cytokines. Figure adapted from (Takeda et al. 2005). LPS, lipopolysaccharide; 
MALP-2, macrophage-activating lipopeptide-2; ECSIT, evolutionarily conserved 
signalling intermediate in toll pathways; MEKK1, mitogen-activated kinase kinase-1; 
TAKT, trans forming-growth-factor- ß-activated kinase-1; NIK, NF-KB-inducing 
kinase. 
In vitro analysis has demonstrated a fully active pathway of innate immunity within 
3T3-L1 adipocytes (Lin et al. 2000), thus emphasising that an increase in adipose 
tissue mass may be responsible for the elevated systemic levels of inflammatory 
factors observed in obese, insulin resistant and T2DM subjects. Future studies will 
however, have to address whether such a scenario exists in human isolated adipocytes. 
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1.5.2 Crosstalk between Metabolic & Inflamatory Signalling Pathways: 
Adipocytes & Macrophages. 
Whilst it is now recognised that obesity is a state of chronic inflammation, several 
studies have recently reported that obese adipose tissue is characterised by profound 
macrophage infiltration (Weisberg et al. 2003; Wellen and Hotamisligil 2003; Xu et 
al. 2003) (Figure 1.5.2). In addition to adipocytes, these macrophages are a 
significant source of inflammation in this tissue. 
Fý' ., 
Adpocyle 
Wolghl gain 
ýö 
1' 
ý.,; , 
ý,. 
ýýýký{ 
i ä 
r 
Figure 1.5.2.1 Illustration demonstrating progressive macrophage infiltration into 
expanding adipose tissue mass in the development of obesity. Adipose tissue becomes 
`inflamed' in states of obesity; equally via infiltration of adipose tissue by 
macrophages and, as a consequence of adipocytes producing inflammatory cytokines. 
Figure obtained from (Wellen et al. 2003). MCP-1, monocyte chemotactic protein-I; 
VEGF, vascular endothelial growth factor; FFA, free fatty acid; JNK, c-Jun N- 
terminal kinase. 
An interesting and novel concept is that the inflammatory response observed in 
obesity is `triggered' by and resides predominantly in adipose tissue (Wellen et al. 
2003); suggesting that adipocytes may propagate recruitment of systemic 
macrophages. Alterations in adipocyte size may thus cause modifications in the 
paracrine function of adipocytes. For example in obesity, the adipocyte begins to 
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secrete low levels of TNF-a, this then stimulates pre-adipocytes to produce monocyte 
chemotactic protein-1 (MCP-1) (Xu et al. 2003); such a stimulus then attracts 
macrophages into the adipose tissue. It is further acknowledged that adipocytes and 
macrophages possess similar functional and molecular roles in inflammatory 
pathways (Hotamisligil et al. 1993), suggesting an overlap in biology and a close 
interrelationship between adipocyte and macrophage lineages. For instance, pre- 
adipocytes have the capability to trans-differentiate into `macrophage-like' cells in 
response to appropriate stimuli, therefore having potent phagocytic capacity and 
antimicrobial properties (Charriere et al. 2003). Moreover, gene expression profiles 
between adipocytes and macrophages are highly similar; many `adipocyte' gene 
products, including fatty-acid binding proteins (FABPs) and PPAR-y are also 
expressed in macrophages (Tontonoz et al. 1998). Similarly, adipocytes secrete 
`macrophage' proteins such as TNF-a, IL-6 and matrix metalloproteinases (MMPs) 
(Figure 1.5.2.2) (Tontonoz et al. 1998; Bouloumie et al. 2001; Makowski et al. 2001; 
Hotamisligil 2003). 
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Figure 1.5.2.2 Diagram highlighting the integration of metabolic and immune factors 
in adipocytes and macrophages. Both cell-types share common features, such as 
expression of cytokines, FABPs and nuclear hormone receptors. Figure obtained from 
(Wellen et al. 2005). FABPs, fatty acid binding-proteins; ap2, adipocyte fatty acid- 
binding protein; mall, adipocyte fatty acid-binding protein-5; LXR, Liver X receptor; 
PPARs, peroxisome proliferator activated receptors. 
1.5.3 Inflammatory Pathways to Insulin Resistance: Overlap of Innate Immunity 
& Insulin Signalling: IKK-ß & JNK as Central Mediators. 
It is established that obesity is closely integrated with a state of inflammation; how 
exactly adipocytokines mediate insulin resistance is however, unclear. It has been 
suggested that activation of certain inflammation pathways impairs insulin signalling 
(Schling et al. 2002; Hotamisligil 2005). This paradigm emphasises crosstalk between 
innate immunity and the insulin signalling pathway; certainly identifying underlying 
mechanisms of these signalling pathways could distinguish central mediators of this 
convergence and presumably lead to the identification of key therapeutic targets. 
1.5.3.1 The Insulin Signalling Cascade: JNK as an Inhibitor of Insulin Signalling. 
Insulin affects cells through binding to its receptor on the surface of insulin- 
responsive cells. Such binding stimulates receptor autophosphorylation and 
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subsequent tyrosine phosphorylation of insulin receptor substrate (IRS) molecules to 
initiate downstream signalling, as detailed in Chapter 1.3.1. Inhibition of downstream 
insulin signalling is a primary mechanism through which inflammatory signalling 
leads to insulin resistance. More specifically, exposure of cells to TNF-a or elevated 
levels of NEFAs stimulates the inhibitory phosphorylation of serine residues of IRS-1 
(Hotamisligil et al. 1996; Yin et al. 1998; Aguirre et al. 2000). This phosphorylation 
reduces tyrosine phosphorylation of IRS-1 and its ability to associate with the insulin 
receptor, thereby inhibiting downstream signalling (Paz et al. 1997; Aguirre et al. 
2002). Several serine/threonine kinases are activated by inflammatory stimuli that 
inhibit insulin signalling, these include JNK and IKK (Zick 2003); of these 
candidates, JNK in particular, has recently emerged as a central metabolic regulator, 
playing a key role in the development of insulin resistance in obesity (Hirosumi et al. 
2002). 
The 3 members of the JNK group of serine/threonine kinases, JNK-1, -2 and, -3 
belong to the `mitogen-activated protein kinase' family of stress-activated protein 
kinases. Such kinases regulate cell development and function through their ability to 
mediate transcription by phosphorylating `activator protein-1' proteins, including c- 
Jun and JunB (Derijard et al. 1994); of which are both implicated in the regulation of 
inflammatory genes (Davis 2000). In response to certain extracellular stimuli, such as 
elevated levels of NEFAs or TNF-a, or more recently established intracellular stimuli, 
such as endoplasmic reticulum (ER) stress, JNK is potently activated (Bennett et al. 
2003). Such stimulation causes JNK to associate with and phosphorylate IRS-1 on 
Ser307 (Aguirre et al. 2000), thus impairing insulin action. 
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In obesity, JNK-1 is the predominant isoform in liver, skeletal muscle and adipocytes 
and, has been demonstrated to be upregulated in murine models of obesity (Hirosumi 
et al. 2002). Alternatively, loss of JNK-1 decreases adiposity, enhances insulin 
signalling and prevents the development of insulin resistance and diabetes in both 
genetic and diet-induced mouse models of obesity (Hirosumi et al. 2002). 
Additionally, synthetic JNK inhibitor and/or inhibitory peptide treatment has been 
reported to improve insulin sensitivity in mouse models of obesity and insulin 
resistance (Bennett et al. 2003). JNK inhibition in T2DM has therefore, the potential 
to serve as a viable therapeutic target for this disease and other chronic inflammatory 
diseases (Kaneto et al. 2004). Future studies examining JNK inhibitors in human 
adipose tissue would be of interest. 
1.5.3.2 IKK-ß as a Central Mediator of Inflammation & Insulin Resistance. 
In addition to JNK, IKK-ß has recently emerged as a central mediator of 
inflammatory and metabolic signalling systems. IKK-ß can significant influence 
insulin signalling through two mechanisms. Firstly, IKK-(3 directly phosphorylates 
IRS-1 on serine residues (Yin et al. 1998; Gao et al. 2002), impairing insulin 
signalling. Secondly, IKK-P phosphorylates IKB, releasing NF-xB, (as detailed in 
Chapter 1.5.1) to initiate the production of inflammatory mediators (Shoelson et al. 
2003). Figure 1.5.3.2 below demonstrates the impact that JNK and IKK-ß have on 
metabolic and inflammatory signalling systems. 
60 
Nutrients overload 
Leptin 
Adiponectin 
TNF-a MCP1 
IL-6 FFAs 
IL"1 Adipocyte 10,0 
L-- > FFAs Macrophag TNF"a 
IL-6 
TNF-cx 
tallf 
IL-1 
tl"8 
MCPI 
TNFR, RAGE TLRs, IL-1 R 
I; Ir l'I"Ilrl 1'u ri, . I' I ifl(lI; II; I; Inir111 irrrlltl ;i 
ý11ýlrllýý(t! II" i.: i' 
ýýf, 
ýý: I!! !. ý ýIýI11 1; 1i/t Ur! ý! I'ýall! Irii' 
Ceramide PKCs 
ROS 
. I. 'JK 
IItS-1 
I AP- 
I'II 
IKKif tKKIi 
IKK7 
li 
iýBie 
-4--- ER stiess ý 
Salicy(ates, 
TZDs. and 
s1auns 
1fi5 p50 
NF-.; B 
NF-; B P 
ý5 P50 Inflammatory 
markers 
and mediator, 
`' 
.f 
4 
Figure 1.5.3.2 Hypothesised integration between metabolic and inflammatory 
pathways in obesity. Extracellular stimuli activating both nuclear factor-KB (NF-KB) 
and c-Jun N-terminal kinase (JNK) signalling, include TNF-a, free fatty acids (FFAs) 
and microbial products. Intracellular stimuli include ER stress and protein kinase C 
(PKC) isoforms. Obesity-induced IKK-(3 activation causes NF-KB translocation and 
increased expression of inflammation molecules that cause insulin resistance. 
Obesity-induced JNK activation promotes serine phosphorylation of insulin receptor 
substrate-1 (IRS-1); this negatively regulates normal signalling through the insulin 
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receptor/IRS-1 axis. Figure obtained and adapted from (Shoelson et al. 2006) and 
(Chen 2006). MCP-1, monocyte chemotactic protein-1; TNFR, tumour necrosis factor 
receptor; RAGE, receptor for advanced glycation end-products; TLRs, toll-like 
receptors; IL-1R, interleukin-1 receptor; pS302/pS307, phosphorylation sites 302/307; 
ROS, reactive oxygen species; ER, endoplasmic reticulum; TZDs, thiozolidinediones; 
AP-1, activator protein-1. 
Recent studies have revealed that tissue and cell-specific activation of IKK-ß in the 
liver and myeloid cells respectively, contributes to obesity-induced insulin resistance 
(Rohl et al. 2004; Arkan et al. 2005; Cai et al. 2005). In contrast, pharmacological 
inhibition of MK-ß using high-dose salicylates, for instance aspirin, was shown to 
significantly improve insulin signalling and glucose metabolism in both obese mice 
and diabetic humans (Hundal et al. 2002; Perseghin et al. 2003). However, targeting 
single mediators of inflammation to treat T2DM may not be fully effective, as other 
components may compensate to continue the propagation of inflammatory responses. 
Nevertheless, targeting both JNK and IKK-ß inflammatory kinases together may 
generate robust antidiabetic action, as both factors integrate signals from multiple 
inflammatory components. Collectively, recent studies highlight that activation of 
JNK and IKK-ß in obesity emphasises the striking overlap of metabolic and immune 
pathways. 
1.6 Aims of Thesis. 
It is evident that with increasing adiposity, several mechanisms operate to enhance the 
pathogenisis of T2DM. It is further apparent that the source of this problem arises 
from adipose tissue itself. From studies to date, it appears that the equilibrium of 
adipose-derived factors is substantially dysregulated with obesity. As a consequence, 
adipocytokines such as resistin, TNF-a and IL-6 assemble to exert pathogenic effects, 
collectively contributing to the development of insulin resistance and T2DM. 
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Neveretherless, unraveling the mechanisms leading from obesity to inflammation will 
have significant implications for the design of novel therapies to reduce the morbidity 
and mortality of obesity. 
This thesis will therefore predominantly explore the adipocytokine resistin and 
further, albeit to a lesser extent, key components of the innate immune system in the 
context of human adult and childhood obesity. Furthermore, these studies will 
investigate the pro-inflammatory actions of resistin in adipose tissue in concordance 
with factors of the innate immune pathway. Finally, the adipokine adiponectin, having 
a somewhat `ying-and-yang' relationship with resistin in terms of obesity and 
inflammation, will be investigated in the context of central action and energy 
homeostasis. 
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General Methods & Materials. 
This section details the methods and materials most frequently used throughout the 
thesis. Precise information outlining specific methods for each study will be covered 
within each appropriate chapter; any further information on specific reagents or 
techniques used is noted in the Appendices. 
2.1 Adipose Tissue Collection & Processing. 
Abdominal Subcutaneous (AbSc) adipose tissue was collected from subjects 
undergoing elective, cosmetic surgery (liposuction) or in accordance with local ethics 
committee guidelines. All subjects with a history of malignancies or under treatment 
or suffering from any endocrine abnormalities were excluded from the study. Fresh 
primary adipose tissue was utilised the following ways; either frozen and stored 
(Chapter 2.1.1) or processed to isolate the mature adipocytes (Chapter 2.1.2). 
2.1.1 Freezing Adipose Tissue. 
Approximately 40 ml of adipose tissue obtained from liposuction was aliquoted into 
sterile 50 ml centrifuge tubes then flash frozen in liquid nitrogen. To ensure minimal 
protein damage or degradation, frozen AbSc adipose tissue samples were placed 
directly from liquid nitrogen into a -80°C freezer for storage until further use. 
2.1.2 Isolation of Abdominal Subcutaneous Adipocytes: Collagenase Digestion. 
Adipose tissue (25 ml) obtained from liposuction was poured directly into sterile 50 
ml centrifuge tubes. For collagenase digestion, adipose tissue was suspended in 20 ml 
of warm collagenase solution then incubated at 37°C in a continuous shaking (100 
cycles/min) water bath for 30-45 min, with additional shaking at 10 min intervals until 
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the consistency of the adipose tissue was a smooth homogeneous liquid. Following 
collagenase digestion, adipose tissue was filtered through a sterile fine cotton mesh 
(Medistore, UK) into another sterile 50 ml centrifuge tube. Centrifugation at 360 xg 
for 5 min separated the collagenase digested adipose tissue into three independent 
layers: the lower stromal-vascular fraction containing a pellet of pre-adipocyte cells, 
the central adipocyte layer and the upper supernatent fraction containing lysed 
adipocyte cells. The supernatent fraction was discarded and the adipocyte layer was 
gently poured into fresh sterile 50 ml centrifuge tubes, leaving the stromal-vascular 
fraction (containing various cell-types, such as pre-adipocytes, leukocytes and 
monocytes and macrophages). The adipocytes were washed twice by adding 30 ml of 
warm (37°C) culture medium (DMEM/F-12 Hams' phenol red free medium 
containing penicillin (100 units/ml) and streptomycin (100 µg/ml) (Sigma, UK)) to 
remove any traces of collagenase and blood. Previous assessment for potential 
blood/macrophage contamination of adipocyte fractions using immunohistochemistry, 
revealed no macrophage or monocyte contamination, as previously detailed 
(McTernan et al. 2002). The adipocytes were dispersed by gently rocking them 
through the medium before centrifugation at 190 xg for 30 s. The lower supernatant 
layer was then carefully removed using a 10 ml pipette and discarded. Approximately 
1 ml of compact adipocyte cells (containing -500,000 adipocytes, as determined by 
haemocytometer analysis) were added to individual sterile 25 cm3 flasks containing 5 
ml of culture medium (DMEM/F12 Hams' phenol red free medium containing 1% 
transferrin (Sigma, Dorset, UK), penicillin (100 units/ml) and streptomycin (100 
µg/ml) (Sigma, UK)). Cells were then incubated for either to 14 hr, 24 hr or a 
maximum of 48 hr with or without drug, or cytokine treatment (as described in 
Chapter 3 and Chapter 4). 
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2.1.3 Purification & Processing of AbSc Adipose Tissue Explants by Erythrocyte 
Lysis Buffer Digestion. 
The purification and subsequent processing of whole adipose tissue explants yields 
non-collagenase treated adipose tissue, comprising of an intact extracellular matrix 
and thus containing several cell-types (as opposed to isolating one cell-type, for 
example adipocytes, as detailed in Chapter 2.1.2). Such cell-types in explanted 
adipose tissue include pre-adipocytes, adipocytes, monocytes, macrophages and 
leukocytes. For comparative studies between isolated adipocytes and whole adipose 
tissue explants, the following procedure was used: as previously described, freshly 
collected adipose tissue obtained from liposuction was poured (25 ml) directly into 
sterile 50 ml centrifuge tubes. For erythrocyte lysis buffer digestion, 20 ml of the lysis 
buffer (Appendix I. 2.1) was added to the adipose tissue. The mixture was left to stand 
at RT for 15 min then centrifuged at 360 xg for 5 min. Centrifugation separated the 
digested adipose tissue into two independent layers: the lower blood liquid-phase 
fraction containing lysed erythrocytes and the upper adipose tissue layer. The lower 
blood fraction was discarded using a 10 ml pipette. The remaining adipose tissue layer 
was then washed twice with 30 ml of warm (37°C) culture medium (DMEM/F-12 
Hams' phenol red free medium containing penicillin (100 units/ml) and streptomycin 
(100 µg/ml) (Sigma, UK)) to remove any traces of lysis buffer and blood. This 
process was repeated until a clean tissue layer remained, as assessed by the 
supernatant layer. The remaining tissue was then ready for culture, as described in 
Chapter 4. 
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2.1.4 Adipocyte Cell Viability Assessed by Trypan Blue Staining. 
Viability of adipocytes was assessed using a dye-exclusion method. An aliquot of 
compact adipocytes was re-suspended in trypan blue dye (Sigma, Dorset, UK) 
containing PBS and distilled water (dH2O). The sample mixture was then vortexed 
and incubated for 5 min at room temperature (RT). Adipocyte cell viability was 
assessed by analysing an aliquot of the homogenous mixture using a haemocytometer. 
Both viable and non-viable cells were analysed under a light microscope and counted 
using a cell counter. Viable adipocytes did not take up the dye, whereas non-viable 
cells stained blue as they take up the dye. 
2.2 Extraction of Protein from AbSc Adipocytes. 
The following methods for the extraction of protein from mature adipocyte cells are 
used throughout the thesis. Any specific alteration of the treatment of adipocytes in 
the studies covered is outlined in the appropriate chapters. 
2.2.1 Extraction of Protein from AbSc Adipocytes using Sodium Dodecyl 
Sulphate (SDS). 
Adipocytes were cultured in an incubator (37°C, 95% 02,5% CO2 mix) for either 14 
hr, 24 hr or a maximum of 48 hr with culture medium (DMEM/F 12 Hams' phenol red 
free medium containing 1% transferrin, penicillin (100 units/ml) and streptomycin 
(100 pg/ml)) with or without the drug or cytokine treatment of interest. Following 
incubation, adipocytes suspended in culture medium (DMEM/F12 Hams' phenol-red 
free medium containing 1% transferrin, penicillin (100 units/ml) and streptomycin 
(100 µg/ml)) were removed from each flask and aliquoted into sterile 15 ml 
microfuge tubes before centrifugation at 190 xg for 30 s. The lower conditioned 
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medium layer was then carefully removed and pipetted into 1.5 ml eppendorfs and 
stored at -80°C until further analysis. From the remaining adipocyte fraction, 500 µl 
was aliquoted into 1.5 ml eppendorfs and boiling 4% SDS (BioRad, Hercules, 
California, USA) solution was added (400 µl) into each tube, heated at 95°C for 4 hr 
before storage at -80°C. 
2.2.2 Extraction of Protein from AbSc Adipocytes using Radio- 
Immunoprecipitation Assay (RIPA) Buffer. 
As previously described, adipocytes were cultured in an incubator (37°C, 95% 02,5% 
CO2 mix) for either 14 hr, 24 hr or a maximum of 48 hr in culture medium 
(DMEM/F12 Hams' phenol-red free medium containing 1% transferrin, penicillin 
(100 units/ml) and streptomycin (100 µg/ml)) along with the treatment of interest. 
Adipocytes suspended in culture medium (DMEM/F12 Hams' phenol red free 
medium containing 1% transferrin, penicillin (100 units/ml) and streptomycin (100 
pg/ml)) were removed from each flask and placed in 15 ml microfuge tubes before 
centrifugation at 190 xg for 30 s. Conditioned medium was carefully pipetted into 
labelled eppendorfs and stored at -80°C until analysis. From the remaining adipocyte 
fraction, 500 µl was aliquoted into a 1.5 ml centrifuge tube then 200 µl of RIPA 
buffer (Table 2.2.2) was added into each tube with gentle shaking to mix the contents. 
Prior to clarification, the sample mixture was then flash frozen in liquid nitrogen to 
prevent denaturing of protein aggregates. Following thawing, samples were spun at 
16,060 xg at 4°C for 30 min. Infranatant containing proteins isolated from the 
adipocyte cells was removed from under the lipid layer, using a syringe and fine bore 
hyperdermic needle, then stored at -80°C until further use. 
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Reagent Quantity Final Concentration 
Phosphate Buffered 
Saline (PBS) 9 ml 120 mM 
(H7.6 
Nonldet P40 0.1 ml 1% (v/v) 
Sodium 0.05 mg 20% (w/v) Deoxycholate 
10% SDS 0.1 ml 0.1% (v/v) 
100 ug/ml ALLN 1000 µg 100 ug/ml (protease inhibitor 
Complete Mini 
Protease Inhibitor 1 Tablet 1X (v/v) 
Cocktail* 
Table 2.2.2 Contents of RIPA buffer mix. *Roche diagnostics, Germany. 
2.2.3 Extraction of Protein from Whole AbSc Adipose Tissue using RIPA. 
Protein samples from whole AbSc adipose tissue for use in Western blot analyses 
were extracted using RIPA buffer (Table 2.2.2). Whole adipose tissue was collected 
from -80°C storage, then, without allowing the sample to defrost, -100 mg of adipose 
tissue was cleaved off using a sterile scalpel and forceps then transferred into a5 ml 
bijou tube. RIPA buffer (600 µ1) was added to the tissue. The sample mixture was 
then homogenised using a rotor-stator homogeniser (PowerGenl25, Fisher Scientific, 
UK) at 1100-4200 xg for 3-5 s. The homogenised mixture was then transferred to 1.5 
ml microcentrifuge tubes and flash frozen in liquid nitrogen. Once thawed, the 
samples were centrifuged at 60,060 xg for 30 min at 4°C. Using a fine bore needle 
and syringe, liquid from below the solid layer was extracted and aliquoted into fresh 
0.5 ml microcentrifuge tubes and stored at -80 °C until further use. 
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2.3 Quantification of Protein. 
For the determination of protein, the BioRad DC (detergent compatible) protein assay 
kit was used, containing Reagent S (Surfactant solution), Reagent A (an alkaline 
Copper Tartrate solution) and Solution B (dilute Folin Reagent) (BioRad, Hercules, 
California, USA). The BioRad DC protein assay allowed the quantification of protein 
extracted from adipocytes and adipose tissue, without alteration from SDS detergent, 
a component used in both protein extraction methods previously detailed. 
To determine protein content of extracted proteins, aliquots of frozen sample were 
thawed and vortexed to ensure a homogenous sample distribution. A solution 
containing 20 µl Reagent S and 980 µl Reagent A was pre-mixed in a glass test-tube. 
To each polypropylene cuvette (Starstedt, Germany), 125 µl of the pre-mixed solution 
was added. Extracted protein from adipose tissue (3 µl) or adipocytes (5 Al) was then 
added to the pre-mixed solution. Solution B (1 ml) was added to each cuvette 
containing the sample mixture then incubated for 15 min at RT. Microfilm was placed 
over each cuvette and inverted to achieve uniform colour dispersion. 
A standard curve of absorbance against protein concentration was generated using 
known dilutions of Bovine Serum Albumin (BSA) (First Link LTD, UK) (2 µg/111) in 
the range of 0-100 µg/µ1, using the method described above. The absorbance of 
protein samples and standard curve were then determined using a spectrophotometer 
(6505 UVNIS, Jenway, UK) at a wavelength of 655 nm. Protein concentrations were 
thus deduced (µg/µl) from the standard curve. 
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2.4 Western blot Analyses of Isolated Adipocytes & Whole Adipose Tissue. 
Western blotting is an immunoassay-based technique that allows the sizing, 
identification and quantification of specific proteins. In brief, proteins of interest 
undergo electrophoresis through a gel. Proteins are separated according to their 
molecular weight (M1). Following electrophoresis, proteins are electrophoretically 
transferred onto a polyvinylidene-fluoride (PVDF)TM or nitrocellulose membrane. 
Proteins of interest are then detected by probing with antibodies raised against them. 
Proteins are then visualised using a chemiluminescent detection system. This method 
is detailed below in full. 
2.4.1 Preparation of Protein Samples for Electrophoresis. 
Quantified protein samples were thawed and vortexed. Equal volumes of protein (20- 
60 µg; relating to Chapter 3 and Chapter 4) were then transferred into 1.5 ml 
eppendorfs containing loading buffer, at a minimum ratio of 1: 2 (sample: loading 
buffer) (Table 2.4.1). Varying quantities dH2O were added to the sample mixture to 
standardise final 'volumes. A rainbow molecular weight marker (Amersham 
Biosciences, UK) (14,300-220,000 Da) was diluted 1: 5 with loading buffer and 
loaded alongside each set of samples (i. e. minimum 1 lane per gel), providing a visual 
protein size record with which protein samples could be compared (Appendix 
111.3.2). The sample mixtures were then heated at 95°C for 5 min to denaturise and 
linearise the proteins. 
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REAGENT QUANTITY 
FINAL 
CONCENTRATION 
Tris HC1(pH 6.8) 
(BioRad, Hercules, CA, 
USA) 
625 µl 125 mM 
SDS (10%) (Sigma, UK) 500 Al 4% 
Glycerol (Sigma, UK) 1000111 20% (w/v) 
DTT (Sigma, UK) 200 µl 6.5x10"3 mM (w/v) 
Bromophenol Blue 125 l 2.5x10" mM (w/v) 
dH2O 250 µl N/A 
J1 
Table 2.4.1 Quantities of reagents in loading buffer for Western blot analysis. 
2.4.2 Electrophoretic Protein Separation. 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was used to separate proteins 
according to their size (4% stacking gel, pH 6.8; 8-15% resolving gel, pH 8.8 
(percentage of resolving gel was chosen according to the size of the protein of 
interest). The reagents and their quantities for each gel used throughout the thesis are 
shown in Table 2.4.2. 
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RESOLVING GEL 
QUANTITY 
FOR 8% GEL 
QUANTITY 
FOR 
QUANTITY 
FOR 
REAGENT 12% GEL 15% GEL 
Protogel* 5.3 ml 8 ml 9.9 ml 
Protogel Resolving 
Buffer* 
5.2 ml 5.2 ml 5.2 ml 
dHZO 9.3 ml 6.6 ml 4.5 ml 
Ammonium Persulphatet 
- -- - - 
200 µl 200 Al 200 µl 
D71 TE M E 20 Al 20 Al 20 Al 
STACKING 
GEL 
QUANTITY FOR 
4% GEL 
REAGENT 
Protogel* 1.3 ml 
Protogel Stacking 
Buffer* 
2.5 ml 
dH20 6.1 ml 
Ammonium 
Persul hatet 
50141 
TEMED 10 l 
Table 2.4.2 Components of resolving gel (8%, 12% and 15%) and stacking gel (4%) 
used for Western blot analysis. 
* See Appendix 1 for full details. 
t 0.1% (w/v) (BioRad, Hercules, California, USA) 
I (BioRad, Hercules, California, USA) 
The gel casting unit was constructed according to the manufacturers' instructions. 
Glass plates were slotted into the clamp assembly and water-tightness tested to ensure 
no leaks. The resolving gel was prepared as detailed above, vortexed and poured to 
-15 mm of the total height of the glass plates. To enhance polymerisation and reduce 
meniscus formation, -3 mm of 70% isopropanol was carefully layered over the 
resolving gel. The gel was then left to set for -30 min at RT. Once set, the surface of 
the resolving gel was gently washed with dH20 and the stacking gel prepared. This 
gel solution was poured onto the surface of the resolving gel and wells created by 
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inserting a comb (1.5 mm thickness, 10 teeth of 5 mm wide each) at an angle to 
minimise introducing air bubbles into the gel. Any loss of gel was immediately 
replaced. Once the stacking gel was set, the comb was removed vertically and wells 
were flushed vigorously with a syringe containing electrode buffer. Gels encased 
within the glass plates were transferred to a tank containing 1L of 1X electrode buffer 
(Appendix I) and secured into place creating two separate reservoirs, allowing ionic 
movement only through the gels. Wells were flooded and any leakages between the 
two reservoirs were stopped. Samples were loaded using specific loading tips (Fisher, 
UK) and air bubbles expelled. Samples were resolved by electrophoresis. 
2.4.3 Electrophoretic Transfer (Blotting). 
Immobilon-PTm PVDF membranes (0.45 µm) (Millipore, Bedford, Massachusetts, 
USA) were briefly immersed in 100% methanol (Fisher Scientific, UK), washed in 
dH2O for 1 min then soaked in transfer buffer (Appendix I) until use. For smaller 
sized proteins, Westran PVDF membranes (0.2 µm) (Geneflow Ltd., UK) were briefly 
immersed in 100% methanol and soaked in Transfer Buffer for 5 min. After -1 hr, 
gels containing the resolved proteins were removed from the glass plate housing. 
Stacking gels were discarded and the resolving gels were soaked in transfer buffer for 
10 min. Fibre pads and filter paper sets (2 sets per gel) were soaked in transfer buffer 
for 10 min. Two pieces of filter paper were laid over a saturated fibre pad and gel 
layered on to the filter paper (orientated to be identical to loading sequence) expelling 
all air bubbles. One piece of permeabilised Immobilon-PTM membrane was then 
layered over the gel, ensuring that no bubbles interrupted the contact between the gel 
and membrane. This was sandwiched between further layers of saturated filter paper 
and fibre pads. These stacks were transferred to transfer casings and placed into a tank 
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containing 1L of transfer buffer. Proteins were transferred electrophoretically at a 
constant voltage of 100V for Ihr. 
2.4.4 Primary Antibody Application. 
Following the transfer of proteins, membranes were removed from between the filter 
paper and fibre pads layers and trimmed to mark orientation and membrane number. 
Membranes were incubated with 10% non-fat milk solution (Marvel Milk Powder, 
Premier Brands, Merseyside, UK) diluted in 0.5% PBS (Tween 20 (0.1% (v/v), 
Sigma, Dorset UK) and placed on an orbital shaker for either 1 hr at RT or overnight 
for -14 hr at 4°C (conditions vary depending on the protein of interest). This 
procedure prevents the primary antibody binding directly to the PVDF membrane and 
further blocks non-specific binding of proteins to the membrane. Following blocking, 
membranes were rinsed 3 times in PBS and once in 0.1% PBS-T. Primary antibody 
was then prepared in sufficient quantity to cover the surface of the membrane at a 
concentration of 0.1% PBS and 0.1% PBS-T and incubated in a 50 ml centrifuge tube 
for 1 hr at RT or 4°C overnight on an orbital shaker. After -14 hr at 4°C, membranes 
were washed 3 times with PBS and once in PBS-T. Membranes were returned to the 
shaker for three 10 min washes in excess 0.1 % PBS-T. 
2.4.5 Secondary Antibody Application. 
Secondary antibody was made up in 0.1% PBS/PBS-T. Membranes were incubated at 
RT for 1 hr on an orbital shaker (80-100 cycles/min). Following incubation with 
secondary antibody, membranes were then rinsed three times in 0.1% PBS/PBS-T 
with three further 10 min washes in excess 0.1% PBS-T. 
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2.4.6 Immunodetection of Antibody Labelled Proteins. 
The secondary antibody allows the detection of specific proteins by serving as a 
catalyst for luminol, a substrate that luminesses, which part of an ECL plus Western 
blotting detection system (Amersham Pharmacia Biotech., Little Chalfont, 
Buckinghamshire, UK). The reaction is based on the oxidation of the cyclic 
diacylhydrazide luminol. Secondary antibody conjugated with horseradish-peroxidase 
(HRP) binds to the specific primary antibody that is attached to the protein of interest. 
Combined HRP and peroxide catalyses the oxidation of the lumigen PS-3 acridan 
substrate generating thousands of acridinium ester intermediates per minute (Figure 
2.4.6). These intermediates react with peroxide under slightly alkaline conditions to 
produce a sustained, high intensity chemiluminescence. The light exuding from the 
reaction can be visualised by application of photographic X-ray film or real-time 
digital photography. 
Peroxide + HRP 
buffer 
Peroxid 
Light -Olt - 
HF 
F 
+ Coe 
Figure 2.4.6 Chemiluminescent reaction of Lumigen PS-3 with horseradish- 
peroxidase (HRP) (Modified from Isacsson and Watermark 1974). 
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(Acrldfnium ester) 
(excited product) 
Following secondary antibody incubation and subsequent washes in PBS (120 mM, 
pH 7.6), membranes were ready for the immunodetection of proteins. Membranes 
were firstly placed protein side-up on saran wrap. ECL plus Solution A (Tris Buffer) 
was mixed with Solution B (Acridin Solution in Dioxane and Ethanol) at a 1/40 ratio 
to a volume required to cover each membrane (4 ml/membrane). This mixture was 
incubated on the membrane for 5 min at RT. Following incubation, ECL plus was 
discarded and the corner of the membrane blotted on tissue paper to remove excess 
ECL mixture. Membranes were then sandwiched between two sheets of clear plastic 
and excess ECL was removed with tissue paper and then placed into a film cassette. 
The filters were then exposed to photographic X-ray film (Kodak, UK) for varying 
times depending on the antibody used (1-60 min). 
2.4.7 Quantification of Western blot Protein Bands. 
Autoradiographs were quantified by gel blot analysis using UVP Gel Blot Analysis 
System (UVP, UK) and appropriate statistical analysis as detailed in individual results 
chapters (Chemigenius, Syngene, Cambridge, UK). 
2.5 Extraction & Quantification of RNA. 
2.5.1 RNA Isolation & Purification from Adipose Tissue for Quantitative PCR. 
A column-based method (RNeasy Lipid Tissue Mini Kit for total mammalian mRNA 
isolation (Qiagen, West Sussex, UK)) was implemented to extract mRNA from the 
adipose tissue in accordance with manufacturer's instructions. This process included a 
deoxyribonuclease (DNase) digestion step with 5µ1 DNase enzyme diluted in 5 µl 
reaction buffer (DNase Kit, Sigma, UK) (Appendix 1.3.1) to remove any 
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contaminating genomic DNA. The tubes containing these reactants were incubated at 
standard RT for 15 min before the reaction was quenched through the addition of 5 111 
of stop solution (Appendix 1.3.1) and immediate incubation at 70°C for 10 min. RNA 
was quantified with a spectrophotometer using a ratio of readings at a wavelength of 
260 and 280 nm. Once quantified the isolated RNA samples were stored at -70°C. 
2.5.2 Reverse Transcription of Isolated mRNA from Adipose Tissue. 
An aliquot containing 1µg of mRNA from each sample was pipetted into a sterile 
microcentrifuge tube along with 0.5 µl of random hexamers mixed in equal quantities. 
To standardise, nuclease free water was then added to each aliquot to make up a final 
volume of 10 µl. Each reactant mixture was then incubated at 70°C for 10 min. 
Reverse transcriptase (RTn) master mix was then prepared (Table 2.5.2) in sufficient 
quantities to allow for the required number of RTn reactions. After a thorough vortex, 
10 µl of master mix were added to each incubated sample of mRNA. Each sample 
was then vortexed, centrifuged briefly and heated at 37°C. After 1 hr, the reaction was 
quenched by a consecutive incubation at 95°C for 5 min to denature the enzymes. The 
resultant cDNA product was stored at -20°C for further use. The theory behind 
reverse transcription is outlined in Appendix 11.2.3. 
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Contents of Reverse Concentration in Final 20 
Transcription Master µL Volume 
Quantity Added (µL) 
Mix 
Reverse Transcription 
10X Reaction Buffer lx (v/v) 2.0 
(Mg2++ free) 
M2 25mM 5mM 4.0 
dNTPS 10 mM 
1 mM 2.0 
AMV (20 U/µl) 0.5 u/µl (v/v) 0.5 
RNasin (40 U/ 1 1 u/µl (v/v) 0.5 
Nuclease free H2O 5% 1.0 
Table 2.5.2 The contents of the reverse transcription master mix. The final volume of 
cDNA sample is 20 Al where 1 µl equals 50 ng of single stranded cDNA. 
2.5.3 Quantitative Real-Time PCR. 
The real-time PCR reaction was performed in 25 µl volumes on 96 well plates, in a 
reaction buffer (Taqman universal PCR master mix), containing 3 mM Mn(Oac)2, 
200 pM dNTPs, 1.25 units ampliTaq gold polymerase, 1.25 units ampErase LING, 
100-200 nmol Taqman probe, 900 nmol primers and 25-125 ng cDNA. All reactions 
were multiplexed with the housekeeping gene for the 18S ribosomal subunit, provided 
as a pre-optimised control probe (PE Biosystems, UK) enabling data to be expressed 
in relation to an internal reference to allow for differences in RT-PCR efficiency. Data 
were obtained as the cycle number at which logarithmic PCR plots cross a calculated 
threshold line or the Ct value. In accordance of the manufacturer's guidelines ACt 
values were determined (OCt=Ct of the target gene minus Ct of the housekeeping 
gene). Measurements were carried out in triplicate and the target gene probes were 
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labelled with the fluorescent label FAM, and the housekeeping gene with the 
fluorescent label VIC. Reactions are as described in Table 2.5.3. 
Times and Temperatures 
Thermal 
Cycler 1 of 44 cycles 
First Steps 
Melt Anneal/ Extend 
ABI Prism Hold Hold Cycle 
7700 
Sequence 2 min 10 min 15S 1 min 
Detector 50°C 95°C 95°C 62°C 
Table 2.5.3 RT-PCR reaction conditions as pre-set on the ABI 7700. 
2.5.4 Data Handling & Statistical Analysis. 
For RNA analysis to exclude potential bias due to averaging data, which had been 
transformed through the equation 2"54c`, all statistics were performed at the ACt stage. 
For both mRNA and protein findings, statistical analysis was undertaken using an 
unpaired Students' t-test. The threshold for significance was p<0.05. Data in the text 
and figures are presented as mean±SD. 
2.6 Separation of Serum from Blood. 
In preparation of serum samples, whole blood was drawn directly into a BD- 
vacutainer® (BD) serum tube containing silica clot activator. Each sample was left at 
RT for 30 min to allow the blood to clot. Once clotted, the samples were centrifuged 
at 698 xg for 15 min at RT. Supernatant was carefully drawn off; flash frozen then 
stored in labelled 1.5 ml centrifuge tubes at -80°C. 
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2.7 Collection & Processing of Cerebrospinal Fluid (CSF). 
Lumbar puncture was performed as part of a diagnostic evaluation. The sampling of 
CSF was performed according to standardised procedures with the examined subject 
in a lateral recumbent position and lumbar puncture at the L3-L4 or L5-L6 interspace 
with a standard needle. Prior to spinal anaesthesia injection, a clear volume of CSF 
was extracted. CSF samples were passed through a 0.2 microl syringe filter 
(Whatman, Florham Park, NJ, USA), aliquoted, flash frozen and stored at -80°C until 
analysis. 
2.8 Enzyme Linked Immunosorbent Assay (ELISA) & Radioimmunoassay 
(RIA). 
All ELISA and RIA based assays applied in this thesis were performed using ready 
prepared commercially available kits. The sources of these kits are outlined in the 
relevant chapters. In all cases, both ELISA and RIA analyses were carried out in 
accordance of the manufacturers' instructions of the individual kits. All the 
corresponding CV, intra- and interassay values are given for each individual assay in 
the relevant chapters. Appropriate statistical analysis for ELISA and RIA was carried 
out using a statistical software package (SPSS for Windows, Version 14.0, Woking, 
UK). 
2.8.1 Principles of ELISA & RIA Analysis. 
ELISA is an immunological technique for the detection and quantification of specific 
proteins. An antibody, specific to the protein of interest, is coated onto individual 
wells of a microtiter plate. Standardised samples (for example, serum samples), in 
which the protein of interest is contained, are then pipetted into the wells. During the 
first incubation, antigens of the protein of interest bind to the immobilised antibody, 
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on the base of the well. The wells are then washed and an antibody specific for the 
protein of interest is added. During the second incubation, this antibody serves as a 
detection antibody by binding to the immobilised protein captured during the first 
incubation. After removal of excess antibody, a HRP-labelled antibody is added, 
which binds to the detection antibody to complete the four-member sandwich. 
Following a third incubation and subsequent washing, a substrate solution is added, 
which is activated by the bound enzyme to produce colour. The colour intensity is 
directly proportional to the concentration of the protein of interest present in the 
original sample. The intensity of the colour is then read on a plate-reader (Tecan, 
UK), alongside a standard curve that is set up concurrently with the samples of 
interest. 
2.9 Principles of Bioplex Luminex Assays. 
The luminex multiplex system is a method of measuring several target proteins of 
interest simultaneously from small amounts of conditioned media, serum or plasma. 
The technology utilises 5.6 µm microspheres that are internally dyed with red and 
infra-red molecules. The molecular reactions then take place on the surface of 
microsphere sets that have been colour-coded using a blend of different fluorescent 
intensities of the two dyes. By using this method, multiple distinct microsphere sets 
can be created. The microspheres serve as molecular carriers that capture a sample; 
they are then tagged with a fluorescently-labelled reporter tag that binds to the 
captured sample on the microsphere. The microspheres are then injected into the 
instrument using microfluidics to align them in single file, where they pass through 
two lasers. One laser illuminates the colours inside the microsphere to identify which 
bead is being read and the second laser excites the colour on the bead surface. The 
83 
advanced optics capture the colour signals, digital signal processing translates the 
signals into real-time and quantitates data for each reaction. 
2.9.1 Laboratory Methodology for Luminex Assay. 
Multiple serum analytes were assayed using LincoPlex kits (Linco Research, 
Missouri, USA) details of individual kits are described in the relevant chapters. 
2.9.2 Panel Preparation. 
The human adipokine standard cocktail was reconstituted with 250 µl deionised and 
prepared into seven standards by serial dilution. The human adipokine controls were 
reconstituted with 250 µl dH2O and allowed to settle for at least 5 min. Wash buffer 
(Linco Research, Missouri, USA) (10X) was brought to RT and mixed to bring all 
salts into solution. This was then diluted with 270 ml of dH2O to form a 1X solution. 
Bottles containing the antibody beads were sonicated for 30 s and vortexed for 1 min. 
Each antibody (150 µl) was added to the mixing bottle and brought to final volume of 
3 ml with bead diluent. The filter plate was blocked by pipetting 200 µl of assay 
buffer into each well of the microtiter plate. This was sealed and mixed on a plate 
shaker for 10 min at RT. Assay buffer was removed by vacuum being careful not to 
invert plates and the bottom of the plates dried by using paper towels. Assay buffer 
(25 µl) was added to the 0 Standard (Background) wells. Each Standard or Control 
(25 µl) was added to the appropriate wells. Assay buffer (25 µl) was added to all 
wells. The sample of interest (25 Al) was then added the appropriate designated wells. 
A solution containing the mixed micospheres/beads (25 µ1) was then added to each 
well. The plate was sealed and covered with aluminium foil to reduce light 
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interference in on the reaction, then incubated with agitation on a plate shaker 
overnight (16-18 hr) at 4°C. 
2.9.3 Antibody Incubations. 
Following overnight incubation, the plate and reagents were allowed to warm to RT 
before continuing with the assay. The fluid was gently aspirated by vacuum. The plate 
was then washed 3 times with 200 µl per well of wash buffer, and wash buffer 
removed using vacuum filtration between each wash. The bottom of the plate was 
then dried by using paper towels. Detection antibody cocktail (50 111) was pipetted 
into each well having allowed the detection antibody to warm to RT prior to addition. 
This was then sealed, covered with aluminium foil, and incubated with agitation on a 
plate shaker for 30 min at RT. 
2.9.4 Detection & Analysis. 
Streptavidin-Phycoerythrin (SAPE) (50 µl) was then added to each well having 
allowed the SAPE to warm to RT prior to addition. This was sealed, covered with 
aluminium foil, and incubated with agitation on a plate shaker for 30 min at RT. All 
contents were then gently removed by vacuum. The plate was washed 3 times with 
200 µl per well wash buffer, with the wash buffer removed by vacuum filtration 
between each wash. Excess buffer was removed from the bottom of plate with tissue. 
Sheath fluid (100 µl) was then added to all wells. The plate was then covered with 
aluminium foil and the beads were re-suspended on a plate shaker for 5 min. The plate 
was then read on the Luminex10° multiplex reader (BioRad, UK). The median data 
was then evaluated using the appropriate software using 5-parameter data reduction. 
85 
2.10 Principles of Fast Protein Liquid Chromatography (FPLC): Separation of 
Protein Complexes by Size-fractionation. 
Gel-filtration (also termed size-exclusion chromatography) is a liquid- 
chromatography technique that separates proteins according to their size (sub- 
fractionation) as they pass through a high performance gel-filtration medium, pre- 
packed in a glass column (in this case, the Superdex 200 10/300 GL column was 
utilised). Ultimately, allowing analysis of the molecular-weight distribution within a 
protein of interest, further allowing the separation of monomers from their 
corresponding aggregates. 
To perform a separation, gel filtration medium is packed into a column to form a 
`packed bed'. The packed bed is a porous matrix consisting of stable and inert 
spherical particles. The medium is equilibrated with a choice of column running 
buffer (Appendix 1.4) that fills the pores of the matrix and the space in between the 
particles. The liquid inside the pores is called the `stationary phase' and this is in 
equilibrium with the liquid outside the particles, the `mobile phase'. 
The sample of interest is then applied to the column. The buffer (mobile phase) and 
sample move through the column. Molecules diffuse in and out of the pores of the 
matrix (partitioning of the sample between the mobile and stationary phase). Smaller 
molecules move further into the matrix and so stay longer on the column. As buffer 
passes continuously through the column, molecules that are larger than the pores of 
the matrix are unable to diffuse into the pores and pass through the column. Smaller 
molecules diffuse into the pores and are delayed in their passage down the column. 
Large molecules leave the column first followed by smaller molecules in order of 
their size. The entire separation process takes place as one total column volume. 
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2.10.1 Equilibration of the GL Column (Sephadex 20010/300). 
To equilibrate the GL Column prior to use, sterile Column running buffer was firstly 
de-gased for 20 min using a vacuum pump to remove air-bubbles. Following de- 
gasing, 15 ml of the column running buffer (25 mM HEPES, 150 mM NaCl, 1 mM 
CaC12; pH 8.0) (Appendix 1.4) was flushed through the column at a constant flow- 
rate of 0.25 mS/ml and pressure of 100 psi for 1 hr at RT. Following equilibration, the 
column was ready for sample injection as described below. 
2.10.2 Preparation & Injection of Serum Prior to Size-fractionation. 
Prior to use, serum samples were gently thawed over ice. Once thawed, 30 pl of 
sample was spun at 16,060 xg for 10 min. Column running buffer (20 µl) (25 mM 
HEPES, 150 mM NaCl, 1 mM CaC12; pH 8.0) was added to the sample. The sample 
mixture was then injected into a GL column (Superdex 200 10/300, Amersham 
Biosciences Corp., New Jersey, USA). Samples were run down the column at a flow- 
rate of 0.70 mS/ml, the pressure of 100 psi and conductivity set to -20 m/s. In total, 
25 (200 Al) gradient-fractions were collected sequentially from the sample. Serum 
fractions were then analysed by quantitative Western blot analysis (Chapter 6). 
2.10.3 Preparation & Injection of CSF Prior to Size-fractionation. 
Adiponectin knockout mouse serum (20 µl) (kindly donated by A. Nawrocki, Scherer 
laboratory, New York, USA) was added to 200 Al of CSF sample to mimic in vivo 
conditions and serve as a protein carrier. The sample mixture was then spun at 16,060 
xg for 10 min before injected into the Superdex 200 10/300 GL column undiluted. In 
total, 25 (200 µl) gradient-fractions were sequentially retrieved from the sample. The 
CSF fractions (200 µl) were further vacuum concentrated for 1 hr (SpeedVac Plus, 
USA). Fractions were subsequently analysed by Western blot analysis (Chapter 6). 
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2.10.4 Visualisation of Sub-fractionated Protein & Subsequent Statistical 
Analysis. 
Following Western blot procedure, fluorescently-labelled protein bands were then 
visualised using an Infrared Imager (LI-CUR Biosciences, Nebraska, USA) using 
imaging software (Odyssey Infrared Imaging System; Version 1.2). A typical protein 
Western blot following sub-fractionation and scanned using the described Infrared 
Imager and software system is shown in Figure 2.10.4. 
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Figure 2.10.4 An example of a Western blot following sub-fractionation protein. The 
Infrared Imager allowed visualisation of proteins, probed with a fluorescent-dye 
conjugated antibody system (as detailed in Chapter 6). 
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CHAPTER 3 
The Expression of Resistin in Human Obesity 
& the Innate Immune Signalling Pathway in Obesity & T2DM 
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3.1 Introduction. 
Resistin, the recently discovered 14 kDa adipokine, is a member of the RELM family 
of cysteine-rich proteins (Steppan et al. 2001). Initially, rodent studies implicated 
resistin as a factor linking obesity and diabetes (Steppan et al. 2001). Subsequent 
analysis demonstrated that resistin administration or transgenic over-expression 
severely induces hepatic insulin resistance by increasing glucose production (Rajala et 
al. 2003; Rangwala et al. 2004). Alternatively, resistin anti-sense oligonucleotide 
treatment reverses hepatic insulin resistance and normalises glucose homeostasis 
(Muse et al. 2004); similarly, resistin knockout mice exhibit lower blood glucose 
levels due to reduced hepatic glucose production (Banerjee et al. 2004). Similar 
metabolic defects occur in peripheral skeletal muscle tissues, as transgenic over- 
expression of resistin and adenovirus-mediated hyper-resistinemia in rats was shown to 
impair insulin-stimulated glucose utilisation (Pravenec et al. 2003; Satoh et al. 2004). 
Resistin therefore serves primarily to exacerbate hepatic insulin sensitisation in vivo 
(Rajala et al. 2003; Banerjee et al. 2004; Muse et al. 2004; Rangwals et al. 2004), 
with secondary peripheral effects on lipid oxidation in skeletal muscle and adipose 
tissues (Pravenec et al. 2003; Satoh et al. 2004). 
With regards to obesity, systemic levels of resistin are increased in various diet- 
induced and genetic models of obesity (Steppan et al. 2001; Lee et al. 2004), which 
are further concordant with increasing levels of insulin, glucose and lipids (Rajala et 
al. 2004). Additionally, high-fat fed mice have induced adipocyte differentiation, as 
denoted by fatty acid binding-protein-2 (FABP-2) expression and a positive 
correlation with resistin expression (Asensio et al. 2004). Human adipose tissue 
studies have demonstrated increased resistin expression in obese adipose tissue 
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(Degawa-Yamauchi et al. 2003), particularly central abdominal depots (McTernan et 
al. 2002; McTernan et al. 2002). Furthermore, obese subjects have higher circulating 
resistin levels in comparison to lean subjects (Degawa-Yamauchi et al. 2003; Schaffler 
et al. 2004; Vendrell et al. 2004), which positively correlate with BMI (Azuma et al. 
2003; Degawa-Yamauchi et al. 2003; Yannakoulia et al. 2003; Vozarova de Courten 
et al. 2004) and body-fat content (Zhang et al. 2002). In contrast, circulating resistin 
levels are significantly reduced following moderate weight loss (Valsamakis et al. 
2004) and post gastric bypass (Vendrell et al. 2004). 
In addition to its role in obesity, the concept of resistin as a pro-inflammatory 
adipokine in humans is emerging (Bokarewa et al. 2005; Silswal et al. 2005). 
Circulating levels of resistin are associated with TNF-a receptor-2 (TNF-R2) and are 
predictive of coronary atherosclerosis (Reilly et al. 2005). Furthermore, endotoxemia 
has been shown to increase serum resistin levels, concurrently with soluble TNF-R2 
levels in T2DM patients (Lehrke et al. 2004). The precise role of resistin inflammation 
is, however, yet to be established. 
It is recognised that obesity is associated with a pro-inflammatory milieu, leading to 
chronic activation of the innate immune system (Dandona et al. 2004); this eventually 
causes progressive impairment of glucose tolerance. Innate immunity provides the first 
line of defence against invading pathogens and noxious stimuli (Goldstein 2004). The 
innate immune signal transduction pathway is initiated when certain microbial 
components or endogenous lipoproteins are recognised by a group of pattern- 
recognition receptors, the TLRs (Takeda et al. 2005). TLR activation causes its 
association with the cytoplasmic adapter molecule MyD88 through its Toll-interleukin 
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1 receptor-resistance (TIR) domain (Hoebe et al. 2004). MyD88 recruitment thus 
triggers a downstream signalling cascade, which includes activation of the common 
signalling adapter molecule, TRAF-6. Consequently, sequential activation of 
downstream kinases and the primary transcriptional regulator, NF-KB, thus initiates 
transcription of inflammatory factors (Zhang et al. 2001). 
Reduced atherosclerosis in MyD88-null mice has been proposed to link elevated 
serum cholesterol levels to activation of innate immune signalling pathways 
(Bjorkbacka et al. 2004). Moreover, NF-KB is activated in rodent liver in two common 
models of obesity, high-fat diet and genetic hyperphagia (ob/ob mice and fa/fa rats) 
(Cai et al. 2005); such hepatocelluar activation of NF-KB in mice further caused 
profound hepatic insulin resistance and moderate systemic insulin resistance (Cai et al. 
2005). Recent rodent studies thus highlight associations between increased lipid levels 
and insulin resistance with components of the innate immune pathway. The expression 
of these key intermediates of the innate immune pathway in obese and type 2 diabetic 
human adipose tissue are, however, yet to be determined. 
It has been acknowledged that with increasing adiposity, there is profound 
macrophage infiltration into expanding adipose tissue (Weisberg et al. 2003; Xu et al. 
2003); macrophages may thus represent an alternative site of an innate immune 
response within adipose tissue. It has further been proposed that the initial innate 
immune response originates from pre-adipocytes and adipocytes (Wellen et al. 2003); 
secreting low levels of TNF-a and monocyte chemotactic protein-1 (MCP-1), 
respectively. Such factors `initiate' an innate immune inflammatory response, thereby 
recruiting circulating macrophages into the expanding adipose tissue; consequently 
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macrophages serve to `amplify' such an inflammatory response in obese adipose 
tissue. Alternatively, it has been proposed that macrophage recruitment may arise from 
phenotypic alteration of pre-adipocytes (Charriere et al. 2003), possessing potent 
phagocytotic capacity (Wellen et al. 2003). Furthermore, many genes that are critical 
to adipocytes, such as PPAR-y and FABP-2, are also expressed in macrophages 
(Tontonoz et al. 1998; Makowski et al. 2001). Similarly, adipocytes have been shown 
to express inflammatory genes, such as TNF-a (Xu et al. 2003). It has further been 
proposed that increased adipose tissue mass is responsible for the elevated circulating 
levels of resistin in obesity. In rodents, resistin is expressed primarily in adipocytes 
(Steppan et al. 2001). In humans however, although the macrophages that have 
infiltrated adipose tissue in states of obesity serve as the primary source of circulating 
resistin, it has not been fully substantiated as to whether or not human resistin is 
expressed and secreted from adipocytes, particularly within states of obesity. 
The focus of this study was therefore to (1) establish the association between 
increasing adiposity and the expression of resistin and CD45, a known marker for 
macrophages, in human isolated Abdominal Subcutaneous (AbSc) adipose tissue (AT) 
(2) investigate whether resistin is expressed in human isolated AbSc adipocytes at a 
protein level, in relation to obesity; (3) examine the innate immune pathway in human 
AbSc adipose tissue, in particular the expression of key intracellular components of 
the pathway, in relation to increasing adiposity and type 2 diabetic status, (4) 
validation of a commercially available resistin ELISA. Finally, determine whether 
systemic levels of resistin are influenced by the antigenic stimuli, LPS and zymosan, 
within human isolated AbSc adipocytes. 
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3.2 Subjects, Methods & Materials. 
3.2.1 Subjects. 
For non-diabetic studies, whole AbSc AT was obtained from a human non-diabetic 
Caucasian population (BMI: 26.5±5.9 kg/m2; age: 36-49 yrs; n=35; 4 smokers, 31 
non-smokers; all female subjects) undergoing elective liposuction surgery. Those 
patients receiving endocrine therapy (steroids, hormone replacement therapy or 
thyroxine), anti-inflammatory therapy (aspirin, cyclooxygenase-2 inhibitors), statins, 
TZDs or any antihypertensive therapy were excluded from the study. For diabetic 
studies, whole AbSc AT was obtained from Caucasian type 2 diabetic subjects (BMI: 
28.2±1.6 kg/m2; age: 61±4 yrs; n=6; male subjects, n=5; female subjects, n=1; all non- 
smokers) and BMI-matched Caucasian non-diabetic subjects (BMI: 29.2±1.9 kg/m2; 
age: 46±2 yrs; n=6; male subjects, n=2; female subjects, n=4; all non-smokers) by 
liposuction elective surgery. Studies were performed with the approval of the local 
ethics committee with informed consent being obtained from all subjects prior to 
enrolment. 
3.2.2 Isolation & Treatment of Mature AbSc Adipocytes. 
AbSc AT was digested in collagenase (2 mg/ml; Worthington Biochemical, USA) to 
isolate the mature adipocytes, as previously outlined in Chapter 2.1.2. Aliquots of 
mature adipocyte cells (1 ml; -500,000 adipocytes) were then cultured in 5 ml of 
phenol red-free DMEM: F-12 medium, containing 15 mM glucose, penicillin (100 
U/ml), streptomycin (100 µg/ml) and 1% transferrin, with or without antigenic stimuli 
treatment, as highlighted below. 
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For antigenic stimuli studies, adipocytes were maintained in the culture medium for 14 
h, treated with either a bacterial endotoxin, LPS (100 ng/ml; Sigma-Aldrich Company 
Ltd., Poole, UK) or a fungal antigen, zymosan (30 Ug/ml; Sigma-Aldrich Company 
Ltd., Poole, UK) or untreated to serve as matched paired controls. Dose and time- 
responses for LPS and zymosan were previously established (LPS: 1-100 ng/ml; 14, 
24 and 48 h; zymosan: 1-100 µg/ml; 14,24 and 48 h). Adipocytes maintained in 
untreated media were used as controls. A trypan blue dye (Sigma-Aldrich) exclusion 
method was used to assess the viability of the adipocytes, as previously documented in 
Chapter 2.1.4. Following treatment, the adipocytes and conditioned media were 
separated by centrifugation (360 xg for 2 min). Adipocyte conditioned media were 
removed and stored at -80°C. Adipocyte cells were then re-suspended in either 4% 
SDS or RIPA buffer solution for extraction of protein, (as previously detailed in 
Chapter 2.2.2) then stored at -80°C. 
3.2.3 Protein Determination & Western blot Analysis. 
Homogenised human AbSc AT and isolated adipocytes were re-suspended in 4% SDS 
or RIPA buffer solution, as previously detailed in Chapter 2.2. Protein concentrations 
were determined using the Bio-Rad DC (Detergent Compatible) protein assay kit 
(Bradford 1976). Western blot analysis was performed using the method previously 
described in Chapter 2.5. In brief, 20-60 µg of protein was loaded onto a 8-15% 
polyacrylamide gel (Geneflow Ltd., Fradley, UK). A human resistin polyclonal 
antibody (1: 3000, Linco Research, Missouri, USA) was utilised to assess resistin 
expression. rhResistin (1 µg/ml; Phoenix Pharmaceuticals, Belmont, CA, USA) was 
further used to confirm the specificity of the primary antibody. Resistin was developed 
using an anti-guinea-pig HRP secondary antibody (Biogenesis Ltd., Poole, UK). A 
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polyclonal MyD88 antibody (1: 250, TCS Cellworks, UK) and a polyclonal TRAF-6 
antibody (1: 500, TCS Cellworks, UK) were used to assess MyD88 and TRAF-6 
protein expression respectively. Both MyD88 and TRAF-6 were developed using an 
anti-rabbit HRP secondary antibody (The Binding Site, Birmingham, UK). Protein 
expression of NF-KB (1: 250, TCS Cellworks, UK) was assessed using mouse 
monoclonal antibodies. Equal protein loading was confirmed by examining a-tubulin 
(1: 5000) (The Binding Site, Birmingham, UK) protein expression. No statistical 
difference was observed in a-tubulin expression for all samples analysed. For reducing 
conditions, samples were mixed in a 1: 2 ratio with sample buffer containing 20% ß- 
mercaptoethanol. A chemiluminescent detection system ECLIECL+ (Amersham 
Pharmacia Biotech, Little Chalfont, UK) enabled visualisation of bands, whilst 
intensity was determined using densitometry (Genesnap, Syngene, UK). 
3.2.4 RNA Extraction & Quantitative RT-PCR. 
RNA was extracted from whole AT using the RNeasy Lipid Tissue Mini Kit (Qiagen, 
UK). RNA extraction was followed by a deoxyribonuclease (DNase) digestion step to 
remove any contaminating genomic DNA. 1 µg of RNA was reverse transcribed using 
RevertAid H Minus M-MuLV reverse transcriptase (Helena Biosciences Europe, 
Sunderland, UK) and random hexamers in 20 µl reaction volumes, according to the 
manufacturers' instructions. Messenger RNA levels were determined using an ABI 
7500 Real-time PCR Sequence Detection system. The reactions were performed in 25 
µl volumes in reaction buffer containing TaqMan Universal PCR Master Mix, 150 
nmol TaqMan probe, 900 nmol primers and 50 ng cDNA (for CD45 expression, a 
known marker for macrophages) or 115 ng cDNA (for resistin expression). Previously 
determined quantitative primer and probe sequences for the resistin and CD45 genes 
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were utilised (McTernan et al. 2003). All reactions were multiplexed with the 
housekeeping gene 18S, provided as a pre-optimised control probe (Applera, Cheshire, 
UK), enabling data to be expressed as delta cycle threshold (ACt) values (OCt=Ct of 
18S subtracted from Ct of gene of interest) in order to correct for differences in the 
efficiency of reverse transcription. Measurements were carried out on at least three 
occasions for each sample. 
3.2.5 Assessment of Resistin Secretion from Treated AbSc Adipocytes. 
Conditioned media from cultured control untreated AbSc adipocytes and LPS or 
zymosan treated adipocytes, were assayed using the previously validated human 
resistin ELISA (Phoenix Europe GmbH, Germany) (Intra-assay CV, <3%; Inter-assay 
CV, <10%). Minimum Detectable Concentration (sensitivity of assay) was 0.016 
ng/ml. 
3.2.6 Statistical Analyses. 
Protein expression data between control and treatments were compared using an 
unpaired Student's t-test. Due to the normal distribution of resistin, an unpaired t test 
was used to assess protein expression data. Results are presented as mean±SD. 
Analyses were carried out using the SPSS (SPSS Inc. 14.0, Woking, UK) statistical 
software package. Correlation analyses were calculated using a Pearson' Correlation 
Coefficient test. The threshold for significance was p<0.05. 
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3.3 Results. 
3.3.1 Resistin & CD45 mRNA Expression in Human AbSc Adipose Tissue. 
Resistin mRNA expression in AbSc AT (AT obtained form all Caucasian subjects) 
was evaluated with increasing adiposity (BMI range, 19.2-37.04 kg/m2; n=24; all 
female subjects). Results demonstrated that resistin expression positively correlates 
with increasing BMI in AT (ACT range, 25.0-30.7; r2=0.461; p<0.001) (Figure 3.3.1). 
Further analysis of CD45 expression with increasing adiposity showed a similar but 
weaker correlation (ACT range, 20.0-23.6; r2=0.226; p<0.02) (Figure 3.3.1). 
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Figure 3.3.1 Relative resistin mRNA expression levels (ringed data points) and CD45 
mRNA (solid data points) expression levels in AbSc AT positively correlates with 
increasing adiposity. The median OCt, in the range of values, was assigned an 
arbitrary value of 1; the other expression levels were standardised to this. (Resistin: 
rz=0.461; p<0.001; CD45: r2=0.226; p<0.02). 
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3.3.2 Resistin Protein Expression in Lean & Obese Adipose Tissue & Isolated 
Adipocytes. 
Resistin mRNA data was confirmed with assessment of resistin protein expression in 
AbSc AT in lean (BMI: 21.2±1.4 kg/m2 , n=8) and overweight (BMI: 33.9±4.6 
kg/r2, 
n=8) subjects. Resistin protein expression in Abd Sc AT was 1.5-fold higher in obese 
AT (BMI: 33.9±4.6 kg/m2, n=8) when compared with lean AT (BMI: 21.2±1.4 kg/m2, 
n=8) (p<0.001) (Figure 3.3.2.1). 
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Figure 3.3.2.1 The relative fold change in resistin expression in AT of lean subjects 
(BMI: 21.2±1.2 kg /m`; n=8) when compared to obese subjects (BMI: 33.9±4.6 kg/m2; 
n-g) *** p<O. 001. 
Furthermore, when examining isolated AbSc adipocytes, a 2.2-fold higher level of 
resistin protein expression was observed in overweight subjects (BMI: 28.3+2.7 
kg/m2, n=4) in comparison to lean subjects (BMI: 23.2±1.6 kg/m2, n=4; p<0.001) 
(Figure 3.3.2.2). 
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Figure 3.3.2.2 The relative fold change in resistin expression in adipocytes of lean 
subjects (BMI: 23.2±1.6 kg/m2; n=4), in comparison to overweight subjects (BMI: 
28.3±2.7 kg/m2; n=4) ***, p<0.001. Equal protein loading was determined by a- 
tubulin. 
3.3.3 Analysis of Protein Expression of Components of the Innate Immune 
Pathway in Lean & Obese Adipose Tissue: The `Effect of Obesity'. 
Assessment of MyD88, TRAF-6 and NF-KB protein expression in obese AbSc AT in 
comparison to lean AbSc AT demonstrated that these components were all increased 
within AbSc AT taken from obese subjects compared with AbSc AT taken from lean 
subjects (MyD88: 1.94-fold increase in obese AbSc AT, p<0.001, n=6; TRAF-6: 1.13- 
fold increase in obese AbSc AT, p<0.05, n=6; NF-KB: 1.23-fold increase in obese 
AbSc AT, p<0.05, n=6) (Figure 3.3.3). 
100 
Lean ove«veight 
AbSe Adipocytes AbSc Adipocytes 
R 
0 
17 
L 2.5 
c. s 
Y' 
a 
=Z2.0 
C EO 
1.0 
vx C o0 
V ý, 
Zo 2 0.5 
Gý Cf. 
iº C 
. 
2- 0.0 
Q# 14 
MyD88.32 kl>a TRAF-6; 54 kDa NF-, d3; 65 kDa 
Non-obese AbSc 
Adipose Tissue 
  Obese AbSc 
Adipose ]'issue 
Figure 3.3.3 The relative fold change in MyD88, TRAF-6 and NF-xB protein 
expression in AbSc AT from obese subjects (BMI: 32.6± 1.1 kg/m2; n=8) in 
comparison to AbSc AT from lean subjects (BMI: 23.0±1.1 kg/r2; n=8) p<0.05; 
***, p<0.001. MyD88, myeloid differentiation primary response gene-88; TRAF-6, 
TNF receptor-associated factor-6; NF-KB, nuclear factor-KB. 
3.3.4 Assessment of Protein Expression of Factors of the Innate Immune Pathway 
in AbSc AT from T2DM Subjects & Non-diabetic Controls: The `Effect of 
Diabetic Status'. 
Western blot analysis of MyD88, TRAF-6 and NF-KB revealed that protein expression 
of these components were significantly increased within AbSc AT from T2DM 
subjects in comparison to non-diabetic AbSc AT (MyD88: 1.38-fold increase in 
T2DM AT, p<0.01, n=6; TRAF-6: 1.32-fold increase, p<0.01, n=6; NF-KB: 1.93-fold 
increase in T2DM AT, p<0.001, n=6) (Figure 3.3.4). 
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Figure 3.3.4 The relative fold change in MyD88, TRAF-6 and NF-KB protein 
expression in AbSc AT from T2DM subjects (BMI: 28.2±1.6 kg/m2; n=6) in 
comparison to AbSc AT from non-diabetic subjects (BMI: 29.2±1.9 kg/m2; n=6) 
P<0.05; ***, p<0.001. MyD88, myeloid differentiation primary response gene-88; 
TRAF-6, TNF receptor-associated factor-6; NF-KB, nuclear factor-KB. 
3.3.5 Resistin Assay Validation: Recovery of Recombinant Resistin & Cross- 
reactivity with RELMs. 
For this study, the R&D Systems human resistin ELISA (resistin range: 0-10 ng/ml) 
was validated for recovery of spiked recombinant resistin and potential cross-reactivity 
with other RELMs. Known concentrations of recombinant human resistin (rhResistin) 
(1,5 and 10 ng/ml; R&D Systems, UK) were added to pooled serum (10.5 ng/ml). The 
recovery of spiked resistin was above 80% efficiency. To assess cross-reactivity with 
other RELMs, known concentrations of RELM-u/FIZZ I or RELM-(3/FIZZ 2 partial- 
peptides (1,2.5, and 5 ng/ml; Alpha Diagnostics, Eastleigh, UK) and rhResistin (5 
ng/ml) were co-incubated with pooled serum (10.5 ng/ml), an aqueous solution or 
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ý1y 1)88; 32 kl)a TRAF-6; 54 kDa NF-x13; 65 kl)a 
serum matrix containing rhResistin (5 ng/ml). The addition of both RELMs to the 
different treatments did not interfere with the resistin assay, nor alter known or 
expected serum resistin concentrations. The human resistin ELISA previously 
validated (Phoenix Europe GmbH, Germany) was additionally used in this study 
(McTernan et al. 2003). 
3.3.6 The Effect of Antigenic Stimuli on the Level of Resistin Secretion from 
Isolated AbSc Adipocytes: An Introduction to Resistin in the Innate Immune 
Pathway. 
Analysis of resistin secretion from isolated AbSc adipocytes in response to antigenic 
stimuli, demonstrated that LPS stimulates a 2.2-fold increase in the level resistin 
secretion from isolated adipocytes (Control: 1.24±0.2 ng/ml; LPS: 2.75±0.4 ng/ml; 
p<0.001; n=8). Similarly, zymosan also shown to enhance a 2.5-fold increase in the 
level of resistin secretion from adipocytes when compared to control adipocytes 
(Control: 1.24±0.2 ng/ml; zymosan: 3.1±0.3 ng/ml; p<0.001; n=8) (Figure 3.3.6). 
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Figure 3.3.6 The level of resistin secretion from isolated adipocytes in response to the 
antigenic stimuli, lipopolysaccharide (LPS) or zymosan (n=8). Controls were 
untreated adipocytes. Values obtained with LPS or zymosan treatments were 
compared to these untreated controls. ***, p<0.001. 
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3.4 Discussion. 
This study firstly demonstrated that resistin expression positively correlates with 
increasing adiposity in AbSc AT. Furthermore, an established marker of macrophages, 
CD45, demonstrated a comparable, albeit weaker correlation with increasing 
adiposity. Such observations suggest that other cells, in addition to macrophages, may 
contribute to elevated levels of resistin in states of obesity; for instance pre-adipocytes 
(McTernan et al. 2002) or adipocytes. To explore this, resistin protein expression was 
investigated in human AbSc AT and isolated AbSc adipocytes. It was established that 
the level of resistin protein expression was increased in AT obtained from obese 
subjects in comparison with AT from lean subjects. Similarly, an increased level of 
resistin was expressed in AbSc adipocytes isolated from obese AT in comparison with 
AbSc adipocytes isolated from lean AT. Further studies included the examination of 
the adipocyte as a potential site for an innate immune response. 
Previous mRNA studies have demonstrated that resistin gene expression is most 
predominant in human macrophages, whilst virtually undetectable in isolated human 
adipocytes (Savage et al. 2001; Patel et al. 2003), thus suggesting a similar scenario at 
the protein level. Initial and current studies however, demonstrate resistin protein 
expression and secretion from human isolated adipocytes; this has been confirmed by 
recent observations (Pagano et al. 2005; Curat et al. 2006). Possible explanations in 
such diverse quantitative levels between resistin mRNA expression and circulating 
resistin levels include differences in post-transcriptional and post-translational 
modifications (Rajala et al. 2003; Asensio et al. 2004), consequently affecting the 
secretory rates of resistin. Alternatively, increased systemic levels of resistin may 
enhance transcript degradation rates via negative feedback mechanisms, or the 
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initiation and recruitment of inhibitors of transcription. The secreted form of resistin is 
believed to possess paracrine properties; this implies that the majority of regulation of 
resistin may occur at the protein level. 
It is now acknowledged that increased infiltration of macrophages into adipose tissue 
occurs in states of obesity (Weisberg et al. 2003; Xu et al. 2003). Macrophages are 
thus considered to account for the majority of circulating levels of resistin in states of 
obesity (Kaser et al. 2003; Patel et al. 2003). In addition to this, adipocytes have been 
shown to secrete approximately a quarter of the total amount of resistin produced by 
macrophages (Curat et al. 2006), suggesting that both cell-types are responsible for the 
elevated levels of resistin in circulation. Adipocytes may, therefore, make a 
considerable contribution to the increased systemic levels of resistin in humans, which 
may become increasingly relevant in states of increased adipose tissue mass. More 
specifically, the adipocyte may therefore serve as an undervalued contributor to the 
circulating levels of resistin in obesity. Future studies will further have to address 
resistin levels in adipose tissue and isolated adipocytes in relation to ethnicity and 
gender. Yannakoulia et al. reported that systemic resistin levels are higher in females 
than males; whether this is true for adipose tissue protein expression levels is yet to be 
determined. 
This study demonstrated that in addition to the adipokine resistin, protein expression 
of key intermediates of the innate immune signalling cascade, in particular, MyD88, 
TRAF-6 and NF-xB is significantly increased in obese AT in comparison to lean AT. 
Moreover, Western blot analysis further revealed that MyD88, TRAF-6 and NF-KB 
protein expression was also significantly increased in AbSc AT obtained from T2DM 
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subjects in comparison to BMI matched non-diabetic AbSc AT. Such increased 
expression levels of components of innate immune pathway implies that in states of 
obesity and T2DM, there is enhanced activation of innate immunity. Consequently, 
this may produce abnormal levels of inflammatory molecules, such as TNF-a and IL- 
6, thus contributing to an altered pro-inflammatory milieu and potentially exacerbating 
insulin resistance. Taken together, this study re-affirms interrelationships between 
excess adipose tissue mass, inflammation, insulin resistance and T2DM. 
Whilst a role for resistin and components of the innate immune pathway in human 
obesity are highlighted, a paradigm of resistin as a pro-inflammatory factor is 
emerging. To further analyse resistin in relation to the innate immune pathway, we 
examined whether bacterial and fungal antigenic stimuli, previously known to 
stimulate an inflammatory cascade in fully intact 3T3-L1 adipocytes (Lin et al. 2000), 
could influence the level of resistin secretion from isolated human AbSc adipocytes. 
Following validation of a commercially available ELISA, it was established that the 
bacterial antigen LPS, in addition to the fungal antigen zymosan, increased the level of 
resistin secretion from isolated adipocytes. Such observations coincide with recent 
studies, demonstrating that endotoxemia increases circulating resistin levels in healthy 
subjects (Lehrke et al. 2004), highlighting antigenic stimuli can increase resistin levels 
in vivo. Collectively, these studies suggest that resistin may directly contribute to an 
altered pro-inflammatory cytokine status and, therefore promote inflammation. 
In conclusion, this study suggests that adipocytes may be a contributory source of 
resistin in human obesity. Furthermore, resistin responds to LPS and zymosan 
treatment, suggesting an involvement of resistin in the innate immune pathway in 
human adipose tissue. Further studies thus examining resistin function in concordance 
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with factors of the innate immune signalling pathway would prove beneficial in 
defining a role for resistin in inflammation. 
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CHAPTER 4 
The In vitro Pro-inflammatory Actions of rhResistin 
on Components of the 
Innate Immune Pathway & Insulin Signalling Cascade 
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4.1 Introduction. 
The association between central obesity, insulin resistance and T2DM has been 
established; however, the underlying mechanisms of this association remain unclear. 
Besides its metabolic functions, increased adipose tissue mass is now recognised to 
have immunological characteristics, primarily through the secretion of adipokines, such 
as leptin, TNF-a and IL-6 (Rajala et al. 2003). Such inflammatory mediators are 
increased in the insulin resistant states of obesity and T2DM, which suggests that 
inflammatory mechanisms may underly these conditions. Within this context, adipose 
tissue is now considered to integrate metabolic and immune functions. Such a duality of 
function may represent a conserved evolutionary mechanism, as suggested by 
observations examining the `fat body' in Drosophila fruitfly; in which a single cell-type 
with developmental heritage serves as a primary integrator for both pathogen and 
nutrient-sensing pathways (Tzou et al. 2002). 
The adipokine resistin was originally described as a potential molecular link between 
obesity and insulin resistance in rodents; this has however, remained somewhat 
controversial in humans, due to contrasting data (Steppan et al. 2004). In rodents, 
resistin is expressed primarily in adipocytes and employs a more metabolic role, by 
impairing glucose tolerance and inducing liver-specific antagonism of insulin 
sensitivity in vivo (Rangwala et al. 2004). In humans however, a more `pro- 
inflammatory' function for resistin has been defined (Bokarewa et al. 2005; Silswal et 
al. 2005). Although resistin gene expression is largely confined to macrophages 
(Savage et al. 2001; Patel et al. 2003), recent studies have reported resistin protein 
expression and secretion from human isolated adipocytes (McTernan et al. 2002; 
McTernan et al. 2003; Pagano et al. 2005; Curat et al. 2006). 
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Human serum profiles have highlighted increased circulating levels of resistin in obese, 
insulin resistant and T2DM states, which further correlate with CRP (McTernan et al. 
2003), a marker of inflammation and a recently established predictor of cardiovascular 
disease (CVD) (Ridker et al. 2002). Such a correlation between CRP and serum resistin 
has also been identified by subsequent studies on pre-diabetic, T2DM subjects (Stejskal 
et al. 2003; Shetty et al. 2004) and individuals with acute rheumatoid arthritis 
(Bokarewa et al. 2005), further identifying resistin as a potential pro-inflammatory 
marker. Although the majority of studies report associations between resistin and 
inflammatory conditions, the precise mechanistic action of resistin in inflammation, 
particularly in concordance with components of the innate immune pathway, is 
currently unclear. 
Innate immunity serves as the first line of defence against pathogens, contributes to the 
eradication of such pathogens and further forms the basis of adaptive immunity. 
Furthermore, the innate immune system is a potential candidate for the production of 
elevated circulating levels of cytokines in obesity and T2DM. Previous studies have 
demonstrated the presence of a fully intact pathway of innate immunity in the adipocyte 
(Lin et al. 2000), activated when specific pattern-recognition receptors, the Toll-like 
receptors (TLRs), recognise and bind a broad spectrum of microbial components. For 
instance, TLR-4 binds the bacterial antigen LPS, through its co-receptor, CD14; 
alternatively, TLR-2 binds the fungal antigen, Zymosan. Interestingly, activation of 
TLR-4 by LPS has been shown to induce TLR-2 expression in 3T3-L1 adipocytes (Lin 
et al. 2000), highlighting potential crosstalk between TLR activation systems. The 
activation of TLRs initiates a cascade of downstream intracellular signalling events, 
which in turn cause phosphorylation, hence degradation of IiBa (Doyle et al. 2006). 
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Consequently, this allows the sequestered transcription factor, NF-KB, to translocate 
into the nucleus, initiating the production of immunomodulatory factors, such as IL-6, 
IL-1 and TNF-a. Several serine/threonine kinases are activated during the innate 
immune response that influence insulin signalling (Hirosumi et al. 2002). For example, 
IKK-ß mediates activation of NF-KB; whereas JNK, a central metabolic regulator, 
contributes to the development of insulin resistance in obesity (Hirosumi et al. 2002; 
Tuncman et al. 2006). The activation of JNK and IKK-ß within innate immunity, 
particularly in obesity and T2DM, highlights crosstalk between metabolic and immune 
pathways. 
An integration of metabolic and immune systems may thus reflect the mode of resistin 
action within adipocytes and immune cells, exerting metabolic and immune functions 
in both cell-types. It has recently been reported that resistin impairs insulin signalling, 
via the upregulation of `suppressor of cytokine signalling-3' (Steppan et al. 2005) and 
further inhibits glucose transport in 3T3-L1 adipocytes (Fu et al. 2006). Additionally, 
resistin promotes glucose-dependent lipogenesis and lipid accumulation in human 
macrophages (Rae et al. 2006). On the other hand, the pro-inflammatory functions of 
resistin in human macrophages (Silswal et al. 2005) and 3T3-L1 adipocytes (Fu et al. 
2006) have been documented. Resistin may thus function in adipocytes to influence 
both metabolic and pro-inflammatory changes, suggesting that the effects of resistin are 
to some extent linked. Such a duality in function for resistin may be a consequence of 
the crosslink initially proposed between metabolic and inflammatory pathways in 
adipocytes and immune cells (Weisberg et al. 2003; Xu et al. 2003). Where resistin 
may influence key factors in the sequential stages from one signal transduction 
pathway, this may consequently alter components from another. 
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The aims of this study were therefore to examine the effect of recombinant human 
resistin (rhResistin) on the expression of components of the innate immune pathway, 
progressively through TLRs and intracellular factors mediating NF-KB. Additionally, 
determine whether rhResistin may influence the expression of JNK, a key inhibitor of 
the insulin signalling cascade in isolated human AbSc adipocytes. Furthermore, 
evaluate the combined effects of rhResistin, insulin and RSG on the pro-inflammatory 
response. Finally, determine the effects of NF-KB inhibitor or JNK inhibitor on the 
level of resistin secretion from isolated AbSc adipocytes. 
113 
4.2 Subjects, Methods & Materials. 
4.2.1 Subjects. 
AbSc adipose tissue (AT) was obtained from a human Caucasian non-diabetic 
population (BMI: 26.5±5.9 kg/m2: age 36-49 yrs; n=35; all female subjects; 4 smokers, 
31 non-smokers) undergoing elective liposuction surgery. Patients receiving endocrine 
therapy (steroids, hormone replacement therapy or thyroxine), anti-inflammatory 
therapy (aspirin, cyclooxygenase-2 inhibitors), statins, TZDs or any antihypertensive 
therapy were excluded. Studies were performed with the approval of the local ethics 
committee with informed consent being obtained from all subjects prior to enrolment. 
4.2.2 Isolation of Mature Adipocytes. 
AbSc AT was digested in collagenase (2 mg/ml; Worthington Biochemical, USA) to 
isolate the mature adipocytes, as previously detailed in Chapter 2.1.2. Following 
isolation of the adipocytes, cells were re-suspended in either 4% SDS or RIPA Buffer 
solution (150 mM NaCl, 1.0% IGEPAL® CA-630,0.5% sodium deoxycholate, 0.1% 
SDS and 50 mM Tris) for extraction of protein. Adipocytes were additionally 
maintained in phenol red-free DMEM: F-12 medium containing 15 mM glucose, 
penicillin (100 U/ml), streptomycin (100 µg/ml) and 1% transferrin with the various 
treatment regimens described in the following sub-section. 
4.2.3 Treatment of Cultured Adipocytes. 
For pro-inflammatory cytokine secretion studies, isolated AbSc adipocytes were treated 
with rhResistin (30 ng/ml, 48 h; Phoenix Pharmaceuticals, Belmont, CA, USA) 
(endotoxin concentration below 0.1 ng/µg, at final concentrations of 10-50 ng/ml). To 
assess whether resistin has a `direct' influence on the level of cytokine secretion, 
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resistin treated adipocytes were further cultured with human resistin polyclonal 
antibody (10 µg/ml, 48 h; Linco Research, Inc., Missouri, USA). Dosage of resistin 
antibody was based on data previously documented (Bokarewa et al. 2005). AbSc 
adipocytes were also treated with insulin alone (10 nM; Sigma-Aldrich Company Ltd., 
Poole, UK) or in combination with rosiglitazone (RSG) (10"8 M; GlaxoSmithKline, 
Harlow, UK). rhResistin, insulin and RSG concentrations and time-points were chosen 
based on secretion data previously described (McTernan et al. 2003). Adipocytes were 
further treated with rhTNF-a (10,50,100 ng/ml; Biosource Europe, S. A., Belgium) or 
rhIL-6 (10,50,100 ng/ml; Sigma-Aldrich). Additional assessment of resistin secretion 
included the treatment of isolated AbSc adipocytes with NF-KB inhibitor (SN50, 
CalBiochem, Nottingham, UK) (50 µg/ml; 24 h). A dose and time-course study was 
performed to assess changes in the level of resistin secretion at 14,24, and 48 h with 
control and NF-KB inhibitor-treated adipocytes (10,25,50 and 100 µg/ml). AbSc 
adipocytes were also treated with JNK inhibitor (SP600125, A. G. Scientific, Inc., San 
Diego, USA) (10 LM; 24 h). JNK inhibitor conditions were based on data previously 
described (Baan et al. 2006). For protein expression analysis, adipocytes were treated 
with increasing concentrations of rhResistin, using the previously established time- 
point (10,30,50 ng/ml; 48 h). For all treatment regimens, adipocytes maintained in 
untreated media were used as controls. A trypan blue dye (Sigma-Aldrich) exclusion 
method was used to assess viability of the adipocytes; as described in Chapter 2.1.4. 
Following treatment, adipocyte cells and conditioned media were separated by 
centrifugation (360g for 2 min). Adipocyte conditioned media was removed, aliquoted 
and stored at -80°C, whilst adipocyte protein was extracted (as previously detailed in 
Chapter 2.2.2), then stored at -80°C. 
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4.2.4 Processing AbSc Adipose Tissue to Obtain Explants & Treatment of the 
Explanted Adipose Tissue. 
To assess differences between isolated adipocytes and matched whole explant adipose 
tissue, liposuction material was processed using erythrocyte Lysis Buffer, as detailed 
previously in Chapter 2.1.3. The resulting adipose tissue explant was treated with 
either NF-KB inhibitor (SN50, CalBiochem, Nottingham, UK) (50 µg/ml; 24 h) or JNK 
inhibitor (SP600125, A. G. Scientific, Inc., San Diego, USA) (10 µM; 24 h). AbSc AT 
explants were maintained in untreated media to serve as controls. Following treatment, 
AbSc AT explants and conditioned media were separated by centrifugation (360g for 2 
min). AbSc explants and conditioned media were removed, aliquoted and stored at - 
80°C. 
4.2.5 Protein Determination & Western blot Analysis. 
AbSc adipocytes were re-suspended in 4% SDS or RIPA buffer, as previously 
described (Chapter 2.2). Protein concentrations were determined using the Bio-Rad 
DC (Detergent Compatible) protein assay kit (Bradford, 1976). Western blot analysis 
was performed using the procedure highlighted in Chapter 2.5. In brief, 20-60 µg of 
protein was loaded onto a 8-15% polyacrylamide-gel (Geneflow Ltd., Fradley, UK). 
Human TLR-2 monoclonal and TLR-4 polyclonal antibodies were utilised (1: 500 and 
1: 1000, respectively; Insight Biotechnology Ltd., Wembley, UK). TLR-2 and TLR-4 
were developed using an anti-sheep/goat conjugated HRP secondary antibody (The 
Binding Site, Birmingham, UK). Polyclonal anti-JNKI &2 SAPK phosphospecific and 
MyD88 antibodies (1: 1,750; Biosource UK, Belgium and 1: 250; TCS Cellworks, UK 
respectively) were utilised. JNK and MyD88 were both developed using an anti-rabbit 
HRP secondary antibody (The Binding Site, Birmingham, UK). Protein expression of 
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NF-xB, (1: 250; TCS Cellworks, UK), IKK-ß (1: 500; TCS Cellworks, UK) and IKK-a 
(1: 500; Abcam, UK) in Abd Sc adipocytes was assessed using mouse monoclonal 
antibodies. Equal protein loading was confirmed by examining a-tubulin (1: 5000; The 
Binding Site, Birmingham, UK) protein expression. No statistical difference was 
observed in a-tubulin expression for all samples analysed. For reducing conditions, 
samples were mixed in a 1: 2 ratio with sample buffer containing 20% ß- 
mercaptoethanol. A chemiluminescent detection system ECL/ECL+ (Amersham 
Pharmacia Biotech, Little Chalfont, UK) enabled visualisation of bands, whilst 
intensity was determined using densitometry (Genesnap, Syngene, UK). 
4.2.6 Assessment of Resistin, TNF-a & IL-6 Secretion from Isolated AbSc 
Adipocytes. 
The human resistin ELISA previously validated (Phoenix Europe GmbH, Germany) 
was used in this study (McTeman et al. 2003). Conditioned media from rhTNF-a or 
rhIL-6 treated adipocytes was assessed using the human resistin ELISA from R&D 
Systems, UK (intra-assay CV 4.7%, inter-assay CV 8.4%); validation of this resistin 
ELISA is described in Chapter 3.3.6. Conditioned media from AbSc adipocytes treated 
with rhResistin, insulin, or insulin in combination with RSG, was assayed for IL-6 and 
TNF-a (QuantiGlo ELISA, R&D Systems, Abingdon, UK) (IL-6, intra-assay CV 3.1%, 
inter-assay CV 2.7%; TNF-a, intra-assay CV 6.7%, inter-assay CV 11.0%). For NF-KB 
and JNK inhibitor studies, resistin concentrations were measured using Bioplex assays 
(Linco Research, Missouri, USA) with a sensitivity of 6.7 pg/ml (intra-assay CV 1.4- 
7.9%, inter-assay CV <21%). 
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4.2.7 Statistical Analysis. 
Protein expression data between control and treatments were compared using an 
unpaired Students' t-test. Data is presented as mean±SD. Analyses were carried out 
using the SPSS (SPSS Inc. 14.0, Woking, UK) software package. The threshold for 
significance was p<0.05. Correlation analyses were calculated using a Pearson's 
Correlation Coefficient test. 
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4.3 Results. 
4.3.1 The Pro-inflammatory Effect of Resistin on TLR-2 & TLR-4 Protein 
Expression in Isolated AbSc Adipocytes. 
For protein expression studies, rhResistin was shown to stimulate TLR-2 (90 kDa) 
expression in AbSc adipocytes when compared to matched untreated control adipocytes 
(Control: 1.00±0.11; TLR-2: 1.28±0.10; p<0.001, n=6) (Figure 4.3.1). However, no 
significant alteration in TLR-4 (90 kDa) protein expression in response to rhResistin 
was observed (Control: 1.00*0.05; TLR-4: 0.98±0.07; p=N. S, n=6) (Figure 4.3.1); this 
was expected, due to the known constitutive expression of TLR-4 in other tissues. 
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Figure 4.3.1 Relative fold-change of TLR-2 (n=6; ***, p<0.001) and TLR-4 (n=6; 
p=N. S) protein expression in AbSc adipocytes treated with rhResistin. Expression for 
each component is shown as relative fold difference compared to their matched control 
untreated adipocytes. Equal protein loading was determined by a-tubulin. 
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4.3.2 The Effect of Resistin on Key Components of the NF-KB Pathway & Insulin 
Signalling Cascade in Isolated AbSc Adipocytes. 
When examining the effect of rhResistin on components of the NF-KB pathway in Abd 
Sc adipocytes, rhResistin was shown to stimulate MyD88 expression in the isolated Sc 
adipocytes (Control: 1.00±0.13; MyD88 50 ng: 1.80+0.04; Tp<O. 01, n=6) (Figure 
4.3.2). Similarly, NF-KB (Control: 1.00+0.04; NF-KB 50 ng: 1.37+0.02; Tp<0.05, n=4) 
expression was increased in response to rhResistin dose (Figure 4.3.2). Additionally, 
rhResistin was shown to further upregulate factors of the insulin signalling cascade; as 
both phosphospecific JNK1 (Control: 1.00±0.03; JNKI-P 50 ng: 1.29±0.05; Tp<0.05, 
n=6) and phosphospecific JNK2 (Control: 1.00±0.08; JNK2-P 50 ng: 1.53+0.03; 
Tp<0.001, n=6) expression was increased in response to rhResistin (Figure 4.3.2). 
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Figure 4.3.2 The relative fold change of MyD88 (white), JNK1-P (grey), JNK2-P 
(stripes) and NF-KB (black) expression in response to rhResistin in isolated AbSc 
adipocytes. *, p<0.05; **, p<0.01; ***, p<0.001. Expression for each component is 
shown as relative fold difference compared to their matched control untreated 
adipocytes only. Equal protein loading was determined by a-tubulin. 
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4.3.3 The Effect of Resistin on the IKK Complex. 
When examining the expression of the catalytic subunits of the IKK complex, both 
IKK-ß and IKK-a were upregulated in response to increasing rhResistin concentrations 
(Control: 1.00±0.04; IKK-ß 50 ng: 1.17±0.03 Tp<0.01, n=4) (Control: 1.00±0.06; IKK- 
a 50 ng: 1.50±0.02 Tp<0.01, n=4) (Figure 4.3.3). 
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Figure 4.3.3 Relative fold change of IKK-ß (grey) and IKK-a (black) expression in 
response to rhResistin in adipocytes. **, p<0.01. Expression for each component is 
shown as relative fold difference compared to their matched control untreated 
adipocytes. Equal protein loading was determined by a-tubulin. 
4.3.4 Regulation of TNF-a & IL-6 Secretion from Isolated Adipocytes: The Effects 
of Resistin, Insulin & RSG. 
Assessment of pro-inflammatory cytokine secretion from Abd Sc adipocytes in 
response to rhResistin, insulin and RSG treatment revealed that rhResistin alone (30 
ng/ml), and in combination with insulin (10 nM), significantly increased the level of 
TNF-a secretion from AbSc adipocytes (Control: 74±10 pg/nil; rhResistin: 435±36.5 
pg/ml; p<0.001). Additionally, RSG (10-8 M) was shown to significantly reduce this 
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resistin-stimulated increase in TNF-a secretion from Abd Sc adipocytes (p<0.001); 
following this reduction, TNF-a secretion levels still however, remained higher than the 
control (p<0.01) (Figure 4.3.4.1). 
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Figure 4.3.4.1 The level of TNF-a secretion in response to rhResistin alone, insulin 
alone or in combination with RSG, or RSG alone (n=8). Control samples were 
adipocytes maintained in medium in the absence of treatment. Values obtained with 
control samples were compared with those of resistin alone (***, p<0.001), with insulin 
(***, p<0.001) and RSG (**, p<0.01). A comparison of resistin in combination with 
insulin versus resistin, insulin and RSG was also performed. **, p<0.01. 
Similar to the effect on TNF-a, rhResistin (30 ng/ml) and insulin (10 nM) significantly 
increased the level of IL-6 secretion from isolated AbSc adipocytes (Control: 1962±130 
pg/ml; rhResistin: 2906.4±297.0 pg/ml; p<0.01). Furthermore, RSG was shown to 
reduce this resistin-induced increase in IL-6 secretion from the adipocyte cells (Figure 
4.3.4.2). 
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Figure 4.3.4.2 The level of IL-6 secretion in response to rhResistin alone, in 
combination with insulin and RSG, or RSG alone (n=8). Values obtained with controls 
were compared with those of resistin alone and in the presence of insulin. **, p<0.01. 
4.3.5 A `Direct' Effect of rhResistin on the Level of TNF-a & IL-6 secretion from 
Isolated AbSc Adipocytes. 
To assess the specificity of resistin-induced effects, additional experiments were 
performed using monoclonal anti-resistin antibodies (Abs). The anti-resistin Abs were 
added to resistin-treated adipocytes prior to analysis of pro-inflammatory cytokine 
secretion from the isolated adipocytes. It was demonstrated that addition of anti-resistin 
Abs could significantly reduce the level of TNF-a secretion from isolated AbSc 
adipocytes (Control: 76.5±6.2 pg/ml; rhResistin (30 ng/ml): 89.2±4.6 pg/ml; Anti- 
resistin Abs (10 µg/ml): 71.5±5.9 pg/ml; p<0.05). A similar scenario was also 
demonstrated for the level of IL-6 secretion from AbSc adipocytes (Control: 
362.0±22.6 pg/ml; rhResistin (30 ng/ml): 1115.5±40.6 pg/ml; Anti-resistin Abs (10 
11g/m1): 351.5±55.9 pg/ml; p<0.01). This consequently reinforces the potential for 
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resistin exerting a significant impact on the level of cytokine secretion from human 
AbSc adipocytes. 
4.3.6 The Effect of TNF-a & IL-6 on the Level of Resistin Secretion from Isolated 
Adipocytes: Feedback Mechanism Between Resistin, TNF-a & IL-6? 
To establish whether a pro-inflammatory cytokine feedback mechanism exists within 
AbSc adipocytes, we further examined the level of resistin secretion from isolated 
adipocytes treated recombinant human TNF-a (rhTNF-a) and recombinant human IL-6 
(rhIL-6). However, resistin secretion from adipocytes was unaffected by rhTNF-a, at 
any concentration up to 100 ng/ml (Control: 135±19 pg/ml; 10 ng/ml rhTNF-a: 129±15 
pg/ml; 50 ng/ml rhTNF-a: 141±11 pg/ml; 100 ng/ml rhTNF-a: 116±11 pg/ml; n=12) 
(Figure 4.3.6.1). 
0.14 
0.12 
0.10 
GU 
Z 
0.08 
0.06 
ö 
0.04 
4 0.02 
0.00 
rhTNF-a (ng/ml) Treated Adipocytes 
Figure 4.3.6.1 The level of resistin secretion from isolated AbSc adipocytes in response 
to increasing concentrations of rhTNF-a (n=12; p=N. S). Matched untreated AbSc 
adipocytes were used as controls. 
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Furthermore, rhIL-6 also had no significant effect on the level of resistin secretion from 
Abd Sc adipocytes (Control: 129±12 pg/ml; 10 ng/ml rhIL-6: 135±13 pg/ml; 50 ng/ml 
rhIL-6: 123±10 pg/ml; 100 ng/ml rhIL-6: 125±12 pg/ml; n=8) (Figure 4.3.6.2). 
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Figure 4.3.6.2 Resistin secretion from AbSc adipocytes in response to increasing 
concentrations of rhIL-6 (n=8; p=N. S). Control matched samples were adipocytes 
maintained in medium in the absence of treatment. 
4.3.7 The Effects of NF-KB or JNK Inhibitors on the Level of Resistin Secretion 
from Isolated AbSc Adipocytes. 
When examining the effects of JNK or NF-xB inhibitor on resistin secretion from 
isolated adipocytes, the level of resistin secretion was significantly reduced with NF-KB 
inhibitor treatment (Control: 83.1±20.5 pg/ml; NF-xB inhibitor: 61.6±16.6 pg/ml; n=7, 
p<0.05) (Figure 4.3.7). Similarly, with the addition of JNK inhibitor, the level of 
resistin secretion from AbSc adipocytes was shown to significantly decrease (control: 
101.5±19.2 pg/ml; JNK inhibitor: 77.0±11.4 pg/ml; n=8, p<0.05) (Figure 4.3.7). 
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Figure 4.3.7 The level of resistin secretion from isolated AbSc adipocytes in response 
to NF-KB inhibitor (n=7; p<0.05) (left). Resistin secretion from AbSc adipocytes in 
response to JNK inhibitor (n=8; p<0.05) (right). In both figures, inhibitor treated AbSc 
adipocytes were compared to matched control untreated adipocytes from the same 
patient. 
4.3.8 The Effects of NF-KcB or JNK Inhibitors on the Level of Resistin Secretion 
from AbSc Adipose Tissue Explants. 
The level of resistin secretion from AbSc adipose tissue explants was significantly 
reduced with NF-KB inhibitor treatment (Control: 1225.9±195.4 pg/ml; NF-KB 
inhibitor: 913.0±147.4 pg/ml; n=8, p<0.05) (Figure 4.3.8). However, no significant 
difference in the level of resistin secretion was observed for JNK inhibitor treated AbSc 
adipose tissue explants (Control: 125.9±63.9 pg/ml; JNK inhibitor: 205.7±59.8 pg/ml; 
n=8, p=N. S) (Figure 4.3.8). 
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Figure 4.3.8 The level of resistin secretion from AbSc adipose tissue (AT) explants in 
response to NF-xB inhibitor (n=8; p<0.05) (left). Resistin secretion from AbSc AT 
explants in response to JNK inhibitor (n=8, p=N. S) (right). In both cases, inhibitor 
treated AbSc adipose tissue explants were compared to matched control untreated AbSc 
adipose tissue explants from the same patient. 
450 
400 
350 
++ v 300 
250 
db 
200 
5 150 
.ý 100 m 
ai 50 
127 
4.4 Discussion. 
This study demonstrated the pro-inflammatory actions of resistin in isolated human 
AbSc adipocytes. It was firstly determined that rhResistin stimulated protein expression 
of a key receptor in the innate immune pathway, TLR-2, in addition to two central 
metabolic and inflammatory kinases, JNK and IKK-ß respectively. It was further 
established that rhResistin positively influenced the secretion of pro-inflammatory 
cytokines, such as TNF-a and IL-6, from human AbSc adipocytes. Furthermore, 
induction of cytokine secretion by rhResistin is attenuated by the insulin sensitiser, 
RSG. Collectively, these findings implicate resistin in the stimulation of pro- 
inflammatory cytokine release from human AbSc adipocytes; additionally, this further 
highlights human adipose tissue as an important site for the progression of low-grade 
inflammation. 
Whilst a more pro-inflammatory role for resistin is emerging in humans, the metabolic 
actions of resistin remain uncertain. Rodent studies implicate the liver as the major 
physiological target of resistin action; as administration of exogenous resistin was 
shown to impair glucose tolerance and cause hepatic insulin resistance (Rajala et al. 
2003). Similarly, adenovirus mediated hyper-resistinemia was shown to abrogate 
hepatic and peripheral insulin action (Sato et al. 2005). Conversely, resistin null mice 
exhibit low fasted blood glucose levels, due to reduced hepatic glucose production 
(Banerjee et al. 2004). Moreover, in vitro adipocyte studies highlight that resistin 
impairs insulin-stimulated glucose uptake (Steppan et al. 2005) and the insulin 
signalling cascade itself (Graveleau et al. 2005). It was additionally reported that 
human resistin has properties similar to its murine counterpart; whereby mouse and 
human resistin impair glucose transport (Graveleau et al. 2005). 
128 
To address the potential mechanism of resistin action in human AbSc adipocytes, 
studies examined whether rhResistin could influence the protein expression of key 
components of the innate immune pathway and insulin signalling cascade. It was 
observed that resistin upregulated the expression of TLR-2, MyD88 and NF-i B in 
AbSc adipocytes. When examining the key intermediate activating NF-KB, the IKK 
complex, protein expression of the catalytic subunits IKK-ß and IKK-a increased in 
response to rhResistin treatment. Interestingly, rhResistin also upregulated 
phosphospecific JNK1 and JNK2 protein expression, suggesting NF-KB activation may 
overlap into a JNK-mediated pathway. Such a role for JNK as a mediator of NF-KB 
activation has been identified in macrophages and alveolar epithelial cells (Li et al. 
2003; Roeder et al. 2004), consistent with crosstalk between metabolic and 
inflammatory pathways. Alternatively, elevated TNF-a and IL-6 levels induced by 
resistin may activate JNK and NF-KB systems, rather than via a direct effect by resistin. 
To further examine the importance of the NF-KB and JNK signalling on resistin action 
in human adipocytes, cells were treated with NF-icB or JNK inhibitors. It was 
demonstrated that by inhibiting either NF-KB or JNK, the level of resistin secretion 
from isolated AbSc adipocytes was significantly reduced, thus suggesting a potential 
overlap of resistin function in both inflammatory and insulin signalling pathways. 
Furthermore, whilst NF-icB inhibition appeared to reduce the level of resistin secretion 
from AbSc adipose tissue explants, no effect was observed on resistin secretion with 
JNK inhibitor treatment. Consequently, although an overlap between NF-KB and JNK 
systems in resistin action is implicated for isolated AbSc adipocytes, resistin may have 
more prominent effects via the NF-KB pathway in whole AbSc adipose tissue explants. 
The significance of the NF-KB pathway for resistin-induced inflammatory effects 
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within human peripheral-blood mononuclear cells has previously been highlighted 
(Bokarewa et al. 2005). 
In vitro studies further demonstrated that resistin increases the level of TNF-a and IL-6 
secretion from human isolated adipocytes. This is consistent with recent reports, 
whereby human resistin increased TNF-a and IL-12 secretion from human 
macrophages (Silswal et al. 2005) and further, stimulated the secretion of pro- 
inflammatory cytokines TNF-a, IL-6 and monocyte chemoattractant protein-1 from 
3T3-L1 adipocytes (Fu et al. 2006). This study also determined that the addition of 
anti-resistin Abs to rhResistin-treated adipocytes significantly reduces the level of 
TNF-a and IL-6 secretion from AbSc adipocytes. This therefore suggests that resistin 
may directly contribute to an altered cytokine status and thus promote inflammation. It 
is widely acknowledged that systemic levels of TNF-a and IL-6 are elevated in states of 
obesity and T2DM (Hotamisligil et al. 1995). Therefore, future analysis examining 
cytokine secretion levels in response to rhResistin in chronically obese, pre-and post 
TZD-treated patients, may further elucidate the mechanistic action of resistin in 
obesity-related inflammation. 
The current literature documents the metabolic effects of resistin in the human 
macrophages (Rae et al 2006) and 3T3-L1 adipocytes (Steppan et a12004, Fu Y et al 
2006). Similarly, the pro-inflammatory effects of resistin are reported in human 
macrophages (Silswal et al 2005) and 3T3-L1 adipocytes (Fu Y et a! 2006). Our study 
further demonstrated that resistin exerts pro-inflammatory effects in metabolically 
active cells i. e. human isolated adipocytes. Resistin may thus function in adipocytes to 
influence both metabolic and pro-inflammatory changes, suggesting that the effects of 
resistin are to some extent linked. Such a duality in function for resistin may be a 
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consequence of the crosslink initially proposed between metabolic and inflammatory 
pathways in adipocytes and immune cells (Weisberg et al. 2003; Xu et al. 2003). 
Collectively, these studies suggest a potential overlap between metabolic and immune 
functions for human resistin. 
Finally, it is known that hyper-restinemia contributes to an inflammatory response. 
rhResistin was shown to alter the level of cytokine release from cultured adipocytes 
when compared to control. Insulin was utilised to observe the effects of RSG in this 
system; as such, this study demonstrated that the PPAR-y agonist, RSG, attenuated this 
resistin-induced secretion of TNF-a and IL-6 from AbSc adipocytes. Although the 
mechanisms for this are as yet unclear, it is known that the resistin gene promoter 
contains a PPAR-y binding site (Patel et al. 2003), through which RSG may coordinate 
the recruitment of transcriptional co-repressors (Aranda et al. 2001), thereby 
suppressing resistin expression at the genetic level. However, this did not appear to be 
the mechanism through which the observations in this study were mediated, as 
exogenous resistin was used to stimulate cytokine production. This suggests that RSG 
can act downstream of the resistin promoter to mitigate resistin-mediated TNF-a and 
IL-6 stimulation, potentially via NF-KB (Ye et al. 2004). 
In conclusion, this study demonstrated that resistin can influence the secretion of pro- 
inflammatory cytokines from isolated human AbSc adipocytes. The intracellular 
mechanism for such positive mediation of resistin on TNF-a and IL-6 release appears 
to act via the NF-KB pathway and furthermore, potentially influences the insulin 
signalling cascade. Consequently, the elevated levels of pro-inflammatory factors, 
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enhanced by resistin, may thus contribute to the pro-inflammatory milieu proposed in 
obesity-related insulin resistance and T2DM. 
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CHAPTER 5 
Resistin & Bacterial Endotoxin in Sub-clinical Inflammation 
Associated with Childhood & Adolescent Obesity 
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5.1 Introduction. 
The prevalence of childhood obesity and its related co-morbidities are increasing at an 
alarming rate worldwide (Hedley et al. 2004), to such an extent that obesity is now a 
worldwide paediatric health risk factor (Freedman et al. 2004). Over the past decade, 
20% of children are now classified as overweight in Europe (Lobstein et al. 2004). 
Obesity is an important early risk factor for much of adult morbidity and mortality 
(Dietz 1998). In parallel to this, the incidence of obesity-related T2DM is rising 
dramatically (Weiss et al. 2005). In particular, there is an increased number of young 
obese populations diagnosed with the metabolic syndrome (MS), which at present, 
affects a quarter of overweight children and adolescents (Invitti et al. 2003; Duncan et 
al. 2004) and worsens with the degree of adiposity. The MS is manifested by the 
coexistence of central obesity, hypertension, dyslipidemia, insulin resistance and 
glucose intolerance; all of which are risk factors for coronary heart disease and T2DM 
(Ninomiya et al. 2004). Many of these metabolic and cardiovascular complications of 
obesity may be present in as many as 30% of obese adolescents (Cook et al. 2003). 
Similarly, circulating levels of low-grade inflammatory markers are elevated with 
increasing childhood adiposity, such as TNF-a, CRP and PAI-l. Moreover, decreased 
systemic levels of adiponectin have also been associated with MS (Ryo et al. 2004; 
Dandona et al. 2005). As such, childhood obesity and its later progression to T2DM 
are therefore now associated with sub-clinical inflammation and increased pro- 
inflammatory cytokine production. 
The adipokine resistin, a member of a cysteine-rich RELM family of protein (Steppan 
et al. 2001), has demonstrated a pertinent role in regulating fasting glucose level 
(Banerjee et al. 2004) and reducing insulin sensitivity in vivo (Pravenec et al. 2003; 
Satoh et al. 2004) and in vitro (Moon et al. 2003; Steppan et al. 2005). Recent studies 
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have further implicated human resistin as a key player in several inflammatory 
processes (Lehrke et al. 2004; Bokarewa et al. 2005; Silswal et al. 2005). As 
previously detailed, several studies have documented contradictory findings on resistin 
in relation to adult obesity. Supportive findings include increased resistin expression 
(McTeman et al. 2002; Degawa-Yamauchi et al. 2003; Pagano et al. 2005) and, 
elevated systemic concentrations (Azuma et al. 2003; Valsamakis et al. 2004) in adult 
obesity. However, others report no changes in resistin levels following weight loss 
(Lee et al. 2003; Vendrell et al. 2004). Whilst is it apparent that the incidence of 
childhood and adolescent obesity is increasing, new questions are emerging in the field 
of resistin; does resistin follow a similar pattern of expression in juvenile obesity and 
insulin resistance as in adult obesity? To date, limited studies have addressed the role 
of resistin as a potential marker of juvenile obesity (Gerber et al. 2005; Reinehr et at. 
2006). Such studies however, did not support a relationship between resistin, insulin 
resistance index and weight status in children (Gerber et al. 2005; Reinehr et al. 2006). 
Further studies are therefore required to fully establish whether resistin is a critical 
participant in childhood and adolescent obesity. 
Another adipokine, adiponectin, is a protein secreted exclusively by adipocytes 
(Scherer et al. 1995), which possesses anti-diabetic, anti-inflammatory and anti- 
atherogenic properties (Trujillo et al. 2005). Both in vivo and in vitro studies have 
revealed that adiponectin decreases the production of pro-inflammatory cytokines and 
enhances hepatic insulin action (Ouchi et al. 2003; Brakenhielm et al. 2004; Goldstein 
et al. 2004; Shetty et al. 2004; Kadowaki et al. 2005). Circulating adiponectin levels 
are decreased in obesity, T2DM and coronary artery disease and, are further negatively 
correlated with inflammatory markers and the MS (Cnop et al. 2003; Engeli et al. 
2003; Schulze et al. 2005). Finally, hypoadiponectinemia is now considered a 
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biomarker of insulin resistance, associated with an increased risk of developing T2DM 
(Choi et al. 2004; Duncan et al. 2004; Langenfeld et al. 2004; Kadowaki et al. 2005). 
Whilst it is acknowledged that sub-clinical inflammation may integrate obesity and its 
progression to T2DM, the underlying mechanisms of this association are unclear. 
Previous studies have suggested that the bacterial endotoxin, LPS, potentially derived 
from commensal bacteria in the human gastrointestinal (GI) tract, may contribute to 
sub-clinical inflammation. Human adipose tissue has been demonstrated to express 
Toll-like receptors (Creely et al. 2006), which initiate an innate immune inflammatory 
response in the presence of endotoxin, thus producing inflammatory cytokines, such as 
TNF-a, IL-6 and PAI-1. Elevated systemic levels of endotoxin may thus exacerbate 
inflammatory cascades and contribute to the abnormal circulating levels of 
adipocytokines in obesity and a pro-inflammatory or pro-thrombotic milieu (Dandona 
et al. 2005). In this respect, endotoxin may potentially serve as one of many factors 
modulating the progression of obesity-associated inflammation and T2DM. Several 
studies using cohorts of obese children have demonstrated elevated circulating levels 
of PAI-1 and CRP, with data further highlighting an association with central adiposity 
and an increased risk of developing insulin resistance, T2DM, thrombosis and fibrosis 
(Sudi et al. 2001; Invitti et al. 2004; Ford et al. 2005; Valle et al. 2005). Moreover, 
systemic levels of markers of vascular injury and atherogenesis, such as PAI-1 and 
soluble intercellular adhesion molecule type-1 (sICAM-1), are increased in childhood 
and adolescent obesity (Halle et al. 2004; O'Brien et al. 2006; Syrenicz et al. 2006). 
The aims of this study were 1) Firstly, to examine the circulating levels of resistin in a 
cohort of children and adolescents with varying degrees of obesity, with particular 
emphasis on gender differences. 2) Secondly, compare resistin levels in the following 
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sub-groups: (i) obese only, (ii) insulin resistant only, (iii) high triglyceride and low 
HDL and, (iv) MS only. 3) Finally, examine bacterial endotoxin as a potential mediator 
of sub-clinical inflammation in childhood obesity, by investigating the relationship 
between endotoxin and various markers of inflammation. 
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5.2 Subjects, Methods & Materials. 
5.2.1 Subjects. 
A total of 114 Caucasian obese children and adolescents with varying degrees of 
obesity were analysed in this study (BMI: 35.0f5.2(SD) kg/m2; age: 14±2 yrs; female 
subjects (n=74); male subjects (n=40)). All subjects were therefore above the age and 
sex adjusted 97th BMI percentile, which defines obesity according to the Italian BMI 
charts (Cacciari et al. 2002) and had an age range of 8-18 yrs. This study was approved 
by the Ethics Committee of the Italian Institute and informed consent was obtained 
from all subjects and their parents. All subjects underwent an oral glucose tolerance test 
(1.75 g/kg, up to a maximum of 75 g glucose in 250 ml of water) following an 
overnight fast. Plasma samples were drawn at baseline, after 30 min and 120 min, for 
determination of plasma glucose and insulin concentration. Categorisation of glucose 
tolerance status was made using the WHO criteria (Alberti et al. 1998). The impaired 
fasting glucose was defined by fasting glucose levels >_5.6 mmol/1(Genuth et al. 2003). 
Blood samples were drawn for measurement of resistin, endotoxin, adiponectin, 
markers of inflammation and cardiovascular disease (CVD). Blood pressure 
measurements were taken as previously described (Invitti et al. 2003). Insulin resistance 
was measured by HOMA-IR (fasting insulin x fasting glucose/22.5) (Matthews et al. 
1985). No data was available in relation to smoking status. 
5.2.2 Biochemical Measurements. 
Resistin concentrations were determined using ELISA (R&D Systems Europe Ltd., 
Abingdon, UK), with a sensitivity of 10 pg/ml and an intra- and interassay CV of 4.7% 
and 8.4%, respectively. Serum endotoxin levels were assayed using a Chromogenic 
Limulus Amebocyte Lysate test (Cambex, New Jersey, USA), with a sensitivity of 0.1 
EU/ml and an intra- and interassay CV of 3.9±0.46 and 9.6±0.75 respectively. Previous 
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studies further confirmed the specificity of the endotoxin assay (Creely et al. 2006). 
This study utilised Linco multiplexed CVD biomarker immunoassays (Linco Research, 
Missouri, USA) to examine the levels of the following inflammatory and CVD risk 
markers: TNF-a, PAM, CRP, sICAM-1, soluble vascular cell adhesion molecule-1 
(sVCAM-1), matrix metalloproteinase-9 (MMP-9), myeloperoxidase (MPO), vascular 
endothelial growth factor (VEGF) and adiponectin. This immunoassay had a sensitivity 
of 16-50,000 pg/ml for MMP-9, MPO and PAI-1 and further, a sensitivity of 80- 
250,000 pg/ml for sICAM-1, and adiponectin; with an intra- and interassay CV of 4.5- 
12.3% and 8.5-16.3%, respectively. Plasma glucose was measured using an automated 
glucose analyser (Roche Diagnostics, Mannheim, Germany). Serum insulin levels were 
measured by a chemiluminescent assay (DPC, Los Angeles, USA) with a sensitivity of 
14.3 pmolll and intra- and interassay CV of 3.7% and 6.7%, respectively. 
5.2.3 Statistical Analysis. 
All analyses were performed using statistical software (SPSS, version 14; Woking, 
UK). Variables that were not normally distributed were log transformed. Differences 
between groups were calculated using a Student's t-test for independent samples. A 
Pearsons' correlation analysis was used to analyse bivariate relationships between 
variables such as resistin, endotoxin and, markers of inflammation and vascular injury. 
Data were expressed as mean±SD. A p-value <0.05 was considered statistically 
significant. 
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5.3 Results. 
5.3.1 Sexual Dimorphism of Serum Resistin Levels in Childhood & Adolescent 
Obesity. 
Analysis of total resistin levels with regards to gender, revealed that girls demonstrated 
significantly higher resistin concentrations than boys (girls: 28.85±22.65 ng/ml resistin, 
n=74; boys: 20.66±14.39 ng/ml resistin, n=40; p<0.05), as demonstrated in Figure 
5.3.1 below. 
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Figure 5.3.1 Comparison of circulating resistin levels (ng/ml) in obese girls (n=74) and 
obese boys (n=40). 
In this cohort of subjects, the average circulating resistin levels were determined as 
26.40±20.79 (SD) ng/ml (n=114). Further examination of resistin levels in sub-groups 
within this cohort, revealed that resistin concentrations were significantly higher in 
subjects with obesity only (45.06±23.49 ng/ml; n=30), in comparison to subjects with 
insulin resistance (25.80±15.24 ng/ml; p<0.001; n=42), high triglyceride and low LDL 
levels (11.47±6.26 ng/ml; p<0.001; n=24) or subjects with MS (16.61±16.97 ng/ml; 
p<0.001; n=18). 
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5.3.2 Clinical & Biochemical Characteristics: Gender-differences in Adiponectin 
& Bacterial Endotoxin Levels. 
From the cohort, further biochemical analysis was performed on 55 subjects; of which, 
21 male subjects and 34 BMI and age-matched female subjects were analysed. Clinical 
and biochemical characteristics of male or female obese subjects are provided in Table 
5.3.2 below. 
Clinical or Biochemical 
Characteristic 
Male 
Subjects 
(±SD) 
Female 
Subjects 
(±SD) 
p value 
Age, years 14±3 14±2 - 
BMI, kg/m 34.0±5.1 35.6±5.3 - 
Fasting glucose, mmol/l 4.4±0.3 4.5±0.5 N/S 
2h glucose, mmol/l 6.0±1.0 5.7±1.0 N/S 
HOMA-IR 2.6±1.2 3.3±2.1 N/S 
Endotoxin, EU/ml 10.1±5.4 5.3±3.7 p<0.01** 
Adiponectin, µg/ml 13.4±5.8 16.7±5.4 P<0.05* 
CRP, µg/ml 7.5±8.3 9.0±7.5 N/S 
TNF-a, pg/ml 5.0±2.5 5.9±5.8 N/S 
PAI-1, ng/ml 27.0±10.7 26.0±15.7 N/S 
sICAM-1, ng/ml 110.4±37.4 103.1±47.9 N/S 
Systolic BP, mmHg 121.0±10.8 119.1±8.5 N/S 
Diastolic BP, mmHg 74.0±11.2 72.7±8.5 N/S 
Table 5.3.2 Clinical and biochemical characteristics for obese, BMI and age-matched 
male (n=21) and female (n=34) subjects. Data are expressed as meanf5D. Any 
significant differences in data between male and female subjects are highlighted. 
P<0.05, **, p<0.001. 
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Serum concentration data demonstrated that male subjects had significantly higher 
levels of endotoxin when compared with female subjects (Males: 10.1±5.4 EU/ml; 
Females: 5.3±3.7 EU/ml; p<0.01). In contrast, female subjects had significantly higher 
levels of adiponectin in circulation than male subjects (Males: 13.4±5.8 µg/ml; 
Females: 16.7±5.4 µg/ml; p<0.05). No significant differences were observed in 
HOMA-IR, blood pressure or several markers of inflammation and CVD between the 
sexes. 
5.3.3 Correlation of Resistin with Adiponectin, Markers of Inflammation & CVD 
in Childhood & Adolescent Obesity. 
Further analysis revealed that circulating resistin levels did not significantly correlate 
with any markers of inflammation (CRP: p=0.751, r=-0.044; TNF-a, p=0.111, r- = 
0.221; n=55) vascular injury (PAI-1: p=0.233, r=-0.163; sICAM-1, p=0.166, r=-0.189; 
n=55), insulin resistance index (HOMA-IR: p=0.220, r=-0.171; n=55) or adiponectin 
(p=0.369, r=-0.123; n=55). Similar results were observed when further examining 
resistin levels in relation to such parameters in specific sub-groups within this cohort: 
obesity only, insulin resistance only, high triglyceride and low LDL levels and, MS 
only. Furthermore, in terms of gender, resistin levels did not significantly correlate with 
any of the above mentioned markers of inflammation, vascular injury or insulin 
resistance index in either male subjects (n=21) or female subjects (n=34). 
5.3.4 Correlation of Endotoxin with Markers of Inflammation & CVD in 
Childhood & Adolescent Obesity. 
In this study, bacterial endotoxin was investigated as a potential mediator/marker of 
inflammation in childhood and adolescent obesity. Circulating endotoxin levels were 
shown to correlate with several parameters of inflammation and vascular injury; these 
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included TNF-a (p=0.020, r=0.327; n=50), PAI-1 (p<0.001, r=0.529; n=52), sICAM-1 
(p=0.004, r=0.397; n=52), MMP-9 (p<0.001, r=0.457; n=52), MPO (p=0.016, r=0.331; 
n=52) and VEGF (p=0.003, r=0.419; n=48) (Figure 5.3.4A-F). However, no significant 
correlation was noted between circulating endotoxin levels with CRP (p=0.744, x=- 
0.046; n=52), sVCAM (p=0.623, r=0.070; n=52) or adiponectin (p=0.110, r=-0.224; 
n=52) levels. With regards to gender, endotoxin levels did not significantly correlate 
with the above mentioned markers of inflammation, vascular injury or insulin 
resistance index in male subjects or female subjects separately (data not shown). 
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Figure 5.3.4 Correlation between log endotoxin (EU/ml) and (A) log TNF-a (pg/ml) 
p=0.020, (B) log PAI-1 (ng/ml) p<0.001. 
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Figure 5.3.4 Correlation between log endotoxin (EU/ml) and (C) log sICAM-1 (ng/ml) 
p=0.004, (D) log MMP-9 (pg/ml) p<0.001, (E) log VEGF (pg/ml) p=0.003 and, (F) log 
MPo (pg/ml) p=0.016 in 55 obese BMI and age-matched children and adolescents. 
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5.4 Discussion. 
This study firstly demonstrated that circulating resistin levels in childhood and 
adolescent obesity are subjected to sexual dimorphism. Such gender differences in 
resistin levels coincide with previously documented observations; girls were shown to 
have higher resistin concentrations than boys in two independent studies (Gerber et al. 
2005; Reinehr et al. 2006). Furthermore, such gender regulation of resistin is in 
accordance with studies carried out in adults (Yannakoulia et al. 2003). This study 
further demonstrated that resistin concentrations did not significantly correlate with any 
markers of inflammation or CVD, HOMA-IR or adiponectin in any of the sub-groups 
within this cohort, suggesting that resistin alone may not play a significant role in 
childhood or adolescent obesity. On the other hand, such results may have arisen due to 
all the subjects in this cohort being obese, with additional MS risk factors subdividing 
them. Therefore, as all subjects were at a heightened MS risk, the differences noted in 
resistin serum levels may be minimal. Furthermore, serum resistin concentrations in 
this cohort of subjects were high in comparison to previously documented resistin 
levels (McTeman et al. 2003; Gerber et al. 2005). Such high serum resistin levels may 
be a consequence of the additional risk factors associated with subjects in this cohort; 
alternatively, the sensitivity of resistin assays may affect results. Although no studies to 
date have reported resistin in relation to markers of inflammation or CVD in childhood 
obesity, similar findings were reported whereby circulating resistin concentrations did 
not correlate with any parameters of insulin resistance (Gerber et al. 2005; Reinehr et 
al. 2006). Such findings suggest that resistin may only have a relevant function in adult 
human obesity, as highlighted by several studies (McTernan et al. 2002; Azuma et al. 
2003; Degawa-Yamauchi et al. 2003; McTernan et al. 2003; Valsamakis et al. 2004; 
Pagano et al. 2005). Alternatively, the regulation of resistin may differ considerably 
during puberty in comparison to adulthood. 
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It is now considered that chronic inflammation is a common pathophysiological basis 
for insulin resistance, MS and atherosclerotic CVD disease (Willerson et al. 2004; 
Dandona et al. 2005); this has recently been recognised in childhood obesity (Weiss et 
al. 2005; Meyer et al. 2006). Results from this study demonstrated that bacterial 
endotoxin levels exhibited significant and positive correlations with the inflammatory 
marker, TNF-a. Furthermore, male subjects demonstrated higher levels of endotoxin 
and lower levels of adiponectin than female subjects, despite both cohorts being of 
similar age and BMI. This study, therefore, suggests that an initiator of sub-clinical 
inflammation, circulating commensal bacterial endotoxin, potentially derived from the 
gut, as previously suggested (Cornell 1985; Bauer et al. 2002), may serve as a source, 
or even mediate such inflammatory responses in childhood and adolescent obesity. 
Such potential in vivo inflammatory properties of endotoxin have previous been 
demonstrated in adult insulin resistant, type 2 diabetic and cirrhotic patients 
(Fogelstrand et al. 2004; Creely et al. 2006). Collectively, these studies suggest an 
endotoxin-mediated mechanism of sub-clinical inflammation in childhood and 
adolescent obesity. 
Elevated circulating levels of PAI-1 have been associated with central obesity (Mavri et 
al. 2004), insulin resistance (Juhan-Vague et al. 1991; Bastard et al. 2000) and an 
increased risk of CVD (Juhan-Vague et al. 2000). Additionally, systemic PAI-1 
concentrations have been shown to decrease in obese individuals following weight loss 
(Alessi et al. 1997). Other studies have reported elevated concentrations of ICAM in 
obese children with sleep-disordered breathing, in comparison to non-obese children 
(O'Brien et al. 2006). Moreover, endothelial activation has been associated with 
adiposity in obese children and adolescents (Garanty-Bogacka et al. 2005). In this 
study, several markers of vascular injury, including PAI-1, sICAM-1, MMP-9, MPO 
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and VEGF, significantly and positively correlated with circulating endotoxin 
concentrations. This suggests that such endotoxin-stimulated inflammation in childhood 
obesity, may consequently further contribute to an accelerated risk of cardiovascular 
morbidity. 
In conclusion, although resistin may not be a crucial player in obesity-related 
inflammatory, bacterial endotoxin and several inflammation/CVD markers, on the other 
hand, are all associated with childhood and adolescent obesity. Furthermore, even at 
such an early age in the obese state, girls demonstrate a more favourable metabolic 
profile in terms of endotoxin concentrations, adiponectin levels and risk markers of 
CVD. This may manifest in later life as delayed CVD mortality and morbidity for 
female subjects when compared with male subjects. Furthermore, among the 
inflammatory markers evaluated in this study, endotoxin has potential to serve as an 
indicator or possible mediator of sub-clinical inflammation in childhood and adolescent 
obesity. 
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Chapter 6 
Adiponectin Complexes in Human Cerebrospinal Fluid: 
Distinct Complex Distribution from Serum 
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6.1 Introduction. 
Adipose tissue secretes a vast array of proteins that can exert multiple effects through 
the CNS and peripheral tissues to modulate energy homeostasis (Anima et al. 2000). 
Leptin is one of these adipokines that has been extensively studied in this context. It 
serves as a potent satiety signal to the brain and regulates adiposity by suppressing 
appetite, increasing insulin sensitivity and influencing other anorexigenic hormones that 
mediate energy expenditure (Friedman et al. 1998; Elmquist et al. 1999; Ahima et al. 
2000). Translocation of leptin across the BBB is modulated through a saturable 
transport system, consistent with a role of BBB in regulating behavior and maintaining 
CNS homeostasis (Ahima et al. 2000; Zlokovic et al. 2000). 
Adiponectin is an adipocyte-specific secretory protein involved in numerous aspects of 
energy homeostasis (Scherer et al. 1995). Many studies have reported a strong 
correlation between increased circulating levels of adiponectin and improved insulin 
sensitivity (Berg et al. 2001; Yamauchi et al. 2001; Tsao et al. 2002; Pajvani et al. 
2003). Furthermore, circulating adiponectin levels are reduced in states of obesity- 
induced insulin resistance, whilst weight reduction triggers an increase in adiponectin 
levels (Tsao et al. 2002; Combs et al. 2003). Systemic adiponectin treatment or 
transgenic adiponectin overexpression in rodents improves metabolic status, enhancing 
the ability of insulin to suppress hepatic glucose production (Berg et al. 2001; 
Yamauchi et al. 2001; Tsao et al. 2002; Pajvani et al. 2003; Yamauchi et al. 2003). In 
contrast, adiponectin-null mice exhibit hepatic insulin resistance (Nawrocki et al. 2006). 
Collectively, this suggests that the primary in vivo process targeted by adiponectin 
action in the context of insulin sensitisation is hepatic glucose homeostasis. Consistent 
with these in vivo observations, primary hepatocytes exposed to recombinant 
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adiponectin respond by reducing cellular glucose output as a function of adiponectin 
even at very low insulin concentrations. However, several recent papers have 
highlighted the need for both peripheral and central insulin action on hepatic glucose 
output (Cherrington 2005; Okamoto et al. 2005). Similarly, adiponectin may exert its 
action both peripherally and centrally. 
Adiponectin consists of an N-terminal collagenous domain and a C-terminal globular 
domain (Tsao et al. 2002; Pajvani et al. 2003) that shares homology to types VIII and X 
collagen, in addition to complement factor Clq (Tsao et al. 2002; Pajvani et al. 2003). 
When secreted, adiponectin circulates in serum in distinct stable forms, as trimers and 
LMW hexamers, or HMW multimeric complexes, comprising of 12-18 subunits (Berg 
et al. 2002; Pajvani et al. 2003). A critical cysteine residue in position 39 is the key 
mediator of oligomerisation beyond the basic trimeric building block (Pajvani et al. 
2003). 
Previous studies have documented a characteristic sexual dimorphism in adiponectin 
levels in humans, with female subjects having significantly higher circulating levels 
than male subjects (Arita et al. 1999). This sexual dimorphism is also reflected in 
differential levels of the various circulating adiponectin complexes. The hexamer is the 
more prevalent form of adiponectin in male subjects, whereas female subjects have 
higher circulating levels of the HMW complex; since the HMW form has been 
implicated as the key complex in the context of insulin sensitisation, this may be the 
source of increased insulin sensitivity of female subjects compared to male subjects 
(Pajvani et al. 2003). 
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The adiponectin Cys-39 mutant with its destabilised homotrimeric structure shows 
greater bioactivity in vivo than the native oligomeric complexes in terms of its potency 
to reduce serum glucose levels (Pajvani et al. 2003); additionally, the recombinant 
globular, collagenous stalk-free form of adiponectin influences lipid oxidation in 
peripheral skeletal muscle tissues (Yamauchi et al. 2003), with limited effects on 
hepatic gluconeogenesis (Fruebis et al. 2001). However, the globular form of the 
protein has not yet been identified under normal physiological conditions in vivo. The 
native full-length adiponectin complex exerts more potent effects on the liver. Previous 
studies have demonstrated that transgenic mice overexpressing endogenous full-length 
adiponectin display substantial improvement in hepatic insulin sensitivity (Combs et al. 
2004). It is also recognised that the ratio between HMW to LMW oligomeric forms of 
adiponectin measured by the adiponectin sensitivity index (SA), rather than total 
circulating levels of adiponectin, is a critical determinant of TZD-mediated 
improvements in hepatic insulin sensitivity (Pajvani et al. 2004). Diabetic patients have 
decreased SA values, which improve with TZD-treatment (Pajvani et al. 2004). The 
HMW oligomers are thus established as important adiponectin forms with regard to 
hepatic insulin sensitivity. 
A direct functional impact of adiponectin on metabolism, affected by enhancing insulin 
sensitivity is therefore well established. However, recent studies have shed light on a 
central role for adiponectin, demonstrating profound effects of adiponectin on energy 
homeostasis in the brain. Intracerebroventricular (i. c. v) administration of globular, full- 
length or Cys-39Ser mutant adiponectin into wild-type and ob/ob mice decreased body- 
weight; effect being mediated via increased energy expenditure (Qi et al. 2004). 
Furthermore, peripherally administered adiponectin caused an increase in CSF 
151 
adiponectin, suggesting serum-to-CSF transport (Qi et al. 2004). However, these studies 
measured the adiponectin levels by RIA in mice only and lacked a more detailed 
examination of the specific complex distribution of adiponectin. Central treatment with 
adiponectin proved more potent than systemic treatment of adiponectin in wild-type and 
ob/ob mice, further highlighting the brain as an important target for adiponectin action 
(Qi et al. 2004). Additionally, adiponectin was shown to induce Fos protein 
immunostaining and increase hypothalamic corticotrophin-releasing hormone (CRH) 
synthesis in the paraventricular nucleus (PVN), suggesting the activation of 
hypothalamic sympathetic circuits (Qi et al. 2004). Further evidence suggesting a role 
for adiponectin in the CNS originates from several studies reporting the expression of 
adiponectin receptors (ADIPOR) 1 and 2 in the brain (Yamauchi et al. 2003) and, more 
specifically, in mouse hypothalamus and on brain endothelial cells of the BBB 
(Spranger et al. 2006); the latter may potentially serve as a transport system for 
receptor-mediated transcytosis of adiponectin across the BBB. However, a more 
specific role for these receptors remains to be defined. These studies suggest that 
adiponectin may act centrally to exert metabolic actions. However, the question whether 
adiponectin serves a role centrally under normal physiological conditions is yet to be 
resolved. One recent study failed to detect the presence of adiponectin in human CSF 
(Spranger et al. 2006) and, with another, reported that exogenous adiponectin does not 
cross the BBB in mice (Pan et al. 2006; Spranger et al. 2006), concluding that direct 
effects of adiponectin on CNS pathways may not be relevant. 
The focus of this study was to firmly establish the presence of adiponectin in human 
CSF and subsequently to establish the distribution of the various oligomers by means of 
sub-fractionation and quantitative Western blot analysis of CSF samples. 
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6.2 Subjects, Materials & Methods. 
6.2.1 Subjects. 
A total of 22 subjects (all of whom were Caucasian) were analysed in the study (BMI: 
28.0±4.7 kg/m2; age: 58-81 yrs). Half of the subjects were male (BMI 28.1±3.8 kg/m2; 
age range 58-80 years) and half were female (all post-menopausal; BMI 28.0±5.7 
kg/r2; age range 62-81 years). Of the 22 subjects, 2 subjects were smokers, 6 subjects 
used to be smokers and 14 subjects were non-smokers. CSF and matched serum 
samples were obtained from these consenting subjects undergoing either elective 
liposuction surgery of thigh, hip or knee (n=19), general orthopaedic surgery 
(arthroscopy) (n=2) or gynaecological surgical procedures (n=1) (all non-malignant). 
Prior to surgery, subjects received spinal anaesthesia injection. All samples were 
acquired in accordance with the Ethics Committee of the Birmingham Heartlands 
Hospital (Birmingham, UK) and analysed at the Albert Einstein College of Medicine 
(Bronx, NY, USA) under a protocol approved by the institutional Review Board. 
Patients with malignancy, acute and chronic renal or liver disease, neurological 
disorders, on immunosuppressants, current or recent systemic high dose corticosteroids, 
antibiotics or weight altering medication were excluded from the study. All subjects 
were fasted overnight before examination. The sampling of CSF was performed 
according to standardised procedures with the examined subject in a lateral recumbent 
position and lumbar puncture at the L3-L4 or L5-L6 interspace using a standard needle. 
Prior to spinal anaesthesia injection, a clear volume of CSF was extracted. CSF samples 
were passed through a 0.2 micron syringe filter (Whatman, Florham Park, NJ, USA), 
aliquoted, flash frozen and stored at -80°C until analysis. A fasting blood sample (5 ml) 
was also taken at the time of venous cannulation. Samples were immediately 
centrifuged at 5,000 xg for 20 min, flash frozen and stored at -80°C. 
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6.2.2. Sample Preparation & Size-fractionation of Adiponectin Complexes using 
Fast Protein Liquid Chromatography (FPLC). 
This technique is an adaptation of the FPLC procedure detailed in the General Materials 
& Methods section (Chapter 2.10). 
Analysis of serum samples: Once thawed, 30 µ1 of each serum sample was spun at 
10,000 xg for 10 min. Next, 20 µ1 of Column Buffer (25 mM HEPES, 150 mM NaCl, 1 
mM CaC12; pH 8) was added to each serum sample. The sample mixture was then 
injected into a GL column (Superdex 200 10/300; GE Healthcare Bio-Sciences Corp., 
Piscataway, New Jersey, USA). 
Analysis of CSF samples: Firstly 20 µl of adiponectin knockout mouse serum (kindly 
donated by Nawrocki A, Albert Einstein College of Medicine of Yeshiva University, 
New York, USA) was added to 200 µl of CSF sample, as a carrier. The mixture was 
then spun at 10,000 xg for 10 min before injected undiluted on to the column. In total, 
200 µl gradient-fractions were sequentially retrieved for each CSF and serum sample. 
For CSF fractions, 200 µl of each fraction was vacuum concentrated for 1 hr (SpeedVac 
Plus, Savant Instruments, Holbrook, NY, USA). Fractions were analysed by quantitative 
Western blot analysis as described below. 
6.2.3 Detection & Visualisation of Adiponectin Oligomers in Sub-fractionated 
Samples using Western blot. 
This developed protocol is a modified version of the western blotting procedure 
outlined in the General Materials & Methods section (Chapter 2.4). In brief, for serum 
fractions, 20 µl of 5X Laemmli loading buffer (Appendix I) was added to 60 µl of each 
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fraction then heated at 95°C for 20 min. Lyophilised CSF fractions were reconstituted in 
25 µl Sample Buffer then heated at 95°C for 5 min. Separation of proteins and 
immunoblotting were performed as previously described (Chapter 2.4.2 and 2.4.3). 
Briefly, 20 Al of each serum or CSF sample mixture was loaded on a pre-cast 4-12% 
Bis-Tris gel (Bio-Rad Laboratories, Hercules, USA) and electrophorectically ran at 
180Vfor1hr. 
Following SDS-PAGE, proteins were transferred onto a polyvinylidene fluoride 
membrane (Millipore Corp., Billerica, Massachusetts, USA) for 1 hr as previously 
described (Chapter 2.4) then blocked using 4% non-fat dry milk in Tris-buffered Saline 
(TBS) containing 0.1% Tween 20 (TBS-T) for 1 hr. Primaryantibodies specifically 
raised against the human N-terminal hypervariable region of adiponectin 
(DQETTTQGPGV) and the human C-terminal region of adiponectin were diluted 
(1: 200) in TBS-T; these antibodies recognise a single band of 30 kDa by Western blot 
analysis and have equal affinity for all oligomeric forms of adiponectin. Membranes 
were washed 4 times for 5 min in 0.1% TBS-T. CSF blots were additionally probed 
with a biotin-conjugated goat anti-rabbit antibody (Invitrogen Corp., Carlsbad, 
California, USA) (1: 500). 
To allow for visualisation of bands, CSF blots were decorated with a fluorescent 
streptavidin-conjugate secondary antibody (Invitrogen Corp., Carlsbad, California, 
USA) (1: 5000), whilst serum blots were decorated with a fluorescent dye-conjugated 
anti-rabbit secondary antibody (Rockland Immunochemicals Inc., Gilbertsville, USA) 
diluted (1: 5000) in 0.1% TBS-T. Fractions 1 to 8 (HMW adiponectin), 9 to 16 (LMW 
adiponectin) and 16 to 25 (adiponectin trimer) from sedimentation were visualised at 
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700 nm for CSF blots and 800 nm for serum blots using a Phosphor Imager (LI-COR 
Biosciences, Lincoln, Nebraska, USA), then quantified using Odyssey Licor System 
software (LI-COR Biosciences, Lincoln, Nebraska, USA). 
6.2.4 Detection & Visualisation of `Total' Unfractionated Adiponectin Levels by 
Western blot. 
Briefly, 20 µl of loading buffer was added to 100 Al of CSF sample; whereas 20 µl 
loading buffer was added to 1 µl of serum. Sample mixtures were then heated at 95°C 
for 20 min prior to loading onto a pre-cast 4-12% Bis-Tris gel (Bio-Rad Laboratories, 
Hercules, USA). Detection and visualisation of total adiponectin oligomers was 
performed using the Western blot procedure as detailed above in (Chapter 6.2.3). 
6.2.5 Assessment of `Total' Adiponectin, Insulin & Glucose Levels using RIA &a 
Glucose Analyser. 
Total serum and CSF adiponectin levels were determined by RIA (Lino Research Inc., 
St Charles, Missouri, USA). This RIA utilises 125I-labeled murine adiponectin and a 
multispecies adiponectin rabbit antiserum to determine the level of adiponectin in serum 
or CSF. The lower limit of sensitivity of human adiponectin that can be detected by this 
assay was 1 ng/ml for a 100 Al sample size; whereas the upper limit of sensitivity for 
this assay is 200 ng/ml for a 100 µl sample size. 
Glucose levels were determined using a glucose analyser (YSI-2300 STAT PLUS; 
Yellow Springs Instruments, Yellow Springs, Ohio, USA) in accordance with the 
manufacturers' instructions. Calculation of homeostasis model assessment of insulin 
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resistance (HOMA-IR) (Matthews et al. 1985) was performed using a HOMA-IR 
calculator obtained from: www. dtu. ox. ac. uk/index. html? maindoc=/homa/. 
6.2.6 Statistical Analysis of Results. 
The SPSS statistical program, version 14.0 for Windows (SPSS, Woking, UK) was used 
to analyse data. Results are expressed as percentage or mean ± standard deviation. A 
two-tailed Student's t test was used to assess differences between serum and CSF 
adiponectin oligomers in male and female patients as these were Gaussian in 
distribution. A bivariate Pearson's correlation coefficient was used to analyse 
associations between the following variables: (1) log Serum adiponectin, (2) log CSF 
adiponectin, (3) BMI and (4) HOMA-IR. A p-value of <0.05 was considered statistically 
significant. 
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6.3 Results. 
6.3.1 `Total' Matched Serum & CSF Protein Expression Levels of Adiponectin by 
Western blot Analysis. 
To date, adiponectin levels in CSF have only been reported as RIA measurements. 
Using Western blot analysis, this study demonstrates that a single 30 kDa band cross- 
reactive with highly specific anti-adiponectin antibodies can be found in human CSF. In 
parallel, a corresponding serum sample from the same patient was analysed (Figure 
6.3.1.1). 
Gender 
Serum 
adiponectin 
CSF 
adiponectin 
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Figure 6.3.1.1 Total adiponectin in serum and matched CSF by Western blot analysis. 
The CSF-to-serum ratio of adiponectin is given for each patient analysed (n=20). 
Representative Western blots are shown for total serum adiponectin and corresponding 
total CSF adiponectin for each patient. Patient gender: M, male patient; F, female 
patient. 
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Note that the intensities should not be directly compared between the two Western 
blots. The relative ratio of CSF-to-serurn of adiponectin expression is given for each 
patient based on the Western blot quantitation. This ratio varies from patient to patient, 
suggesting that the levels in CSF are actively controlled. The serum and CSF levels by 
RIA were subsequently measured. In absolute terms, the abundance of adiponectin is 
much lower in CSF, namely approximately 0.1% of the levels found in serum 
(serum=14.0±5.7 [mean±SD] µg/ml; CSF=11.9±18.8 ng/ml [n=22]). RIA analysis 
further revealed that generally, higher levels of adiponectin in serum tend to be 
associated with higher levels of adiponectin in CSF; this correlation was significant in 
men (p=0.044; x0.615; n=11), but not in women (p=N. S; r=0.263; n=11), as shown in 
Figure 6.3.1.2 below. 
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Figure 6.3.1.2 Total CSF adiponectin levels in male patients (solid symbols) (p=0.044; 
r=0.615; n=11) and female patients (open symbols) (p=N. S; r=0.263; n=11) were 
measured by RIA. Solid line, trendline for male patients; dashed line, trendline for 
female patients. 
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6.3.2 Trimer & LMW Hexamer Forms of Adiponectin are the Predominant 
Complexes Found in Human CSF. 
Following sub-fractionation of CSF by gel-filtration chromatography and subsequent 
quantitative Western blotting, the distribution of adiponectin oligomers in human CSF 
was visualised (Figure 6.3.2.1); only the adiponectin LMW hexamer, and more 
prevalently, the trimer are found in CSF. 
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Figure 6.3.2.1 The distribution of adiponectin oligomers in CSF (solid line) in 
comparison with that in matched serum (dotted line) from one female patient (n=13). 
The average percentage composition of each adiponectin oligomer in serum was HMW, 
40.2%; LMW, 35.6%; Trimer, 24.2% (n=13). The average percentage composition of 
adiponectin trimer and LMW hexamer in CSF were LMW, 19.2%; Trimer, 80.8%. 
Representative Western blots from the same female patient following size-fractionation 
highlight serum and CSF adiponectin oligomer distribution. 
A comparison of serum and CSF adiponectin oligomer distribution revealed that 
adiponectin displays a diverse oli omeric complex distribution oC oligomers in CSF, 
when compared with matched scrum within the same patient. Serum showed the 
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expected distribution of HMW complexes, LMW hexamers and the adiponectin trimers. 
CSF, in contrast, lacked the HMW form prominent in serum. While a single 
representative example is shown in Figure 6.3.2.1, the analysis was expanded to an 
additional 13 samples. For serum analysis, the fraction of each adiponectin oligomer 
was calculated relative to the total adiponectin levels. The average percentage 
composition of adiponectin oligomers in serum across a range of patients in the study 
was HMW, 40.2±12.5%; LMW, 35.6±6.8%; Trimer, 24.2±8.9% (n=13) (Table 6.3.2.1). 
Male patients (n=6) Female patients (n=7) Total patients (n=13) 
(±SD) (+SD) (+SD) 
% Adipo- 
nectin Serum CSF Serum CSF Serum CSF 
Oligomer 
HMW 36.5E11.3 Not 43.4±13.4 Not 40.2-112.5 Not 
measurable measurable measurable 
LMW 35.4±9.1 17.6±5.2 35.9±4.7 20.6±11.8 35.6±6.8 19.2±9.1 
Trimer 28.2±5.4 82.4±5.2 20.8±10.2 79.4±11.8 24.2±8.9 80.8±9.1 
Table 6.3.2.1 Average percentage compositions of each adiponectin oligomer in serum 
and CSF in male patients (n=6), female patients (n=7) and in both combined. No 
statistical differences in HMW, LMW or trimeric adiponectin were reached between 
male patients and female patients. 
The analysis of CSF revealed: no detectable HMW; LMW 19.2±9.1%; Trimer 
80.8±9.1%. The lack of the HMW form of adiponectin enabled exclusion of the 
possibility that CSF could have been contaminated by serum. 
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6.3.3 Sexual Dimorphism of Total Adiponectin & Oligomeric Complex 
Distribution. 
Further analysis of total adiponectin levels in serum compared with CSF using Western 
blot, revealed that male subjects have a significantly higher CSF-to-serum ratio of 
adiponectin than female subjects (p<0.05; n=20) (Figure 6.3.3.1). 
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Figure 6.3.3.1 The ratio of total CSF-to-serum adiponectin in male patients compared 
with female patients by Western blot analysis. *, p<0.05; n=20. 
It is acknowledged that women have higher levels of HMW adiponectin in serum than 
men. In contrast, men have slightly higher levels of trimeric adiponectin in serum than 
women. Although Table 6.3.2.1 demonstrates no significanct gender-related differences 
in serum HMW and trimeric adiponectin (p=N. S; men, n=6; women, n=7), further 
analysis using a larger cohort may substantiate significance. No significant differences 
were detected at the level of LMW adiponectin hexamer (p=N. S) (Table 6.3.2.1). 
Furthermore, although men displayed slightly higher levels of adiponectin trimer in 
CSF than women, this did not reach statistical significance (p=N. S; men, n=6; women, 
n=7) (Table 6.3.2.1). Additional studies will therefore be required to see whether these 
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Male Female 
trends can be confirmed in larger cohorts. Potentially higher levels of trimeric 
adiponectin levels in men may reflect the general diverse adiponectin oligomeric 
distribution between the sexes. Previous studies have established that females have 
higher levels of HMW adiponectin (Pajvani et al. 2003), whereas males exhibit higher 
levels of the adiponectin hexamer, which, either by potential androgen regulation, may 
yield higher levels of trimeric adiponectin. 
6.3.4 Correlation with BMI & HOMA-IR. 
As in many previous studies, the levels of total adiponectin in serum were inversely 
related to BMI. Furthermore, examining such a correlation in this cohort using RIA 
analysis, revealed that total serum adiponectin significantly correlates with BMI in male 
patients (p=0.047; r-0.609; n=11) (Figure 6.3.4.1); however, this was not the case in 
the female patients in this cohort (p=N. S; r=-0.329; n=11) (Figure 6.3.4.1). 
Additionally, when examining the correlation between CSF adiponectin and BMI in 
men and women, analysis revealed a trend, albeit not significant, towards an inverse 
relationship of CSF adiponectin with BMI (male patients, p=0.067; r=-0.571; n=11; 
female patients, p=N. S; r=0.116; n=1 1) (Figure 6.3.4.2). Non-significant correlations 
in terms of adiponectin levels, gender and BMI may in part, stem from the sample size 
of the study. 
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Figure 6.3.4.1 (Top) Correlation of total serum adiponectin with BMI in male patients 
(solid symbols) (p=0.047; r=-0.609; n=11) and female patients (open symbols) (p=N. S; 
r=-0.329; n=11) by RIA. Figure 6.3.4.2 (Bottom) Correlation of total CSF adiponectin 
with BMI in male patients (P=N. S; r--0.571; n=11) and female patients (p=N. S; x-= 
0.116; n=11) by RIA. 
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Within this cohort of patients, glucose and insulin concentrations were 6.0±1.7 mM and 
9.4±13.3 µU/ml (n=22) respectively. When examining insulin resistance index, serum 
adiponectin levels were shown to inversely correlate with HOMA-IR index in male 
patients only (male patients, p=0.014; r=-0.744; n=10; female patients, p=N. S; r=-0.504; 
n=11). Similarly, CSF adiponectin demonstrated a significant correlation with HOMA- 
IR in male patients, although not in female patients (male patients, p=0.037; r=-0.663; 
n=10; female patients, p=N. S; r=-0.330; n=11). 
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6.4 Discussion. 
This study firstly established the presence of adiponectin in human CSF, confirming the 
ability of adiponectin to traverse the BBB and further identify its potential to function 
centrally under normal physiological conditions. A key finding from this study was the 
diverse oligomeric distribution between CSF and serum within matched samples from 
the same patients. While all forms of adiponectin were present in serum, only the trimer 
and LMW hexamer were present in CSF; in particular, the adiponectin trimer was 
substantially more prevalent in CSF than the LMW form. Interestingly, male subjects 
displayed a higher CSF-to-serum ratio of total adiponectin expression in comparison to 
female subjects. Sub-fractionation analysis of serum further revealed that men have 
slightly more adiponectin trimer than women; although not significant, men also had 
slightly higher levels of adiponectin trimer in CSF compared to women. As in many 
previous studies, the LMW hexamer does not seem to be regulated in any significant 
fashion. 
This study therefore highlights that the trimer is the primary form of adiponectin in 
human CSF. This further supports previous observations that i. c. v. injection of either 
wild-type, Cys39Ser mutant or globular adiponectin had a central effect, whilst the 
collagenous tail domain lacking the globular head domain was ineffective (Qi et al. 
2004). I. c. v. administration of adiponectin proved to have a more potent effect on 
energy homeostasis than systemic administration of equivalent amounts of adiponectin 
(Qi et al. 2004). 
A number of recent papers highlight the relevance of the HMW form for the peripheral 
functions of adiponectin (Waki et al. 2003; Pajvani et al. 2004; Tonelli et al. 2004; 
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Fisher et al. 2005; Wang et al. 2005; Hara et al. 2006; Lara-Castro et al. 2006). In light 
of the very large size of this complex (>500 kDa), it is not surprising that the HMW 
form is very inefficiently translocated across the BBB and not found in any measurable 
quantities in CSF. The HMW form, despite its relevance for peripheral adiponectin 
action, does not seem to play a major physiological role for central adiponectin action. 
In contrast, the trimeric form of adiponectin seems to be most relevant for the central 
action of this protein. 
The BBB plays a major dynamic regulatory role in the passage of circulating peptides 
involved in energy homeostasis (Zlokovic et al. 2000). How, exactly, the adiponectin 
trimer crosses the BBB is currently unknown. Adiponectin receptors (ADIPORI and 
ADIPOR2) have been detected in the brain (Yamauchi et al. 2003) and on BBB 
endothelial cells (Spranger et al. 2006), suggesting that a regulated receptor-mediated 
transport system may be the favourable mechanism of entry. However, the identification 
and kinetic properties of adiponectin transporters remains to be determined. 
Leptin concentrations in CSF are positively related to plasma level and BMI, but the 
CSF-to-plasma leptin ratio is reduced at the highest plasma leptin level, suggesting a 
saturable brain transport mechanism (Caro et al. 1996; Schwartz et al. 1996). The 
decrease in CSF-to-plasma leptin among obese patients is consistent with leptin 
resistance (Caro et al. 1996; Schwartz et al. 1996). CSF leptin levels in children account 
for 5% of plasma levels, but unlike plasma level, which is higher in girls, the CSF leptin 
concentration is similar between girls and boys (Wiedenhoft et al. 1999). Therefore, the 
CSF-to-plasma leptin ratio is lower in girls and, this may underlie the propensity 
towards excess body-fat (Wiedenhoft et al. 1999). A nocturnal plasma leptin surge 
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entrained to meal timing has been demonstrated in lean and obese humans (Sinha et al. 
1996; Schoeller et al. 1997). However, this is not accompanied by an increase in CSF 
leptin (Wong et al. 2004). As leptin transport across the BBB is fully saturated at higher 
serum leptin concentrations, it is possible that the BBB serves as a rate-limiting step to 
prevent increases in CSF leptin concentrations. The BBB could thus contribute to 
`leptin resistance'; such a notion has been reported in obese subjects, where the 
increases in plasma leptin were not followed by parallel increases in the CSF leptin 
levels (Caro et al. 1996; Schwartz et al. 1996). How the lack of a nocturnal increase in 
CSF leptin relates to the periodicity of energy balance and neuroendocrine axis is 
unknown (Wong et al. 2004). Similar mechanisms may apply for adiponectin. Indeed, 
Kim and colleagues recently reported that a mouse model expressing a dominant 
negative version of the IGF-1 receptor transgenically in muscle displayed complete 
adiponectin resistance (Kim et al. 2006). Future experiments will have to address more 
specifically the mechanism of adiponectin BBB transport under different physiological 
conditions. 
ADIPOR1, preferential for globular adiponectin and trimeric adiponectin, is abundantly 
present in skeletal muscle, mediating AMPK activation to increase glucose uptake and 
lipid oxidation (Yamauchi et al. 2003). ADIPOR2, on the other hand, favours full- 
length adiponectin, is more highly enriched in the liver, mediating hepatic glucose 
homeostasis (Yamauchi et al. 2003). Interestingly, higher levels of ADIPORI than in 
ADIPOR2 are found in the brain (Yamauchi et al. 2003), consistent with the findings in 
this study, that the adiponectin trimer is the predominant CSF form. Whether BBB 
endothelial cells specifically express higher levels of ADIPOR1 is, however, uncertain. 
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The relatively low overall protein concentrations in CSF and the low abundance of 
adiponectin in CSF make the biochemical analysis challenging. In addition, the 
concentrations found in CSF may or may not be sufficiently high to bind and activate 
the known ADIPORs, given the affinity constants reported for the receptors. However, 
it is difficult to rule out the possibility that other mechanisms are in place to increase the 
local concentrations of the adiponectin trimer to levels that would effectively trigger 
receptor activation. Alternatively, additional, yet-to-be identified receptors may exist 
that display higher affinities. 
Within this study, antibodies that specifically recognise human adiponectin and do not 
show any cross-reactivity with murine adiponectin were used. To avoid introducing an 
exogenous source of adiponectin altogether, serum from adiponectin null mice was used 
as a carrier during the biochemical sub-fractionation of the CSF samples, a step that 
proved to be essential for the efficient detection of CSF adiponectin. 
Putative transport systems for both leptin and TNF-a have been identified or postulated 
to exist (Zlokovic et al. 2000); these transport systems should be able to independently 
facilitate receptor-mediated transcytosis of peptides across the BBB (Pan et al. 2004). 
Whether such a scenario exists for adiponectin transport is currently unknown. Once 
across the BBB, the influence of adiponectin on peripheral energy expenditure may be 
mediated by the hypothalamus. Adiponectin induces c-fos expression in the PVN (Qi et 
al. 2004) and increases the synthesis of hypothalamic CRH (Qi et al. 2004), suggesting 
activation of adiponectin-responsive neurons via the melanocortin pathway. Agouti A 
Y/a mice, incapable of melanocortin signalling (Dinulescu et al. 2000), are resistant to 
central administration of adiponectin (Malaki et al. 2003), further indicating that the 
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melanocortin pathway is essential for the anorexigenic effects of adiponectin on energy 
expenditure. Leptin ob/ob mice are particularly sensitive to CNS and systemic 
adiponectin treatment (Berg et al. 2001; Qi et al. 2004), suggesting perhaps a 
compensatory role for adiponectin to counteract reduced leptin signalling in the 
melanocortin pathway. Furthermore, mice lacking leptin receptors only in pro- 
opiomelanocortin (POMC) neurons have a modest increase in body weight (Balthasar et 
al. 2004). Future studies examining mice lacking adiponectin receptors in POMC 
neurons may prove illuminating and may establish whether leptin and adiponectin act in 
concordance to activate such neurons. 
Western blot analysis of total adiponectin revealed that male subjects have a higher 
CSF-to-serum ratio than female subjects. Sexual dimorphism in terms of total systemic 
adiponectin, with women having higher levels of adiponectin than men, has been 
reported (Nishizawa et al. 2002; Cnop et al. 2003; Combs et al. 2003); Although this 
was preserved in CSF (Qi et at. 2004), such findings were achieved using assay-based 
measures. As it is currently unknown whether available RIAs and ELISAs are biased 
towards some adiponectin oligomers, total adiponectin data should be interpreted with 
care. Although this study demonstrated that the adiponectin oligomeric distribution was 
not significantly different in serum and CSF with regards to gender, further analysis 
using a larger cohort of subjects for sub-fractionation would be beneficial and may 
further establish significance. 
The three oligomeric adiponectin complexes have differential secretion rates (Xu et al. 
2005), possibly dependent on the status of energy expenditure and on peripheral and 
hepatic insulin sensitivity. The rate of HMW adiponectin secretion from adipocytes is 
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slower than that of the other two oligomeric complexes (Xu et al. 2005). Testosterone 
has been shown to selectively impede the secretion of the HMW form of adiponectin 
from adipocytes, possibly by activating intracellular sequestering molecules (Xu et al. 
2005). Interestingly, testosterone elevates the relative levels of trimeric and hexameric 
adiponectin forms at the expense of the HMW form in circulation (Xu et al. 2005), 
consistent with the increased susceptibility of men to hepatic insulin resistance. 
Androgens may therefore serve as one of many factors modulating the pattern of 
adiponectin oligomeric complex distribution within target tissues. Consequently, 
healthy women displaying higher levels of HMW adiponectin also display improved 
hepatic insulin sensitivity compared to men. Additionally, post-menopausal women may 
exhibit a more androgenic setting of adiponectin oligomers in comparison to young pre- 
menopausal women. Future examination of menopausal status in terms of adiponectin 
oligomer distribution in serum and CSF may further define the role of hormonal factors 
as modulators of adiponectin. 
A recent paper reported negative data regarding the presence and/or transport of 
adiponectin into CSF (Spranger et al. 2006). It is unclear why these authors were unable 
to detect adiponectin in CSF. However, given the negative data reported for the 
transport of bacterially produced globular trimer in these studies, it is possible that the 
collagenous stalk or some additional post-translational modification associated with it 
may be important for the transport process. 
Several key questions remain outstanding with regards to central adiponectin action. 
What factors determine the distribution of adiponectin forms between CSF and the 
periphery? Is this distribution altered in obese or insulin resistant patients, i. e. is there a 
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specific defect in the BBB translocation machinery under some pathological conditions? 
Does the nutritional status affect this distribution? Future studies examining adiponectin 
oligomeric distribution in CSF in diabetic or in chronically obese patients, as well as 
pre-and post peroxisome proliferator-activated receptor-y agonist intervention treatment, 
may clarify the mechanisms underlying central adiponectin action. In conclusion, 
adiponectin is present in human CSF, predominantly in the trimeric form. More 
specifically, CSF adiponectin employs a distinct oligomeric pattern to that of serum and 
may be further modulated by gender. 
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Chapter 7 
Discussion 
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The molecular mechanisms underlying the link between obesity, inflammation, 
insulin resistance and the progression to T2DM are still only partially understood. At 
the centre of these conditions however, is the `adipocyte cell' itself. It is now 
recognised that adipocytes integrate and respond to numerous autocrine, paracrine and 
endocrine signals (Rajala et al. 2003; Scherer 2006), by secreting a vast array of 
adipokines (Tilg et al. 2006). It is also suggested that inflammation, particularly 
within obesity, employs an enhanced activation of innate immunity (Dandona et al. 
2004), through a series of complex interactions amongst components of the innate 
immune signalling pathway and the insulin signalling cascade, which results in 
abnormal systemic levels of adipokines. Consequently, dysregulation of such 
signalling processes may therefore alter glucose homeostasis and lipid metabolism, 
thus contributing to insulin resistance and the progression to T2DM (Wellen et al. 
2005; Shoelson et al. 2006). Principally, this thesis investigated obesity-associated 
inflammation in human adipose tissue, followed by the potential central actions of 
adipokines in human CSF; by assessing the expression, secretion and functionality of 
two major adipokines, resistin and adiponectin. 
7.1 The Role of Resistin in Human Obesity & Inflammation. 
This thesis firstly explored resistin in relation to human obesity, as previous studies 
have shown contradiction (Azuma et al. 2003; Degawa-Yamauchi et al. 2003; Lee et 
al. 2003; Heilbronn et al. 2004). More specifically, real-time PCR analysis revealed a 
correlation between resistin and increasing adiposity in AT. Subsequent, Western blot 
analysis established that resistin was expressed at higher levels in obese AbSc AT. As 
such, both mRNA and protein data complied with previous observations highlighted 
elevated resistin levels in obesity (McTernan et al. 2002; McTernan et al. 2003). 
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Resistin has been identified in many cell-types in the humans, including adipocytes, 
pre-adipocytes and macrophages (Table 1.4.1.2). Within adipose tissue, the majority 
of studies to date have reported that the predominant source of human resistin is the 
macrophage (Kaser et al. 2003; Patel et al. 2003); this study established that human 
resistin is also expressed and secreted from isolated adipocytes. It could be suggested 
that, as adipose tissue mass accumulates during obesity, increased levels of resistin 
enter into circulation to potentially exert a significant impact on various inflammatory 
and metabolic signalling systems. 
Numerous studies have suggested an inflammatory role for adipokines in conjunction 
with the insulin signalling cascade (Hotamisligil 2003; Arkan et al. 2005; 
Hotamisligil 2005; Shoelson et al. 2006). This thesis therefore explored the role of 
human adipose tissue as a potential inflammatory target. Subsequent studies identified 
elevated expression levels of key intermediates of the innate immune system, in 
particular, MyD88, TRAF-6 and NF-KB, in obese and type 2 diabetic adipose tissue. 
This firstly implicated human adipose tissue as a site for an innate immune response 
and secondly, suggested that in states of severe increased adipose tissue biomass and 
T2DM, there is an enhanced level of activation of innate immunity. Such enhanced 
innate immunity has resulted in adipose tissue itself being considered as `inflamed' 
(Lehrke et al. 2004). This inflammatory state may consequently propagate and recruit 
circulating macrophages into the inflammatory site, and, in conjunction with 
adipocytes, produce an immense level of inflammatory mediators. Elevated systemic 
levels of such inflammatory mediators may contribute to a state of insulin resistance 
and accelerate the progression to T2DM. 
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This thesis further addressed the adipocyte itself as site for an innate immune 
response in human obesity and T2DM. In particular, studies examined the duality in 
function of resistin on components of the innate immune pathway and insulin 
signalling cascade in isolated adipocytes. In vitro analysis of resistin revealed that 
antigenic stimuli were capable of increasing resistin levels from isolated adipocytes. 
Additionally, human recombinant resistin itself increased the level of inflammatory 
cytokine secretion from adipocytes; this affect was enhanced by insulin and further, 
suppressed by the insulin sensitiser, RSG. Previous studies have suggested NF-xB and 
JNK as central inflammatory and metabolic regulatory kinases in innate immunity and 
insulin signalling, respectively (Hirosumi et al. 2002; Arkan et al. 2005; Wellen et al. 
2005). Resistin was shown to stimulate the expression of these central kinases; 
suggesting that resistin may influence more than one mechanism to stimulate 
inflammatory cytokine release from human isolated adipocytes; potentially via the 
integration of both inflammatory and metabolic signalling systems, as highlighted in 
Figure 7.1. 
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Figure 7.1 Illustration of the hypothesised model of resistin action within the 
adipocyte. Resistin affects several key components of the innate immune signalling 
pathway and factors of the insulin signalling cascade, therefore altering the production 
of inflammatory mediators. Consequently, resistin may indirectly influence the 
progression of T2DM and CVD. 
Several studies have highlighting the importance NF-KB in the regulation of 
inflammatory processes that may affect insulin sensitivity (Shoelson et al. 2003; Cai 
et al. 2005; Shoelson et al. 2006). To further analyse the significance of resistin in 
both NF-KB and JNK signalling pathways, subsequent studies included inhibition of 
both signalling systems. Results identified both NF-KB and JNK as potential master 
regulators of resistin secretion from adipose tissue; this is paralleled by other studies 
demonstrating reduced pro-inflammatory cytokine secretion when such key regulators 
are pharmacologically inhibited (Creely et al. 2006). Collectively, these studies 
suggest NF-KB and JNK as potential therapeutic targets for the treatment of 
inflammatory-associated insulin resistance and T2DM. 
TLR-2 
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The analysis of resistin in relation to obesity and the innate immune response was 
examined in abdominal `subcutaneous' adipose tissue and isolated adipocytes 
respectively, hence this study was limited to subcutaneous adipose tissue due to the 
lack of availability of omental adipose tissue. Considering omental adipose tissue 
confers a high pathogenic profile in relation to the metabolic syndrome (Freedland 
2004), future studies examining the expression of resistin and its' pro-inflammatory 
effects in omental adipose tissue in comparison to its' effects in subcutaneous adipose 
tissue would certainly be of interest. Furthermore, the majority of adipose tissue in 
this study was obtained from Caucasian subjects. Future examination of resistin 
expression levels and pro-inflammatory effects in adipose tissue obtained from obese 
and lean Asian populations would also be beneficial. Finally, it has been highlighted 
that tobacco smoke contributes to insulin resistance in the metabolic syndrome 
(Wietzman et al. 2005; Strauss et al. 2001). Future studies evaluating the association 
of environmental tobacco smoke exposure and active smoking, as measured by 
circulating cotinine concentrations, in relation to resistin would further be of interest. 
7.2 A Central Role for Adiponectin. 
In contrast to resistin, adiponectin reduces insulin resistance and thrombogenic risk 
and, is expressed and secreted from adipocytes at higher levels in healthy lean 
subjects (Scherer et al. 1995; Bouskila et al. 2005; Trujillo et al. 2005). Paradoxically, 
an increase in adipose tissue biomass results in decreased levels of adiponectin 
mRNA and protein (Arita et al. 1999; Hara et al. 2003; Reinehr et al. 2004; 
Fernandez-Real et al. 2005). Figure 7.2 highlights that adiponectin can be influenced 
by several conditions. 
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Figure 7.2 Summary of the most significant factors and disease states that result in an 
up-rcgulation or down-regulation of adiponectin in adipose tissue. Figure obtained 
frone (Trujillo et a!. 2005). 
In serum, adiponectin circulates in several different complexes, each of which have 
predominant functions (Berg et al. 2002; Pajvani et al. 2003). Several studies have 
demonstrated that pharmacological treatment with recombinant adiponectin affects 
both glucose and lipid metabolism (Fruebis et al. 2001; Tsao et a!. 2002; Yamauchi et 
al. 2002, Yamauchi et al. 2003). More specifically, administration of a recombinant 
proteolytic fragment of adiponectin (globular adiponectin) into mice, decreases 
plasma glucose, without altering food-intake (Fruebis et al. 2001). Although the 
potent effects of the pharmacologically generated recombinant globular adiponectin 
have been described in relation to lipid oxidation and glucose uptake in muscle 
(Fruebis et al. 2001; Yamauehi et al. 2002); it has been suggested that such affects are 
unlikely to be a reflection of the function of the endogenous protein, as no molecular 
equivalent to the globular form to date, has been identified in vivo (Rajala et al. 2003; 
Nawvrocki et al. 2004). The studies in this thesis have, for the first time, identified the 
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trimeric form of adiponectin in vivo. Other studies have also suggested that although 
globular adiponectin is known to circulate in human plasma at low abundance of -1% 
of total adiponectin, levels of adiponectin are -'100-fold greater than other adipokines 
(Fruebis et al. 2001), thus highlighting the importance of trimeric adiponectin. 
In addition to studies demonstrating the effects of adiponectin on peripheral insulin 
sensitisation, recent rodent studies have revealed that adiponectin can exert its effects 
on energy homeostasis via central mechanisms (Qi et al. 2004). However, no studies 
to date have fully established whether adiponectin is able cross the BBB in humans. 
The studies in this thesis determined that the adiponectin trimer is the most 
predominant oligomer expressed in human CSF. Such a result may have major 
implications for adiponectin in energy homeostasis. The globular form of adiponectin 
is implicated to function predominantly by regulating skeletal muscle insulin 
sensitisation and energy expenditure (Fruebis et al. 2001), by promoting lipid 
catabolism and glucose uptake. This study suggests that such effects may occur via 
the CNS; therefore proposing a secondary anorexigenic function for adiponectin to 
hepatic insulin sensitisation in humans. The globular form of adiponectin may 
function in a similar manner to leptin; signalling from adipose to peripheral skeletal 
muscle tissues, via the hypothalamus; serving as an adipogenic hormone with 
neurogenic properties. Such a mode of action for trimeric adiponectin may be 
subsequently altered by gender. Western blot analysis revealed sexual dimorphism of 
adiponectin levels, in that males have a higher CSF-to-serum ratio of total 
adiponectin; this was only partly reflected by sub-fractionation data. Although not 
significant, male subjects express slightly higher levels of trimeric adiponectin in 
serum and CSF. Further adiponectin FPLC studies using a larger cohort of subjects 
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could be beneficial and may establish significant differences in adiponectin 
oligomeric structures in relation to gender. Such results also suggest androgens as 
potential contributory factors in the alteration of adiponectin complex distributions, 
thus influencing peripheral insulin sensitivity. 
7.4 Future Perspectives for Resistin & Adiponectin. 
Recent studies have shed light on differences between resistin in rodents and humans, 
indicating the diversity of resistin action in these species. However, further studies are 
required to establish the relevance of resistin to human T2DM, in particular its effects 
on the CNS and ß-cell function. Further work is also required to understand the basis 
for formation of different HMW and LMW oligomers of resistin in circulation and, 
their functionally effects. Recent work has determined that resistin undergoes post- 
translational modification, leading to the molecule being secreted as two major 
oligomers (Patel et al. 2004). Moreover, HMW forms of resistin have recently been 
identified in both rodents and humans serum (Patel et al. 2004; Gerber et al. 2005). In 
contrast, HMW forms of adiponectin, rather than total amounts, have been shown to 
correlate better with TZD-mediated improvements in insulin sensitivity (Pajvani et al. 
2004); a similar scenario may well apply for resistin. As it is unknown which resistin 
oligomer is more associated with increased disease risk, development of assays 
specific for the different molecular weight forms of resistin, rather than absolute 
measurements, would prove beneficial. Furthermore, future studies examining the 
oligomeric distribution of resistin in serum and matched CSF using FPLC, would 
certainly be interest. It should also be noted that resistin-like molecules, such as the 
RELM-ß, may have relevance to pathological states, which may need further 
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investigations. Additionally, identification of a receptor for resistin would be a major 
advance to a clearer understanding of its function and signalling mechanisms. 
With regards to adiponectin, whilst this study determined the presence of trimeric and 
LMW forms of adiponectin in human CSF; future studies using FPLC to examine the 
adiponectin oligomeric distribution in serum and matched CSF from T2DM subjects' 
pre and post-TZD treatment or in relation to pre-and post-prandial insulin levels, may 
further elucidate the central properties of adiponectin in the brain. Additionally, 
deducing whether the human trimeric or LMW hexameric forms of adiponectin exert 
similar effects on energy expenditure as those observed in rodents would be of 
interest (Qi et al. 2004). Furthermore, determining what factors maintain the 
equilibrium between globular adiponectin in central and peripheral energy 
homeostasis versus HMW full-length adiponectin in hepatic insulin sensitisation 
would prove beneficial. In addition to this, establishing how exactly adiponectin 
signals through anorexigenic POMC neurons in the arcuate nucleus and 
paraventricular nucleus (PVN) to maintain energy expenditure would further define 
the central actions of adiponectin in humans. Finally, as receptors for adiponectin 
have been identified in the PVN (Qi et al. 2004), exploring the expression of 
adiponectin receptors in the hypothalamus in various pre- and post-fasted states and 
explore the possibility of other high-affinity receptors within the hypothalamus would 
also prove illuminating. 
In summary the results of this thesis have shown that resistin and adiponectin play an 
important role in the obesity-related inflammation and energy homeostasis 
respectively. It is apparent that alteration in the production of adipokines via chronic 
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activation of the innate immune system may promote obesity-related T2DM. 
Maintaining such an adipokine balance is therefore critical to the health of the 
individual. However, the growing knowledge of the role of inflammatory molecules 
generated within adipose tissue and, their link to T2DM, means that interventions that 
reduce the production of pro-inflammatory cytokines, for instance NF-KB or JNK 
inhibitors, may have therapeutic potential. 
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APPENDIX I 
AI. 1 WESTERN BLOTTING SOLUTIONS. 
1.1 Sodium Dodecyl Sulphate (SDS) (4%) 
10 ml 20% SDS solution 
50 ml dH2O 
Solution stored at room temperature (RT) 
1.2 Loading buffer 
625 µl Tris-HC1(pH 6.8) 125 mM 
500 Al SDS 4% 
1 ml Glycerol 
200 µl Dithiothreitol (DTT) 
125 µl Bromophenol Blue 
250 µl Distilled H2O 
1.3 5X Laemmli Loading buffer 
0.5 M DU in 2M Tris HCI pH 8.8 
10% SDS 
50 % v/v glycerol 
10% w/v bromophenol blue 
dH2O 
Electrode Buffer for SDS-PAGE Electrophoresis 
FINAL CONCENTRATION QUANTITY 
REAGENT (X5) (DILUTED IN 1L) 
Tris 
1.24 x 10"1 M l5 g 
Glycine 
(Biorad, Hercules, 9.6 x 10"1 M 72 g 
CA, USA 
SDS 
20% (v/v) 25 ml 
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Transfer Buffer for Electrophoretic Transfer 
REAGENT FINAL CONCENTRATION 
OX) 
Quantity 
(DILUTED IN 4L) 
Tris 25 mM 15.15 g 
Glycine 192 mM 72.0 g 
Methanol 100% 1L 
1.4 Phosphate Buffered Saline (PBS) (pH 7.6) 
PBS 120 mM 
NaC12.7 mM 
KCL, 10 mM 
1.5 PBS-Tween (PBS-T) (1.0%) 
1L PBS (prepared as above) 
1 ml Phosphate Buffered Saline (PBS) ('Tween 20' (0.1% (v/v), Sigma UK). 
Solution stored at RT. 
1.6 PBS/PBS-T solution for antibody preparation (0.5%) 
X quantity 1.0% PBS-T (prepared as above) 
X quantity PBS (prepared as above) 
1.7 Tris-buffered Saline-Tween (TBS-T) (10X): 0.5M Tris Base, 9% NaCI, pH 7.6 
61 g Trizma base 
90 g NaCl 
1L dH2O 
Solution mixed to dissolve and pH adjusted using HCI. Solution stored at RT. 
1.8 TBS-T (1X) 
TBS-T (10X) diluted (1: 10) with dH2O 
1.9 Blocking Solution for Millipore® filters (20%) 
20 g non-fat milk solution (Marvel Milk Powder, UK) 
200 ml PBS 0.5% PBS (Tween 20 (0.1% (v/v), Sigma UK) 
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AI. 2 GENERAL CELL-CULTURE SOLUTIONS. 
2.1 Lysis buffer 
Ammonium Chloride (NH4CI) 0.154 moUl 
Potassium Bicarbonate (KHCO3) 10 mmolJl 
2.2 Phenol red-free medium 
Dulbecco's minimal essential medium (DMEM/F-12) Phenol red free 
1% transferrin (see below) 
Penicillin (100 U/ml) and streptomycin (100 mg/ml) added. 
Medium was stored at 4°C. 
2.3 Transferrin 
Transferrin binding-protein found in serum, is responsible for the transfer of iron to 
cells. Transferrin binds Fe 2+ and prevents its oxidization to Fei+, preventing loss of 
iron from the medium. The stimulatory activity of transferring is proposed to be 
associated with its iron binding properties and, it is further capable of binding other 
metal irons in the medium at concentrations which are toxic (Barnes et al. 1980). 
AI. 3 BUFFERS & SOLUTIONS USED IN RT-PCR PROCEDURES. 
3.1 DNase Treatment 
DNase I REACTION 
BUFFER 
STOP 
SOLUTION 
1 U/µl in 200 mM Tris-HC1 (pH 50 mM EDTA 
50% Glycerol 8.3) 
10 mM Tris-HCI (pH7.5) 20 mM MgC12 
10 mM CaC12 
10 mM MgC12 
3.2 Reverse Transcription (RTn) Buffer 
100 mM Tris-HC1(pH 9.0 at 25°C) 
500 mM KC1 
1% Triton® X-100 
3.3 Taq DNA polymerase stored in RTn Buffer 
50 mM Tris-HC1(pH 8.0) 
100 mM NaCl 
0.1 mM EDTA 
1 mM DTT 
50% Glycerol 
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Al 4 FPLC SOLUTION 
Column Running buffer 
25 mM HEPES 
150 mM NaCl 
1 mM CaC12 
Solution stirred to dissolve contents then adjusted to pH 8.0 
Solution was stored at RT 
APPENDIX II 
RTn & REAL-TIME PCR 
2.1 mRNA sequence. 
Within any gene, the deoxyribonucleic acid (DNA) or genetic code that encodes the 
protein structure is divided into introns (non-coding) and exons (coding) regions. 
When a gene is transcribed from the DNA strand inside the nucleus by RNA 
polymerase, messenger ribonucleic acid (mRNA) is produced, which comprises of 
only the exons. Each gene can consist of a varied number of exons. It is these regions 
that will ultimately describe the specific polypeptide chain that will be assembled 
within the ribosomes located in the cytoplasm of cells. Therefore, quantitative 
analysis of mRNA will give an accurate analysis of the `blueprint' prepared for 
protein synthesis. 
2.2 RT-PCR. 
The initial materials for PCR are reliant on complementary DNA (cDNA) to serve as 
a template; DNA must therefore be synthesised from the extracted RNA. This process 
is termed reverse transcription (RTn) and subsequently allows the synthesis of cDNA. 
Such a process involves `reading' mRNA sequences to then assemble a cDNA chain, 
that comprises the complimentary bases to that on the mRNA strand (guanine bonds 
with cytosine and, adenine to thymine) (Figure AII. 2.1). 
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Figure A11.2.1 Diagram illustrating mRNA, which is then transcribed in a reverse 
transcription process to yield single strands of cDNA. G, guanine; U, uracil; A, 
adenine; C, cytosine; T, thymine. 
2.4 Quantitative Real-Time PCR. 
Quantitative Real-time PCR uses fluorescence technology to monitor amplicon 
production during each PCR cycle (for instance, in real-time). This allows analysis of 
the amount of template rather than the amount of amplified product at the endpoint of 
the reaction. In this study, the rnRNA levels were analysed using an ABI 7700 
Sequence Detection system, which utilises TaqMan chemistry for highly accurate 
quantification of specific mRNA levels (Figure A11.2.4). TaqMan probes contain a 
fluorescent reporter dye usually on the 5' base and a quenching dye typically on the 3' 
base, which suppresses the reporter. Due to the close proximity of the two, the 
quencher prevents emission of any fluorescence while the probe is intact. If the gene 
of interest is present, the probe anneals between the forward and reverse primer sites 
within the PCR product. When the Taq DNA polymerase replicates a template on 
which a TagMan probe is bound, its 5' exonuclease activity cleaves the probe. This 
removes the reporter from the proximity of the quencher, resulting in a florescent 
signal that accumulates with each cycle. The fluorescent signal yielded can be 
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quantitatively measured by a laser and charged coupled device (CCD) camera, 
enabling real time detection of eDNA amplification. 
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Figure A11.2.4 Diagram showing TaqMan chemistry. When probe is cleaved from the 
DNA during amplification, the reporter dye is removed from the quencher and 
fluoresces. This increases in intensity with every amplification cycle, allowing for 
real-time assessment of the reaction. 
190 
APPENDIX III 
WESTERN BLOTTING 
3.1 Calculation of Protein Content of Samples for Western blot Analysis. 
Protein samples were analysed using a spectrophotometer at 655 nm. Conversion of 
optical densities to protein content (µg) was calculated by the construction of a standard 
curve (Figure AIII. 3.1) using bovine serum albumin (BSA) diluted in dH2O, each time 
samples were assayed. No protein signal (optical density) was detected in a mixture 
containing only Reagent S, Reagent A and Solution B, therefore excluding interference 
with calculated protein sample concentrations. 
0.16 
0.14 
0.12 
w 0.10 
N 0.08 
d 
0.06 
0.04 
0 
0.02 
0.00 
Bovine Serum Albumin (µg! µ1) 
Figure AIII. 3.1 Graph to show standard curve used as a reference to calculate protein 
content in samples of proteins extracted from adipose tissue and isolated adipocytes. 
Bovine serum albumin was diluted in dH2O to known concentrations and absorbance 
read at 655 nm on a spectrophotometer. 
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3.2 Rainbow Marker for Protein Size Comparison in Western blot Analysis. 
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Figure . x111.3.2 A 
ladder of proteins used as a marker (Amersham Pharmacia 
Biotech, Buckinghamshire, UK), which is resolved on a 8-15% SDS-PAGE gel 
(Laemmli 1970). Black bands represent the same gel exposed to photographic film 
(Hyperf lmTNI (3-max). 
192 
APPENDIX IV 
DEFINING PLASMA GLUCOSE LEVELS & HOMA INDEX 
4.1 Glucose Oxidase Method. 
The glucose oxidase method is a technique that allows for accurate quantification of 
glucose concentration in both serum and plasma preparations of blood (Lott et al. 
1975). The procedure works on the knowledge that glucose present in blood is 
oxidized to gluconic acid, liberating hydrogen peroxide by an enzyme called glucose 
oxidase. The liberated hydrogen peroxide is converted to water and oxygen, by 
peroxidase. The level of converted oxygen can be measured using an oxygen accepter 
termed 4 aminophenazone, which takes up oxygen to form a pink covered chromogen, 
which is then detected. Plasma glucose levels remain stable at RT for up to 6 hr. 
4.2 The Homeostasis Model Assessment (HOMA) Index. 
The HOMA model evaluates insulin sensitivity and ß-cell function as a percentage of 
a normal reference population. This index works on the premise that blood insulin and 
glucose levels are determined by a feedback loop between the liver and pancreatic 0- 
cell. As described in this thesis, high glucose levels are accounted for by a 
compensatory mechanism that increases insulin secretion from the ß-cell. Thus the 
proportion of insulin and glucose should be directly reflective of insulin sensitivity. A 
mathematical model was derived to estimate the amount of ß-cell function and insulin 
resistance which would equate to steady plasma levels of insulin and glucose in each 
individual. The formula used in this thesis to interpret HOMA was as follows: 
(Fasting insulin (µU/1) x Fasting Glucose (mmol/1))/ 22.5 = HOMA index. 
Alternatively, a HOMA-IR calculator can be downloaded from the following website: 
www. dtu. ox. ac. uk/index. html? maindoc=/honia/. 
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